<SEC-DOCUMENT>0000320017-13-000084.txt : 20130830
<SEC-HEADER>0000320017-13-000084.hdr.sgml : 20130830
<ACCEPTANCE-DATETIME>20130830165424
ACCESSION NUMBER:		0000320017-13-000084
CONFORMED SUBMISSION TYPE:	DEFA14A
PUBLIC DOCUMENT COUNT:		3
FILED AS OF DATE:		20130830
DATE AS OF CHANGE:		20130830
EFFECTIVENESS DATE:		20130830

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			NeoStem, Inc.
		CENTRAL INDEX KEY:			0000320017
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-MISC HEALTH & ALLIED SERVICES, NEC [8090]
		IRS NUMBER:				222343568
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		DEFA14A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-33650
		FILM NUMBER:		131072935

	BUSINESS ADDRESS:	
		STREET 1:		420 LEXINGTON AVENUE
		STREET 2:		SUITE 450
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10170
		BUSINESS PHONE:		212-584-4171

	MAIL ADDRESS:	
		STREET 1:		420 LEXINGTON AVENUE
		STREET 2:		SUITE 450
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10170

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PHASE III MEDICAL INC/DE
		DATE OF NAME CHANGE:	20030819

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CORNICHE GROUP INC /DE
		DATE OF NAME CHANGE:	19951117

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	FIDELITY MEDICAL INC
		DATE OF NAME CHANGE:	19951025
</SEC-HEADER>
<DOCUMENT>
<TYPE>DEFA14A
<SEQUENCE>1
<FILENAME>defa14a.htm
<DESCRIPTION>DEFA14A
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using WebFilings 1 -->
		<!-- Copyright 2008-2013 WebFilings LLC. All Rights Reserved -->
		<title>Def A14A</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<a name="s8665e062a8534660b7d82dd23d865eb8"></a><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">UNITED STATES </font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">SECURITIES AND EXCHANGE COMMISSION </font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Washington, D.C. 20549 </font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">SCHEDULE 14A </font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Proxy Statement Pursuant to Section 14(a) </font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">of the Securities Exchange Act of 1934 </font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Filed by the Registrant </font><font style="font-family:Wingdings;font-size:12pt;">x</font><font style="font-family:inherit;font-size:12pt;">&#32;</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Filed by a Party other than the Registrant </font><font style="font-family:Wingdings;font-size:12pt;">&#168;</font><font style="font-family:inherit;font-size:12pt;">&#32;</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Check the appropriate box: </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:87.6953125%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td width="4%"></td><td width="96%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Wingdings;font-size:10pt;text-align:center;">&#168;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Preliminary Proxy Statement</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Wingdings;font-size:10pt;text-align:center;">&#168;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Wingdings;font-size:10pt;text-align:center;">&#168;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Definitive Proxy Statement</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Wingdings;font-size:10pt;text-align:center;">x</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Definitive Additional Materials</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Wingdings;font-size:10pt;text-align:center;">&#168;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Soliciting Material Pursuant to &#167;240.14a-12</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">NEOSTEM, INC. </font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(Name of Registrant as Specified in its Charter) </font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">______________________________________________________________________________________</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(Name of Person(s) Filing Proxy Statement, if Other Than the Registrant) </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td width="3%"></td><td width="6%"></td><td width="91%"></td></tr><tr><td colspan="3" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Payment of Filing Fee (Check the appropriate box):</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Wingdings;font-size:10pt;text-align:center;">x</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">No fee required.</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Wingdings;font-size:10pt;text-align:center;">&#168;</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Title of each class of securities to which transaction applies:</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Aggregate number of securities to which transaction applies:</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Proposed maximum aggregate value of transaction:</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(5)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total fee paid:</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Wingdings;font-size:10pt;text-align:center;">&#168;</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Fee paid previously with preliminary materials.</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:10pt;"><font style="font-family:Wingdings;font-size:10pt;text-align:center;vertical-align:top;">&#168;</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Amount Previously Paid:</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Form, Schedule or Registration Statement No.:</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Filing Party:</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Date Filed:</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><br><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><a name="s99baecda2a5c4e6c9bbe03947076babd"></a><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;text-align:center;"><img src="neostemlogohiresa01.jpg" style="height:97px;width:286px;"></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">ANNUAL REPORT TO SHAREHOLDERS</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">August 30, 2013&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dear NeoStem Shareholders,</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">NeoStem, a leader in the emerging cellular therapy market, continues to position itself for success through scientific discovery; a diversified product development pipeline that addresses cardiovascular and autoimmune diseases as well as regenerative medicine; an expanding contract development and manufacturing business that serves as our revenue generating arm; and a professional and experienced management team. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are proud to be at the forefront of a paradigm shift in medicine toward cell therapy - a shift away from treating disease with drugs and toward treating disease with our own cells; a shift away from treating symptoms and toward cures for illnesses that cause the most suffering; a shift away from chemical drug development and toward looking inside ourselves to understand and then amplify our bodies' natural repair mechanism. We firmly believe that the future of medicine emanates from within each of us and NeoStem is dedicated to unlocking the potential of cellular therapy for humankind.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">NeoStem prides itself on not being &#8220;just another biotech company.&#8221; In the ever changing global economy, ingenuity is rewarded. We are building the Company based on the foundation and sector expertise provided by our contract development and manufacturing subsidiary, Progenitor Cell Therapy (&#8220;PCT&#8221;). As a leader in the cell therapy industry in process development innovation and cost effective scale-up, PCT supports NeoStem's internal development of its therapeutic programs. Our investments in our therapeutic pipeline, which we have approached with scientific discipline and business and market analysis, include significant opportunities which are protected by an expanding intellectual property portfolio, positioning the Company for dynamic partner collaborations. Finally, our search for the brightest talent to make our Company the &#8220;best in class&#8221; has brought us experienced industry executives that we believe will assist in maximizing shareholder value. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:240px;text-indent:192px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We are proud to be at the forefront of a</font></div><div style="line-height:120%;text-align:justify;padding-left:240px;text-indent:192px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">paradigm shift in medicine toward cell therapy.</font></div><div style="line-height:120%;text-align:left;text-indent:336px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As more cellular therapies enter clinical trials and therapies start to become commercially available, scores of scientists, doctors and patients are awakening to a simple reality - cell therapies hold the potential to vanquish a plethora of diseases and dangerous medical conditions. NeoStem is dedicated to its leadership role in cellular therapy and we look forward to an amazing future built on the accomplishments of today.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have been extremely busy and productive at NeoStem as we continue to implement our Company's strategic growth and development plans, all the while never losing sight of our responsibility to the health and wellness of the public. Our pipeline of proprietary cell therapy products continues to develop and, most notably, we are on track to complete enrollment of our PreSERVE Phase 2 clinical trial this year, investigating the Company's most advanced product candidate, AMR-001, in preserving heart function after a severe heart attack, with data read out 6-8 months after the last patient is infused. PCT continues to strengthen its presence in the contract development and manufacturing arena. And lastly, our Company has undergone a positive corporate change by moving our stock listing to NASDAQ to make ourselves more competitive in the marketplace and more attractive to investors.  </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">I'd like to share details on some of our recent highlights and developments.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><br><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><a name="s99baecda2a5c4e6c9bbe03947076babd"></a><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#010000;font-weight:bold;">KEY MANAGEMENT ADDITIONS</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">NeoStem continues to attract some of the most experienced leaders in the industry</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">.</font><font style="font-family:inherit;font-size:10pt;">&#32;In the past two months we have added four new key members to our management team - each a seasoned executive in the field - raising the Company's profile in the industry, increasing our core knowledge and skill base, and increasing our competitiveness amongst our peers.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are excited to have these key individuals join our existing experienced management team to help prepare the Company for significant growth through our pursuit of strategic partnerships and M&amp;A. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">NeoStem continues to attract some of the&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Dr. Douglas Losordo, Chief Medical Officer</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">most experienced leaders in the industry.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:288px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In August, Dr. Douglas Losordo, a leader in cell therapy research and a</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">renowned cardiologist, joined NeoStem as Chief Medical Officer to assist the Company in its pursuit of promising cell therapies, including a product candidate using CD34+ cells to repair ischemic tissue. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dr. Losordo is well-regarded for his career-long efforts to develop novel therapeutics.  As a scientist he obtained over $35 million in National Institutes of Health funding for discovering and developing new therapeutic concepts in the laboratory, providing the basis for clinical studies. He led first-in-human studies in multiple gene therapies and adult stem cell therapies in patients with cardiovascular diseases, including therapies now in Phase 3 testing. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Most recently, Dr. Losordo held the position of Vice President, New Therapies Development, Regenerative Medicine and Baxter Ventures at Baxter International. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dr. Andrew L. Pecora, the Company's outgoing Chief Medical Officer, has assumed the role of Chief Visionary Officer of NeoStem, where he will continue to assist in building a leading global cell therapy company. Dr. Pecora will continue his roles within NeoStem's companies - as Chief Medical Officer of PCT and Chief Scientific Officer of Amorcyte - as well as remain a member of NeoStem's Board of Directors.</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#32;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Robert Dickey IV, Chief Financial Officer</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In August, we welcomed Robert Dickey IV as Chief Financial Officer.  Mr. Dickey is an industry veteran as well as a former investment banker.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Most recently, Mr. Dickey served as Senior Vice President of Hemispherx Biopharma, Inc., a publicly traded company involved in immune-modulatory therapies that is developing treatments for chronic fatigue syndrome and influenza. Prior to Hemispherx, Mr. Dickey was Senior Vice President, Chief Financial Officer and Business Unit Manager for Stemcyte, Inc., an umbilical cord stem cell therapeutics company. Previously, he spent 18 years as an investment banker, 14 of those at Lehman Brothers, with a background split between M&amp;A and capital market transactions across a variety of industries. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Stephen W. Potter, Executive Vice President</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In July, we appointed Stephen W. Potter as Executive Vice President of the Company.  Mr. Potter had previously served on our Board of Directors, and Nominating and Governance Committees.  He is a seasoned and successful senior executive with extensive management experience in the biotechnology and pharmaceutical industries, and will assist the Company with expansion plans and future partnership discussions. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We are excited to have these key&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">Most recently, Mr. Potter served as Senior Vice President of Operations and</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">individuals join our existing experienced&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">Corporate Development for Osiris Therapeutics, Inc. where he worked as a</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">management team to help prepare the &#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">member of the senior leadership that achieved approval of the first-ever stem cell</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Company for significant growth through &#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">drug therapy, Prochymal</font><font style="font-family:inherit;font-size:10pt;">&#174;. He was also responsible for the launch and overall </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">our pursuit of strategic partnerships and &#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">of the Bio-Surgery business unit and had operational oversight for multiple </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">M&amp;A.&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">functional areas including manufacturing, human resources, IT, legal, </font><font style="font-family:inherit;font-size:10pt;">and business</font></div><div style="line-height:120%;text-align:left;text-indent:240px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">development. Prior to his tenure at Osiris, Mr. Potter served as Senior Vice President of Corporate and Business Development at Genzyme Corporation. Over his ten years at Genzyme, he was the senior leader for its global corporate and business development team that provided strategic and transaction support, including support for many of Genyzme's cell therapy opportunities. Mr. Potter has also held positions at DuPont Pharmaceuticals, E.I. Dupont de Nemours and Company, Inc., and Booz Allen &amp; Hamilton. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><br><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><a name="s99baecda2a5c4e6c9bbe03947076babd"></a><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Robert Shaw, Vice President of Commercial Sales, PCT </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In August, Robert Shaw joined the PCT team as Vice President of Commercial Sales. He is tasked with bolstering the Company's top line revenue growth through strategic transactions and additional business lines, as well growing the existing client base through enhanced technical sales and marketing initiatives. Over the last two decades, Mr. Shaw has held several positions at EMD Millipore Corporation, a top tier supplier to the life science industry.  Most recently, he held the position of Commercial Director - Stem Cell Initiative where he was responsible for strategic and technical leadership, including all aspects of product marketing, product development and commercial management.  He previously held the position of Director of Strategic Marketing and World Wide Training Program Director for Vaccines and Emerging Biotech, where he had responsibility for management and development of vaccines and emerging biotech markets across the world, and the position of Program Director, Aseptic Processing, where he had global responsibility for a $300 million business. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CLINICAL AND DEVELOPMENT UPDATES</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">NeoStem continues to advance its research and development efforts.</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:10pt;">Our proprietary product development pipeline targets unmet medical needs in conditions such as cardiovascular disease (acute myocardial infarction, congestive heart failure, and traumatic brain injury), immune disorders (type 1 diabetes, steroid resistant asthma, and organ rejection) and tissue repair (periodontitis, wound healing, osteoporosis, macular degeneration, acute radiation syndrome, and other indications).  </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following are some of the important collaborations and developments in the Company's research and development.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Amorcyte</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are very excited and encouraged by the enrollment progress of the&#160;&#160;&#160;&#160; </font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">NeoStem is on track to complete patient enrollment</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">PreSERVE Phase 2 clinical trial, investigating the Company's most &#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">for the PreSERVE trial in 2013 with data read out</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">advanced product candidate, AMR-001, in preserving heart function &#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">6-8 months after the last patient is infused.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">after a severe heart attack. We have over infused 125 patients to date </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">and we are on track to complete patient enrollment for this trial in 2013 with data read out 6-8 months after the last patient is infused.</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#32;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Amorcyte intellectual property portfolio continues to grow and AMR-001 now has the benefit of 4 granted U.S patents, 8 patent grants outside of the U.S. and 24 additional patents pending around the world.  We are beginning the process of expanding applications for AMR-001 into other ischemic conditions such as congestive heart failure and traumatic brain injury. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Athelos </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Human Regulatory T cells (&#8220;Treg&#8221;) therapy represents a novel approach for restoring immune balance by enhancing T-regulatory cell number and function. NeoStem continues to advance its T cell program with the goal of developing treatments for immune-mediated diseases such as type 1 diabetes, and inflammatory conditions such as steroid resistant asthma. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">NeoStem holds exclusive rights to over 20 issued patents and 6 patents pending related primarily to methods of isolating, purifying and expanding Tregs.  </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Collaboration with UCSF and the Laboratories of Drs. Bluestone and Tang</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In July, the Company executed agreements with the University of California, San Francisco (&#8220;UCSF&#8221;) and the laboratories of Jeffrey Bluestone, PhD, and Qizhi Tang, PhD, to collaborate on the development of a therapy for the treatment of type 1 diabetes. This collaboration will advance the Company's Treg program towards a Phase 2 trial to evaluate the efficacy of autologous Tregs in type 1 diabetes, effectively advancing the Company's pipeline more quickly than if it had developed a program for this clinical indication on its own. Under the agreements, NeoStem will manufacture a Treg product consisting of polyclonally expanded Tregs for the planned Phase 2 trial to treat patients newly diagnosed with type 1 diabetes and will also collaborate with Dr. Bluestone on allo-specific Tregs for organ transplant tolerance in another anticipated clinical study. The collaboration also includes the research effort to develop the next generation of Treg products for therapeutic use. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Advisory Group of Experts Formed for Steroid Resistant Asthma Study</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In August, we engaged the services of three experts at the forefront of asthma research to serve as consultant advisors to the Company's Regulatory T cell program.  William Busse, M.D., of the University of Wisconsin; Mario Castro, M.D., M.P.H, of the Washington University in St Louis; and Prescott Woodruff, M.D., M.P.H., of the University of California, San Francisco will be </font></div><br><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><a name="s99baecda2a5c4e6c9bbe03947076babd"></a><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">advising and providing support in the area of asthma research.  Initially, the group will be assisting NeoStem in designing a protocol for a Phase 1b/2a study on the use of human Regulatory T cells for the treatment of steroid resistant asthma.  </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Each of the consultants brings a breadth of experience in research to assist the Company in determining the appropriate clinical endpoints for a clinical trial in steroid resistant asthma. We are fortunate to have some of the brightest minds in asthma research advising our team to help our own experienced NeoStem scientists create a robust protocol for this clinical trial.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">NeoStem is taking advantage of the dramatic growth in</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;&#160;&#160;&#160;VSEL&#8482; Technology </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">cell therapy industry both for our clients and for our</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">internal pipeline.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;We continue to develop our very small embryonic like stem cell</font></div><div style="line-height:120%;text-align:justify;text-indent:336px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(VSEL</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">TM</sup></font><font style="font-family:inherit;font-size:10pt;">) technology platform in pre-clinical models and expect</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">soon to advance into early clinical studies that assess the therapeutic potential of VSEL</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">TM </sup></font><font style="font-family:inherit;font-size:10pt;">Technology in wound care, bone regeneration and/or macular restoration. NeoStem also continues to receive grant awards to develop this important technology, including a recent award of funds from the National Institute of Allergy and Infectious Diseases (NIAID) supporting the development of VSEL</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">TM</sup></font><font style="font-family:inherit;font-size:10pt;">&#32;Technology for radiation exposure.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Recent pre-clinical data in animal models suggest that VSELs&#8482; may be capable of developing into cells of all three germ layers which, if substantiated by further research, could imply significant potential for restorative healing. Independent investigators in preclinical models have demonstrated the regenerative potential of VSELs&#8482; and we will continue to support preclinical and early clinical studies to further assess the regenerative potential of VSEL&#8482; Technology.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#010000;font-weight:bold;">PROGENITOR CELL THERAPY</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">NeoStem is taking advantage of the dramatic growth in the cell therapy industry both for our clients and for our internal pipeline by vertically integrating the collection, storage and processing of cellular material and by developing, manufacturing, distributing, and delivering cell therapy products.  </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">PCT has built&#160; a strong foundation of services that cater to the entire industry and offers NeoStem, and PCT's clients, cell processing and development capabilities on both the East and West Coasts of the U.S.  PCT is also pursuing plans to expand internationally. PCT currently provides services to over 35 clients and is the only contract development and manufacturing organization (&#8220;CDMO&#8221;) to have worked with a client's product (Provenge&#174;) through all of the phases of clinical trials and ultimately to FDA approval. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">PCT completed three process development contracts in Q2 2013, triggering higher revenue recognition. PCT also recently signed two new clients, including a large pharmaceutical company that is entering the cell therapy sector. PCT's management team is focused on growing the CDMO business through increased services and product offerings, including automation technologies geared toward improving efficiencies and lowering cost of goods.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">PCT's business model uniquely positions NeoStem to take advantage of revenues generated in a growing industry, while reducing our reliance on the success of NeoStem's internal development platforms. This unique revenue-generating CDMO business allows NeoStem to remain up-to-date on the most innovative developments in the sector, informing our decisions as we seek to co-develop and/or acquire new technologies.&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:384px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:384px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">NeoStem moved its exchange listing to the NASDAQ</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">EXCHANGE LISTING MOVED TO NASDAQ&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Capital Market from NYSE MKT effective with the </font></div><div style="line-height:120%;text-align:justify;text-indent:384px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">start of trading on August 5, 2013.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">NeoStem moved its exchange listing to the NASDAQ Capital Market from NYSE MKT effective with the start of trading on August 5, 2013, continuing to trade under the symbol NBS. The move is intended to enhance exposure to institutional shareholders, while at the same time providing investors with the best prices, the fastest execution and lowest cost per trade. We are proud to be joining fellow cell therapy industry companies on the NASDAQ, such as Celgene Corporation, Harvard Bioscience Inc., Osiris Therapeutics, Inc., Mesoblast Limited, Stemline Therapeutics, Inc., Verastem, Inc. and Shire PLC.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><br><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><a name="s99baecda2a5c4e6c9bbe03947076babd"></a><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As the regenerative medicine market continues to grow, NeoStem is uniquely positioned to capture the value of this market and lead the industry.  We appreciate your continued confidence in the Company's agenda and will continue to provide updates on our progress as we work to save lives and end suffering for the millions of people afflicted with chronic disease.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">To learn more, please visit </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">neostem.com</font><font style="font-family:inherit;font-size:10pt;color:#0000ff;">.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Regards,</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;"><img src="robin.jpg" style="height:57px;width:100px;"></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Robin L Smith, M.D., MBA</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Chairman and Chief Executive Officer</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><br><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>neostemlogohiresa01.jpg
<TEXT>
begin 644 neostemlogohiresa01.jpg
M_]C_X``02D9)1@`!`0$!+`$L``#_X2`&17AI9@``34T`*@````@`#0$```,`
M```!!ML```$!``,````!`O(```$"``,````#```(M@$&``,````!``(```$2
M``,````!``$```$5``,````!``,```$:``4````!```(O`$;``4````!```(
MQ`$H``,````!``(```$Q``(````R```(S`$R``(````4```(_H=I``0````!
M```)$NH<``<```@,````J@``$8(<Z@````@`````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M```````````````(``@`"``MQL```"<0`"W&P```)Q!-:6-R;W-O9G0@5VEN
M9&]W<R!,:79E(%!H;W1O($=A;&QE<GDQ-"XP+C@Q,3<N-#$V`#(P,3(Z,#(Z
M,C$@,3,Z,#<Z,#````60```'````!#`R,C&@`@`$`````0``!#Z@`P`$````
M`0```7>D(``"````(0``$6#J'``'```(#```"50`````'.H````(````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M```````````````````````````````Q.31"-S@S.3-!.4$T1#8P.3DR,3-!
M,3-%03%&-#-".`````8!`P`#`````0`&```!&@`%`````0``$=`!&P`%````
M`0``$=@!*``#`````0`"```"`0`$`````0``$>`"`@`$`````0``#AX`````
M````2`````$```!(`````?_8_]L`0P`(!@8'!@4(!P<'"0D("@P4#0P+"PP9
M$A,/%!T:'QX=&AP<("0N)R`B+",<'"@W*2PP,30T-!\G.3TX,CPN,S0R_]L`
M0P$)"0D,"PP8#0T8,B$<(3(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R_\``$0@`-@"@`P$A``(1`0,1`?_$`!\`
M``$%`0$!`0$!```````````!`@,$!08'"`D*"__$`+40``(!`P,"!`,%!00$
M```!?0$"`P`$$042(3%!!A-180<B<10R@9&A""-"L<$54M'P)#-B<H()"A87
M&!D:)28G*"DJ-#4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W
M>'EZ@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(
MR<K2T]35UM?8V=KAXN/DY>;GZ.GJ\?+S]/7V]_CY^O_$`!\!``,!`0$!`0$!
M`0$````````!`@,$!08'"`D*"__$`+41``(!`@0$`P0'!00$``$"=P`!`@,1
M!`4A,08205$'87$3(C*!"!1"D:&QP0DC,U+P%6)RT0H6)#3A)?$7&!D:)B<H
M*2HU-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS='5V=WAY>H*#A(6&
MAXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3U-76
MU]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_:``P#`0`"$0,1`#\`]_HH`**`"B@`
MHH`*Y'QIXNN=!ADATZ&W-Q'$)[BZO2RVUI&Q*HS[06=F92H1`3U)P.M0CS.P
M:;L\@N/C'XBMYOMMGJWVQW^]876E1Q01Y'\+I*9#@],GZU[YH&J?VYX?T_5?
M),/VRW2?RB<[-R@XS@9QGK@9K?$4/9),4:D)KW31HKF&%%`!10`44`%%`!10
M`44`%?)7CKQ;>^,]=N+B>YE.GI(PL[?E5CC!.TE<D;R.2>3DXZ``=N"IJ<FW
MT,ZE5T[.)V7PK\67OAW4],TFXN?/\/:O,\%KYC$O:7`P3'C'<NG3Y3Y@;*G>
MM>S>+?"EAXPT-],OBZ#>)8I8S\T;@$`C/!X)!![$]#@C*I^ZJW1K.TXW[GGF
ME?`.PM[])=4UJ6]MEP3!%!Y.\@@X+;F.",@XP>>"*]<@@AM;>*WMXDBAB0)'
M&BA510,``#H`**^(=9K2R1E3IJ!)17.:!10`44`%%`!10`44`%%`!7RIXQ\!
MZMX9UZYMX]/N9=/:7_1+A$,BLC$[%+`??XP0<'(ST()[<%449-/J85XMJZ.Y
M\.^$=5L_#OA/3;JW$6H3>(TU?R&!WQ6T<8WE^/E.0@P>[H#@G`]RK'$24IMH
MV@K0285P/Q,T/QCK%K:'PMJ3VZ0[FF@AN#!+(W`7#C&0`6R"0/J<8BDXJ:<]
M@E>VFYO^#M.U73?#EG#K5R\M\(@LRF9I@&W,<[WRQ8@C/)4$?*`*WZF5N9VV
M!7MJ%%2,**`"B@#Q7XL>/_$_A3QQ8VFBW86U^Q)<R6S0(ZR$/)NR<;@-JC."
M,`=NM>C^"O&-AXVT!-2LU:*13Y=Q;N<M#)CD9[CN#W'H<@;2II04D:2A:*:+
M'C#4+G2?!NL:A9N([JWM))(G*@[6"G!P>#CWXK%^%7B'4O$W@:#4-6G$]WYT
MD;2A%3<`W&0H`[XX`Z5'*N2_F39<MSM:*@D,XK"/C7PH"0?$VC`C@@W\7'_C
MU-1;V0TF]C0E:PL8KK5I&C1/*\R:X)S^[0$CG^Z`6.!QR3W->:Z%KWC+XC7U
M[?:-JD6@:';L88F-LEQ)*_!^8-TX.3@@#(`W<D;4HQY7.:ND93;NHH=K=]\1
M_!-W:W9NE\4:=*5CD1;(1.C%AQB/)&1P&^89/(SC/9^+O%]IX0\-G5KN&5V<
MB."W'#/*5)"D\A1P<GM@XR<`U*G";C[/2_3L)2<;\W0U-$U`ZOH.G:D8Q$;N
MVCG,8;.W>H;&>^,U>KG:L[&B=T%%(844`%%`'B_C8;OVA_"8_P"G:(_^1)JI
M>)M(UCX1^*Y/%?AV$2^';MP+RS482/)^Z0/NC).QP/E)VD8.'Z4]HOJC>^T7
MU1Z%XJU>SUWX2:OJFGS"6UN=-D=&'^Z<@^A!R".Q!%<A\-_$,/A7X'7&M3Q-
M*MK-*1&IQO8N%49[`L0,]NM0HODY?,A+W;>95T:W\/>*M,75O'OC.WN+R\_?
M#2QJJPP6BD#8!&&R&"@$_7D$@DXWA[Q?_P`(O\2[+0O#VO76O^'KUX;;R[IV
M8P,S;<HQ4#Y2=WRC:0<'D9%V;O&VA=KW5M!_QE\:7-_K<_AFW<?V;:A1<*K$
M>=+PW)4\A>!M_O9)R0N,WPHW@WQC<0Z#KVA6VFWL@$5I?Z<[0Y/&%922I<D'
MYB#G(&`>O4J#C14H[[G%'$RC.W0UO"5QJ'@GQM<?#?Q#+]KT/45:&%Y-R+B0
M':4]`Y)0J#@,3@\',EI8>./A#>7$EK:_VOH4AWR^6&*!5Y+D#F)MJ\GE>1G=
M@8R@X-N$M%+\S7$)\RG$[KPM\7O#WB2XALIO-TZ_EVJL5QRCN0?E5QQVQ\P7
M)(`!/%8/QVTZ&+PW:WZR71EEU"-&1KF1H@/*D^[&6V*>!R`#U]3F:=.5&NHL
MRE)3IMHUK6XM?!OPKM/$D;WLMRNE0>7%->2RQ>8ZH%_=L^T*&(^[C"YQ6!I%
MGX=\2:1'J7CCQK;WU[<J)?L8U-8HK7*C`$8(PX'7CKQ@XR6N;6<5=WML+32+
M>AE>$O%D^A?$BWT+2]=NM?T"[=8(UD#N\0Y`(W8QL/WBORE<G&<!=#Q!<ZEX
MA^-[>%+C6=1M](=0GDVD_E?+]G\T@X&#EO4$X./2M'!*;FUKRWMYD\S<;7ZF
MCXY\&VG@KPW+XA\*7E[I%S9R1M)'%<.Z7`+JN'#,>A(/<$9!!SD.\&>$+;QU
MX4@USQ1J&I:G<7C2LL<ERRQ0$2,N45<`9VY].F`*S]J_9>TLN:]KE<GO<O0S
M/"=[JGA/XO3>"UU2YOM,D4QQ"Z<MY0$)F0@=B!\IQ@'.<<`#TGPI8:O8OJ_]
MJ3W$JSZA+/;">7S-D38VJ.3M`P>!QSP!S48CEO>VZ3*IWV['G?C3_DXCPG_U
MZQ?^AS5[%<VT-Y:RVUS$DL$J%)(W7*LI&"".XK*IM'T.F?0^=?$NEZS\*O[9
MTM&ENO"NMP2Q0MU$4I4[0?[KC&">CJ,\E<+I:+9W%]^S-JL5LF]UE:8C('R)
M*CN>?15)_"MFURJ7=HTNK*7F=;\*!X0\0>%-/EBT?1UUBRB6*Y`MXS,K+\HD
M)*@G<`&SSR2,D@UU7B;QKI_AS4-,TL1M=ZIJ-Q'%#9Q,`P1FVF1O11SC/4C'
M`!(PE&3FTS*2;E9G@_Q;T"71?'=Y<"%EM-0/VF%^2&8X\P9Z9#9..P9?6N&5
MFC=71BKJ<JP."#ZBO:HRYJ<7Y'FS5I,]C\;(=2^,VCW;*<Z)I<>HZBL!#M$(
M6>8IC(Y.4`_ZZ`]*])\#>.['QQITTT$#6MU;MMFMG<,5!^ZP/&0>>PY!]B?)
ME3;I\RZ'?.>L8^1R/QK\.Z(OAEM:,,-MJ@N$1)43#7!/!5L=?E!;)Y^3'>L#
MQU/J-U\"_"\^JG-V]W&2Q;<73RYO+8G)R2FTGW)KHHR<HPYNC.>:LY6['0^+
M=-EU'X`Z885D9[6PL[C8@SE0BAL^P4EC]*TOABOA+6_#%A<6>EZ;_:=C#'#=
M,;6,3+(%QO)QGYL$AN_/<$#.3E[)N+V;*27.K]CH]<\76.CZMIND1H;S4[^X
M2);6$Y:.,D;I7QG:JKD^^/0$CS0_\G0C_/\`RY4J,'%2;ZQ83=VO4[?XN_\`
M)+]8_P"V'_HZ.D^$7_)+]'_[;_\`H^2H_P"8?_M[]"O^7GR.';_DZ%/K_P"V
M5>WT8C['H@I]?4YG4O`^F:IXUT_Q5<377VVQB$<42NHB(!<@D;<YRY[CH/?/
M35@Y-VN:MME#6=&L=?TFXTS4H!-:SKM="<>X(/8@X(-5/"OA>P\(:#%I&GO.
M\$;,^^=@SL6.23@`>W`'2CF=N4+NUCC]8^!O@[5;YKJ-+S3]^2T-G*JQDDDY
M"LK;>N,#```P*U_"7PO\->#;G[78P2W%Z,A+J[<.Z`C!"X`4=^0,\D9P<5HZ
MTG&Q3J2:L=!KN@:9XETQM/U6U6XMV8.`2058=&4CD'KT[$CH2*X>S^"'AJQN
MX[A+G49F3E1.\;*&QPV-@!(.#ALJ<8((.*JGB)TXN*V,94XR=V=MHOAW3M!6
MX-G$3<73![JZE;=+</\`WG;\3P,`9.`*YB\^$GAV75EU/3I=0T:Y7)!TR<1`
M$Y!(R#MX)&%P,=JFG6E!MKJ.<5/<=#\*M$;4HK[5KW5M;DA`$::I=>:JX(/0
M`9''0Y!R<@UU.MZ)8>(=)FTS4H?-M9<;E#%2"#D$$<@Y%.=:4FGM;82@DFNY
MS_ASX=VGABZMI++7==DM[?=LLIKP&W.X'.8PH'5B?KS65JOP3\):I?/<HMY8
MB3EH;211'DDDD!E;'7H,`8&`*I8J<9.22U$Z2:L;GA/X>Z!X.+R:?#)+<OP;
MFY8/(%_NC```^@&>^<"C_A`M+_X3W_A,#<7AU#_GEO7RA^Z\KIMS]WWZU+KS
M<G)]58:II)(U?$F@6OB?0+G1[V2:.WN-F]H"`XVL&&"01U4=J/#F@6OAC0;;
M1[*2:2WM]VQIB"YW,6.2`!U8]JCG?)R=+W'RJ_,9/_"`:7_PGO\`PF'VB\_M
M`'/E;U\K_5>5TV[ON\]>OY5U=$YN=K]%8:BEL?_9_^T9K%!H;W1O<VAO<"`S
M+C``.$))300$``````!('`%:``,;)4<<`@```@``'`)!`#%-:6-R;W-O9G0@
M5VEN9&]W<R!,:79E(%!H;W1O($=A;&QE<GDQ-"XP+C@Q,3<N-#$V````.$))
M300E```````0%=%$!<3C]?'Q5HQ"_.(K`#A"24T$.@``````JP```!`````!
M```````+<')I;G1/=71P=70````$`````%!S=%-B;V]L`0````!);G1E96YU
M;0````!);G1E`````$-L<FT````/<')I;G13:7AT965N0FET8F]O;``````+
M<')I;G1E<DYA;65415A4````&P!#`&$`;@!O`&X`(`!I`%(`(`!#`#,`,``X
M`#``+P!#`#,`-``X`#``+P!#`#,`-0`X`#`````X0DE-!#L``````;(````0
M`````0``````$G!R:6YT3W5T<'5T3W!T:6]N<P```!(`````0W!T;F)O;VP`
M`````$-L8G)B;V]L``````!29W--8F]O;```````0W)N0V)O;VP``````$-N
M=$-B;V]L``````!,8FQS8F]O;```````3F=T=F)O;VP``````$5M;$1B;V]L
M``````!);G1R8F]O;```````0F-K9T]B:F,````!````````4D="0P````,`
M````4F0@(&1O=6)`;^````````````!'<FX@9&]U8D!OX````````````$)L
M("!D;W5B0&_@````````````0G)D5%5N=$8C4FQT````````````````0FQD
M(%5N=$8C4FQT````````````````4G-L=%5N=$8C4'AL0'+````````````*
M=F5C=&]R1&%T86)O;VP!`````%!G4'-E;G5M`````%!G4',`````4&=00P``
M``!,969T56YT1B-2;'0```````````````!4;W`@56YT1B-2;'0`````````
M``````!38VP@56YT1B-0<F-`60```````#A"24T#[0``````$`$L`````0`!
M`2P````!``$X0DE-!"8```````X`````````````/X```#A"24T#\@``````
M"@``________```X0DE-!`T```````0````>.$))3009```````$````'CA"
M24T#\P``````"0```````````0`X0DE-)Q````````H``0`````````".$))
M30/U``````!(`"]F9@`!`&QF9@`&```````!`"]F9@`!`*&9F@`&```````!
M`#(````!`%H````&```````!`#4````!`"T````&```````!.$))30/X````
M``!P``#_____________________________`^@`````________________
M_____________P/H`````/____________________________\#Z`````#_
M____________________________`^@``#A"24T$"```````$`````$```)`
M```"0``````X0DE-!!X```````0`````.$))300:``````-;````!@``````
M```````"`P``!+`````3`$X`90!O`%,`=`!E`&T`(`!L`&\`9P!O`"``:`!I
M`"T`<@!E`',````!``````````````````````````$`````````````!+``
M``(#``````````````````````$`````````````````````````$`````$`
M``````!N=6QL`````@````9B;W5N9'-/8FIC`````0```````%)C=#$````$
M`````%1O<"!L;VYG``````````!,969T;&]N9P``````````0G1O;6QO;F<`
M``(#`````%)G:'1L;VYG```$L`````9S;&EC97-6;$QS`````4]B:F,````!
M```````%<VQI8V4````2````!W-L:6-E241L;VYG``````````=G<F]U<$E$
M;&]N9P`````````&;W)I9VEN96YU;0````Q%4VQI8V5/<FEG:6X````-875T
M;T=E;F5R871E9`````!4>7!E96YU;0````I%4VQI8V54>7!E`````$EM9R``
M```&8F]U;F1S3V)J8P````$```````!28W0Q````!`````!4;W`@;&]N9P``
M````````3&5F=&QO;F<``````````$)T;VUL;VYG```"`P````!29VAT;&]N
M9P``!+`````#=7)L5$585`````$```````!N=6QL5$585`````$```````!-
M<V=E5$585`````$```````9A;'1486=415A4`````0``````#F-E;&Q497AT
M27-(5$U,8F]O;`$````(8V5L;%1E>'1415A4`````0``````"6AO<GI!;&EG
M;F5N=6T````/15-L:6-E2&]R>D%L:6=N````!V1E9F%U;'0````)=F5R=$%L
M:6=N96YU;0````]%4VQI8V5697)T06QI9VX````'9&5F875L=`````MB9T-O
M;&]R5'EP965N=6T````115-L:6-E0D=#;VQO<E1Y<&4`````3F]N90````ET
M;W!/=71S971L;VYG``````````IL969T3W5T<V5T;&]N9P`````````,8F]T
M=&]M3W5T<V5T;&]N9P`````````+<FEG:'1/=71S971L;VYG```````X0DE-
M!"@```````P````"/_`````````X0DE-!!0```````0````".$))300,````
M`!$/`````0```*````!%```!X```@6```!#S`!@``?_8_^T`#$%D;V)E7T--
M``'_[@`.061O8F4`9(`````!_]L`A``,"`@("0@,"0D,$0L*"Q$5#PP,#Q48
M$Q,5$Q,8$0P,#`P,#!$,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,`0T+
M"PT.#1`.#A`4#@X.%!0.#@X.%!$,#`P,#!$1#`P,#`P,$0P,#`P,#`P,#`P,
M#`P,#`P,#`P,#`P,#`P,#`S_P``1"`!%`*`#`2(``A$!`Q$!_]T`!``*_\0!
M/P```04!`0$!`0$``````````P`!`@0%!@<("0H+`0`!!0$!`0$!`0``````
M```!``(#!`4&!P@)"@L0``$$`0,"!`(%!P8(!0,,,P$``A$#!"$2,05!46$3
M(G&!,@84D:&Q0B,D%5+!8C,T<H+10P<EDE/PX?%C<S46HK*#)D235&1%PJ-T
M-A?25>)E\K.$P]-UX_-&)Y2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V-T=7
M9W>'EZ>WQ]?G]Q$``@(!`@0$`P0%!@<'!@4U`0`"$0,A,1($05%A<2(3!3*!
MD12AL4(CP5+1\#,D8N%R@I)#4Q5C<S3Q)086HK*#!R8UPM)$DU2C%V1%539T
M9>+RLX3#TW7C\T:4I(6TE<34Y/2EM<75Y?569G:&EJ:VQM;F]B<W1U=G=X>7
MI[?'_]H`#`,!``(1`Q$`/P#U5))))2DDDDE*22224I))5^H9V-T["OS\M_IX
M^,QUECO)HGV_O/=^8Q)3827EQ_QM=:LSW.QNETV8+`Y_V?>[[06,&ZQ_JM_1
M;FL'JO8S'M].O\__``J[W$S\;ZR=`&5TS(?35G5.:RYOMMJ)FJV-?9DT.W_R
M/5_TC$Z6.4:XA5J%$6#8\$/4/KE]6NG9+L3)S6G(KGU*J667N9!B+OLE=_HN
M_DVJYTGK72NM8WVKI>2S)I!VN+9!:X?FV5O#;:G?\8Q>5_6GH/UKQNHOP,+"
MR!TBDAO3J<!KW4"H?1?:*3N^VO=N^UWYGZ>VW_">CZ2Z[_%O]5^J=%JS,[J@
M]*_/],#&)W.:VKU(LO>USF>K9ZWT/\&S^7[*Y)8HQQB7&"3^BM$K-4=.KVB2
M22A7*22224I))))2DDDDE/\`_]#U5))8/UQ^M3?JOTZG-=C'+-UPH%8>*XEE
MEN_>6V?Z+]U$`DT%`7H[R2R/JQ]9<#ZR=,;G8DUO:=F1CN(+ZK!^8Z/I,=].
MJS_",_[;5[J>:WI_3<O/<PV-Q*;+RP&"X5M=;L!_E;4J-TJNC926)]4?K*WZ
MS=)_:0QSB1:^HU%XLU9M]P>&U_O_`+BVT"*T*E+G?\8.'DYGU0ZA5C-+[&BN
MTL')9597?;_X%6]RZ))&,N&0EV-J(L4_.>(_*9EXUN#)RVW5NQ=HW$V[V^AM
M'YVZS:O8?J-A#I^5]8<&@!N#3U)SL=K0`UILKJMLI9'YM+75,6I1]4_J[BY[
MNIXF!13G&2VT-T:X_GLIW"IC_P"75Z;U4ZIU;HGU)Z2'6[[+,BU[VUMVF_)R
M+#ZN1>_^;9N<]V^ZSV4U?HZ:6?T?'4^;+[IB(Q-K(1X`;.[T2H]:ZA;TSI63
MGTXMF;9CLWMQJOIO,Q_*]K?IV>U_Z/\`P=BY^_ZU_6_&PSU"_P"J[FXK6[WM
M;EL=<UG.]V.VG?\`1_P?\XS\];/U<^LG3?K'@'-P"X!CO3NIL`#V.C=#MI<Q
MS7L=OKLK?Z:B,)`618O6C?\`T5UAR/J;]=<CZRV7-.&*FT$"Q['.(;N!->KZ
MVLL^AM=[Z[O^Z_I;[*NL5+IG6>F]6;>_IU[<FO&M-%EC-6;PUMCA6_Z-C=MC
M?>SV*ZA.N(U'A_JI&W=2222:I22222E))))*?__1]57G_P#CGT^K>&1_W,'_
M`)YR5Z`O/_\`'1_XF\3_`,.#_P`\Y*=#YAYI&X:/6<#-^HW4J?K3T.N>D988
MWJF"W^;;NCZ/^AK>]WZM9_VER?T/]&R/078]8ZCA]4^I74>H85@MQLCI^0^M
MX_XJP.:[]VRMWLL9_@[%JU4U7]/91>QMM-M(996\!S7-<W:]CVN]KFN:O+NK
MXV=]0W]2Z>UMEWU:Z[1?5CN'N]#(LJ>RMKMQ_G&_1?\`]R<7]+^ENQ;*T1ZB
M.X_%(U/BZW^+GJN)T;_%_E=3S"1CXM]SWANKB8J:RMD[?TEMCFUL6C@,^O?7
M\*OJQZK5T&G);ZN-A58U>212[WT69.1DN'Z5]?\`H]G_`%I_Z&OD>GT77?XG
MNH"D$FO+]1[0"?8RS'=8=/S:V_I7_P!1=/\`57ZL?4KKO1L+JAQ1F9`J97D>
MM==;LN8UK;Z7577/8S:[Z#?3_FO3]/\`1HR&I/BH]6?U0^N'4[^M9/U7^L)I
M?U+&!-.5CD>G<&AKW"&>WU/2?Z[-C*_T>^NVFFZGW\Q]8?\`&!=U+J-]%=N5
M5TBMY93^S[FXUM@:2PY-F393?8]EO^"QV?9Z_3V>JN[#/JKTSK-'1<#!IHZE
MFTV^_$IK:ZJIK=SK,JUFRRJNUWZ.K_2W+Q2_$R,&^S"R6[,C%>:;6^#F'8?[
M/YS%-R^.$S+B'0:,661C1CI;UYQ.I]/Z9_SI^IO6<S*P:"3FX66XOMJ('Z7[
M32/U>]K&/W6_HOT57ZQ1?9_.*_UW)ZC]:^D=&^MG1J3;E=+L<,O#:#8:[FNI
MNWLI'NNJ]2BMVQGZ;[/?5_PBS?\`%AF>AUW+HN(^Q9&'8[+#HV`4EA;;;/YK
M&6W5_P#75>_Q;?6'IOU>Z/CXO5'OI_;.59;BOB:F5M%6$+LBR?T+;,FFRG^Q
MZEOIT_I$I1./)Z1Q$;>,3ND2$X6='HNB?XT/JYU$-JS7'IF5.US;]:MW\G*;
M[&?^A/V9;.5TG9TWT_J[=1TAMC_7LMIQZ[66-+3O_1356YUOZ/\`3?R$NN?5
M/H/76.^WXS?7(AN77#+VZ;6[;F^YVS_1V^I3_P`&N1_Q9WYN/D=;Z$;CDX'3
MW.%-@^@U_J7TO-/TME>7Z7K^EO\`3W^IL_G+%'43$SA<>&N*$O5%6NQZ]0U_
M\5N'U>[I3\C"ZDW"PZLP'(Q3CLM-@;7C/L_67O8^GU*?T/T/T?\`.K<P.J_6
M7ZW.ORNBY;.C=&IL-6-DNH%]^06_3L%>1MJJQ_W?9ZG_`*+R_P#%A1;D_4KJ
MV/3I;=;;77V]SL;':S7^L56_Q==%^K'7NC?9NI4.NS\&QPLH?=<&[''?78W%
M;:RAK=VZFS]%_/5?I%)DKBR2/Z)`^6,JOK7Z2!L!W'=TZOK/U_ZO_6;&Z%]8
M,FGJ>)GEK:,ZMC:;6.>[T:_6IJ_1>V[V6L_<M]?UOYRE2ZM]8OK+G?71WU5Z
M/=3TZNIK769CJQ=9'I,R+'[+3Z7^%KJKJV?\)ZRUL[$^IGU:&+:>FXS,BZ^N
MK#9316[(?:YS6,-)=^D_1;O4<_?[/^,]-<_B?_EDS/\`B/\`W7Q4V/#*Y<.T
M"=1Z3*/Z7"HV*%[EL?6+JOUM^IM='4<GJ-?6\&ZPTVT74,QWM<6.MK=7;B#\
M[TK/IL_\^?HKE?3_`/&!G=/;U!O7J<7*OK%U>#7B5NI:7#>RC[3=ZU_]>W])
M_P!=53_'%_XE\?\`\.,_\\Y2[#I7_)>'_P`15_U#4":QQE4>(D@^D?H^"?TB
M-7D_JO\`7/JW6OJ];D&ECNH8MS:;7M:=A:YGJ5W.9N_1/<_]#;_@*?Z1_,_H
MUU^#==?B56WL].UXES8+>_M=Z=GZ2K>WW^E9^DJ_FWK@O\37]`ZI_P`?7_U"
M]%3<X$9RB!5%4+(!/9__TO55C?6GZK8/UGP*\'-MMIKJM%S74EH=(:^K:?49
M:W;MM5[JF:[I_3[\X5&]N*PVV5M,.-;/??Z>AW6MI]1]5?\`A;/T7JU?SJSL
MCZQ9&-EX6)?B-9=E"DOK-WOFZST',PFBK;G_`&#^D=2]]'V;%V7_`*5$`[A(
MMVJV"NMM;>&`-$\P!"K=4Z9A]6P+NGYS/4Q\ANU[>X_.:]A_-LK?[ZW+-=]9
MQMSPS&WV]-IRKKJ@_P!P./8^O%KM'IEU/[1HK^U8^[_`_P`WZ_\`.*U3UEUG
M0K.KG&=OJKNL.*PESR:#8TU-W,KL]5_I?S5M-5]3_P!%?35=OK2HJHHOJ]]6
M.G]`Z4_I5#GY.-:][[!D;7%WJ`->QS6,KK]/:W]Q8%G^*W"Q\I^1T/JF=T<6
M_P`Y7CV';M'#&N!KNV_\;;<MO_G&19TFO;C6?M1UC3?3D[Z&^F6MC'O]%GVJ
MRS?[:]E7Z13=]9L5F&_*?Z;11G'!R0;0/2B]V&V^]VW]%OK#,GT[/S+?YS_"
M(^K[5:L/JW]3^D_5TW78WJ9&;D_TC-R7;[GZ[MN^&M:S=[O;_.?X7U-BK_6;
MZA]&^L-OVJPOQ,Z`TY-,>\#1@R*WAS+=G[W\[_PNQ:=/5_4ZYD=)=6UIIJ%K
M'BP/<X'9OWU5M/V;9ZS/Z1979=].BNROU/3LT9GK963C>A=7]E+!ZUC-M=F]
MOJ3C63^E]/\`F[?W+$A*43Q`T4$7OJ\QTS_%MTO`QK,8Y-UK<H!F;8(KLMK!
MG[$+J_=CX-O_`&JJH_6,G_"97H_H5K]<^J?1.N=/JP,N@5UXPVXKZ(K=2(]/
M91#=C:MC=GH;/0^A^C_1UH%GUFR*\+(R;<-M'V?)&&777;:0_=LNR+<AM3O1
MP&[F>C>^OU;7_P`YCXR<?6D;>G[L4UV=2KQ[*:GOAQ-UM5&176W9^E^Q47?;
M+?\`@/YST?YQ$G(9<5^KNKATJM'/K^HW5*\<8+?K+GCIX&T4C8+`P?X-N7'J
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MTL;6TNY(:-HW1"RZ^O6NZQB],?B&L9.,R]UKG$;'O%[_`+-M?4QC[&?9?H>M
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MJ22G_]D`.$))300A``````!5`````0$````/`$$`9`!O`&(`90`@`%``:`!O
M`'0`;P!S`&@`;P!P````$P!!`&0`;P!B`&4`(`!0`&@`;P!T`&\`<P!H`&\`
M<``@`$,`4P`U`````0`X0DE-!`8```````<`"`````$!`/_A#XEH='1P.B\O
M;G,N861O8F4N8V]M+WAA<"\Q+C`O`#P_>'!A8VME="!B96=I;CTB[[N_(B!I
M9#TB5S5-,$UP0V5H:4AZ<F53>DY48WIK8SED(C\^#0H\>#IX;7!M971A('AM
M;&YS.G@](F%D;V)E.FYS.FUE=&$O(B!X.GAM<'1K/2)!9&]B92!835`@0V]R
M92`U+C`M8S`V,"`V,2XQ,S0W-S<L(#(P,3`O,#(O,3(M,3<Z,S(Z,#`@("`@
M("`@("(^#0H)/')D9CI21$8@>&UL;G,Z<F1F/2)H='1P.B\O=W=W+G<S+F]R
M9R\Q.3DY+S`R+S(R+7)D9BUS>6YT87@M;G,C(CX-"@D)/')D9CI$97-C<FEP
M=&EO;B!R9&8Z86)O=70](B(@>&UL;G,Z>&UP/2)H='1P.B\O;G,N861O8F4N
M8V]M+WAA<"\Q+C`O(B!X;6QN<SID8STB:'1T<#HO+W!U<FPN;W)G+V1C+V5L
M96UE;G1S+S$N,2\B('AM;&YS.GAM<$U-/2)H='1P.B\O;G,N861O8F4N8V]M
M+WAA<"\Q+C`O;6TO(B!X;6QN<SIS=$5V=#TB:'1T<#HO+VYS+F%D;V)E+F-O
M;2]X87`O,2XP+W-4>7!E+U)E<V]U<F-E179E;G0C(B!X;6QN<SIC<G,](FAT
M='`Z+R]N<RYA9&]B92YC;VTO8V%M97)A+7)A=RUS971T:6YG<R\Q+C`O(B!X
M;6QN<SIP:&]T;W-H;W`](FAT='`Z+R]N<RYA9&]B92YC;VTO<&AO=&]S:&]P
M+S$N,"\B('AM<#I#<F5A=&]R5&]O;#TB36EC<F]S;V9T(%=I;F1O=W,@3&EV
M92!0:&]T;R!'86QL97)Y,30N,"XX,3$W+C0Q-B(@>&UP.D-R96%T941A=&4]
M(C(P,3`M,#<M,C%4,#@Z-#(Z,S8M,#0Z,#`B('AM<#I-;V1I9GE$871E/2(R
M,#$Q+3`U+3,Q5#$U.C$Q.C4V+3`T.C`P(B!X;7`Z365T861A=&%$871E/2(R
M,#$Q+3`U+3,Q5#$U.C$Q.C4V+3`T.C`P(B!D8SIF;W)M870](FEM86=E+VIP
M96<B('AM<$U-.DEN<W1A;F-E240](GAM<"YI:60Z0S-!-S5"1$%".3A"13`Q
M,3@R.49!0S9%,C@U-S,Q.3@B('AM<$U-.D1O8W5M96YT240](GAM<"YD:60Z
M,$(X,#=#0S1#-3DT1$8Q,3DT0SA&,C8T1#<X-C8V,D(B('AM<$U-.D]R:6=I
M;F%L1&]C=6UE;G1)1#TB>&UP+F1I9#HP0C@P-T-#-$,U.31$1C$Q.31#.$8R
M-C1$-S@V-C8R0B(@8W)S.D%L<F5A9'E!<'!L:65D/2)4<G5E(B!P:&]T;W-H
M;W`Z0V]L;W)-;V1E/2(S(B!P:&]T;W-H;W`Z24-#4')O9FEL93TB<U)'0B!)
M14,V,3DV-BTR+C$B/@T*"0D)/'AM<$U-.DAI<W1O<GD^#0H)"0D)/')D9CI3
M97$^#0H)"0D)"3QR9&8Z;&D@<W1%=G0Z86-T:6]N/2)C<F5A=&5D(B!S=$5V
M=#II;G-T86YC94E$/2)X;7`N:6ED.C!".#`W0T,T0S4Y-$1&,3$Y-$,X1C(V
M-$0W.#8V-C)"(B!S=$5V=#IW:&5N/2(R,#$P+3`W+3(Q5#`X.C0R.C,V+3`T
M.C`P(B!S=$5V=#IS;V9T=V%R94%G96YT/2)!9&]B92!0:&]T;W-H;W`@0U,U
M(%=I;F1O=W,B+SX-"@D)"0D)/')D9CIL:2!S=$5V=#IA8W1I;VX](F-O;G9E
M<G1E9"(@<W1%=G0Z<&%R86UE=&5R<STB9G)O;2!I;6%G92]B;7`@=&\@:6UA
M9V4O:G!E9R(O/@T*"0D)"0D\<F1F.FQI('-T179T.F%C=&EO;CTB<V%V960B
M('-T179T.FEN<W1A;F-E240](GAM<"YI:60Z,$,X,#=#0S1#-3DT1$8Q,3DT
M0SA&,C8T1#<X-C8V,D(B('-T179T.G=H96X](C(P,3`M,#<M,C%4,#@Z-#0Z
M-3<M,#0Z,#`B('-T179T.G-O9G1W87)E06=E;G0](D%D;V)E(%!H;W1O<VAO
M<"!#4S4@5VEN9&]W<R(@<W1%=G0Z8VAA;F=E9#TB+R(O/@T*"0D)"0D\<F1F
M.FQI('-T179T.F%C=&EO;CTB<V%V960B('-T179T.FEN<W1A;F-E240](GAM
M<"YI:60Z0S-!-S5"1$%".3A"13`Q,3@R.49!0S9%,C@U-S,Q.3@B('-T179T
M.G=H96X](C(P,3$M,#4M,S%4,34Z,3$Z-38M,#0Z,#`B('-T179T.G-O9G1W
M87)E06=E;G0](D%D;V)E(%!H;W1O<VAO<"!#4S4@5VEN9&]W<R(@<W1%=G0Z
M8VAA;F=E9#TB+R(O/@T*"0D)"3PO<F1F.E-E<3X-"@D)"3PO>&UP34TZ2&ES
M=&]R>3X-"@D)/"]R9&8Z1&5S8W)I<'1I;VX^#0H)/"]R9&8Z4D1&/@T*/"]X
M.GAM<&UE=&$^#0H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@(#P_>'!A8VME="!E
M;F0])W<G/S[_X@Q824-#7U!23T9)3$4``0$```Q(3&EN;P(0``!M;G1R4D="
M(%A96B`'S@`"``D`!@`Q``!A8W-P35-&5`````!)14,@<U)'0@``````````
M`````0``]M8``0````#3+4A0("``````````````````````````````````
M`````````````````````````````!%C<')T```!4````#-D97-C```!A```
M`&QW='!T```!\````!1B:W!T```"!````!1R6%E:```"&````!1G6%E:```"
M+````!1B6%E:```"0````!1D;6YD```"5````'!D;61D```"Q````(AV=65D
M```#3````(9V:65W```#U````"1L=6UI```#^````!1M96%S```$#````"1T
M96-H```$,`````QR5%)#```$/```"`QG5%)#```$/```"`QB5%)#```$/```
M"`QT97AT`````$-O<'ER:6=H="`H8RD@,3DY."!(97=L971T+5!A8VMA<F0@
M0V]M<&%N>0``9&5S8P`````````2<U)'0B!)14,V,3DV-BTR+C$`````````
M`````!)S4D="($E%0S8Q.38V+3(N,0``````````````````````````````
M````````````````````````````````````6%E:(````````/-1``$````!
M%LQ865H@`````````````````````%A96B````````!OH@``./4```.06%E:
M(````````&*9``"WA0``&-I865H@````````)*````^$``"VSV1E<V,`````
M````%DE%0R!H='1P.B\O=W=W+FEE8RYC:```````````````%DE%0R!H='1P
M.B\O=W=W+FEE8RYC:```````````````````````````````````````````
M``````````````````!D97-C`````````"Y)14,@-C$Y-C8M,BXQ($1E9F%U
M;'0@4D="(&-O;&]U<B!S<&%C92`M('-21T(``````````````"Y)14,@-C$Y
M-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92`M('-21T(`````````
M````````````````````9&5S8P`````````L4F5F97)E;F-E(%9I97=I;F<@
M0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N,0``````````````+%)E9F5R96YC
M92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR+C$`````````````
M`````````````````````'9I97<``````!.D_@`47RX`$,\4``/MS``$$PL`
M`UR>`````5A96B```````$P)5@!0````5Q_G;65A<P`````````!````````
M`````````````````H\````"<VEG(`````!#4E0@8W5R=@````````0`````
M!0`*``\`%``9`!X`(P`H`"T`,@`W`#L`0`!%`$H`3P!4`%D`7@!C`&@`;0!R
M`'<`?`"!`(8`BP"0`)4`F@"?`*0`J0"N`+(`MP"\`,$`Q@#+`-``U0#;`.``
MY0#K`/``]@#[`0$!!P$-`1,!&0$?`24!*P$R`3@!/@%%`4P!4@%9`6`!9P%N
M`74!?`&#`8L!D@&:`:$!J0&Q`;D!P0')`=$!V0'A`>D!\@'Z`@,"#`(4`AT"
M)@(O`C@"00)+`E0"70)G`G$">@*$`HX"F`*B`JP"M@+!`LL"U0+@`NL"]0,`
M`PL#%@,A`RT#.`-#`T\#6@-F`W(#?@.*`Y8#H@.N`[H#QP/3`^`#[`/Y!`8$
M$P0@!"T$.P1(!%4$8P1Q!'X$C`2:!*@$M@3$!-,$X03P!/X%#04<!2L%.@5)
M!5@%9P5W!88%E@6F!;4%Q075!>4%]@8&!A8&)P8W!D@&609J!GL&C`:=!J\&
MP`;1!N,&]0<'!QD'*P<]!T\'80=T!X8'F0>L![\'T@?E!_@("P@?"#((1@A:
M"&X(@@B6"*H(O@C2".<(^PD0"24).@E/"60)>0F/":0)N@G/">4)^PH1"B<*
M/0I4"FH*@0J8"JX*Q0K<"O,+"PLB"SD+40MI"X`+F`NP"\@+X0OY#!(,*@Q#
M#%P,=0R.#*<,P`S9#/,-#0TF#4`-6@UT#8X-J0W##=X-^`X3#BX.20YD#G\.
MFPZV#M(.[@\)#R4/00]>#WH/E@^S#\\/[!`)$"800Q!A$'X0FQ"Y$-<0]1$3
M$3$13Q%M$8P1JA')$>@2!Q(F$D429!*$$J,2PQ+C$P,3(Q-#$V,3@Q.D$\43
MY10&%"<4211J%(L4K13.%/`5$A4T%585>!6;%;T5X!8#%B86219L%H\6LA;6
M%OH7'1=!%V47B1>N%](7]Q@;&$`891B*&*\8U1CZ&2`911EK&9$9MQG=&@0:
M*AI1&G<:GAK%&NP;%!L[&V,;BANR&]H<`APJ'%(<>QRC',P<]1T>'4<=<!V9
M'<,=[!X6'D`>:AZ4'KX>Z1\3'SX?:1^4'[\?ZB`5($$@;""8(,0@\"$<(4@A
M=2&A(<XA^R(G(E4B@B*O(MTC"B,X(V8CE"/"(_`D'R1-)'PDJR3:)0DE."5H
M)9<EQR7W)B<F5R:')K<FZ"<8)TDG>B>K)]PH#2@_*'$HHBC4*08I."EK*9TI
MT"H"*C4J:"J;*L\K`BLV*VDKG2O1+`4L.2QN+*(LURT,+4$M=BVK+>$N%BY,
M+H(NMR[N+R0O6B^1+\<O_C`U,&PPI##;,1(Q2C&",;HQ\C(J,F,RFS+4,PTS
M1C-_,[@S\30K-&4TGC38-1,U336'-<(U_38W-G(VKC;I-R0W8#><-]<X%#A0
M.(PXR#D%.4(Y?SF\.?DZ-CIT.K(Z[SLM.VL[JCOH/"<\93RD/.,](CUA/:$]
MX#X@/F`^H#[@/R$_83^B/^)`(T!D0*9`YT$I06I!K$'N0C!"<D*U0O=#.D-]
M0\!$`T1'1(I$SD42155%FD7>1B)&9T:K1O!'-4=[1\!(!4A+2)%(UTD=26-)
MJ4GP2C=*?4K$2PQ+4TN:2^),*DQR3+I-`DU*39--W$XE3FY.MT\`3TE/DT_=
M4"=0<5"[40914%&;4>92,5)\4L=3$U-?4ZI3]E1"5(]4VU4H5755PE8/5EQ6
MJ5;W5T17DE?@6"]8?5C+61I9:5FX6@=:5EJF6O5;15N56^5<-5R&7-9=)UUX
M7<E>&EYL7KU?#U]A7[-@!6!78*I@_&%/8:)A]6))8IQB\&-#8Y=CZV1`9)1D
MZ64]99)EYV8]9I)FZ&<]9Y-GZ6@_:)9H[&E#:9II\6I(:I]J]VM/:Z=K_VQ7
M;*]M"&U@;;EN$FYK;L1O'F]X;]%P*W"&<.!Q.G&5<?!R2W*F<P%S77.X=!1T
M<'3,=2AUA77A=CYVFW;X=U9WLW@1>&YXS'DJ>8EYYWI&>J5[!'MC>\)\(7R!
M?.%]07VA?@%^8G["?R-_A'_E@$>`J($*@6N!S8(P@I*"](-7@[J$'82`A..%
M1X6KA@Z&<H;7ASN'GX@$B&F(SHDSB9F)_HIDBLJ+,(N6B_R,8XS*C3&-F(W_
MCF:.SH\VCYZ0!I!ND-:1/Y&HDA&2>I+CDTV3MI0@E(J4])5?E<F6-):?EPJ7
M=9?@F$R8N)DDF9"9_)IHFM6;0INOG!R<B9SWG62=TIY`GJZ?'9^+G_J@::#8
MH4>AMJ(FHI:C!J-VH^:D5J3'I3BEJ:8:IHNF_:=NI^"H4JC$J3>IJ:H<JH^K
M`JMUJ^FL7*S0K42MN*XMKJ&O%J^+L`"P=;#JL6"QUK)+LL*S.+.NM"6TG+43
MM8JV`;9YMO"W:+?@N%FXT;E*N<*Z.[JUNRZ[I[PAO)N]%;V/O@J^A+[_OWJ_
M]<!PP.S!9\'CPE_"V\-8P]3$4<3.Q4O%R,9&QL/'0<>_R#W(O,DZR;G*.,JW
MRS;+MLPUS+7--<VUSC;.ML\WS[C0.="ZT3S1OM(_TL'31-/&U$G4R]5.U='6
M5=;8UUS7X-ADV.C9;-GQVG;:^]N`W`7<BMT0W9;>'-ZBWRG?K^`VX+WA1.',
MXE/BV^-CX^OD<^3\Y83F#>:6YQ_GJ>@RZ+SI1NG0ZEOJY>MPZ_OLANT1[9SN
M*.ZT[T#OS/!8\.7Q<O'_\HSS&?.G]#3TPO50]=[V;?;[]XKX&?BH^3CYQ_I7
M^N?[=_P'_)C]*?VZ_DO^W/]M____VP!#``(!`0(!`0("`@("`@("`P4#`P,#
M`P8$!`,%!P8'!P<&!P<("0L)"`@*"`<'"@T*"@L,#`P,!PD.#PT,#@L,#`S_
MVP!#`0("`@,#`P8#`P8,"`<(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,
M#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`S_P``1"`$H`UX#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#]_****`"B
MBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`***
M*`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH
M`****`"BBD9MHS0`M%-:3'8G-4-=\2V/AG2Y[_4;RVTZPM4,DUS<RI##$H&2
MS,Q```[DXH2Z(%KL7^GI09`*^*OV@O\`@X5_9#_9TNYK34/C!HGB;4HP?]$\
M*PS:Z6/=?.ME>!3[-(M?,GC#_@\/_9\TJZD31/`'Q;UQ$.%F>RL[19/<;K@L
M!]0*ZZ6!Q%3X(-F]/"U9_#%L_6_=\V.,TO'J/RK\<]'_`.#R;X.S3@7_`,)/
MBE:QL<!H);&<X^AE6O:_@[_P=5?LB_$ZXB@U?Q%XO\!32X`.O^'9S%N/8R6O
MGJ![L0/>JJ9;B8*\H,J>#K1^*+/TCH)Q7#?!3]HSP'^TGX1CU_X?>,O"_C?1
M9#M%[H6J07\*-C)5FC8[6'=6P0>",UV:3[FV%2#C-<;BT[,YGIHR:BFK)N/0
MTX'(I`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!
M1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%
M%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`444
M4`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110
M`4444`%%%%`!1110`444$9%`"$X&<8Q6=JVMVNA:7<WU_<VUG9V<;S3W$\BQ
MPP(@RSNYP%50,DG@<U'XD\0V7A'0[W4M2NH;#3=.@DNKFYF8)%;Q(I9W=CP%
M`!)-?S'?\%T?^"\?B/\`X*%^.=2^'WP[U&\\/_`W1IC$/+=H;GQC(C$?:;GH
M1;9'[N#IT=\L52/NR_`3Q4^6&RW?8ZL)A9UIV6W<^\/^"FG_``=?>%/A!?W_
M`(1_9ZTRR\>:];LT$WB?4-PT:T<<9@08:Y(/?*I[FOQ/_:V_;\^,7[<?B.74
M/BCX_P!?\3QR/YD>GO.8=,MO01VJ8B4#UP3ZDFO=/^"<G_!!/X[?\%&(+76M
M+TN'P#\/I6!/B?Q!%)''<+GG[);*/-N6QGD;(N,&0'BOU?\`#?\`P0R_8=_X
M)3?#*W\:?'S78?&%U9J2U[XON2MK=RCG;;:9!GS<]HR)CZY-?24W@L')4J<>
M>?EJV>M*M@\&M?>?<_G3\-:->^*KX66C6-]JMR>EO96[W$@_X"@)_2O0-._8
MV^,.K6RW%K\*/B7<0OP)$\-7F&_\AU^Q_P`8O^#GCX<_!*S?P[^S3^S_`*+9
M:7:?N[?4]<M8M&M&QP#%8VJF4KZ&1XCZJ*^5_B+_`,')'[7'CZ>1K7QOX<\)
MVSG*V^C>&[;"`]@\_FM[<G\*^CPN"S6NE*%)07]YZ_<KV/(K\;4:;Y4KV['Y
M[^-/@9XY^&\,DOB/P5XQT"*#[\FH:+<VR)]6=`!^=<O#<"=-T4B.O^P<XK[V
MA_X+J_M;Q3!I/C9K=XH.?*N]'TR>$^Q4VW/XC%<A\2O^"@#?M&F3_A;OPB^#
M_CVYF7#:QINBCPIKZ'^\+S3RJ.1U`FAD7VKO659C'XXQ?HW?\41A^.\/*5JL
M7%=SYI^`O[0GC?\`9>^(EOXM^'?BS6_!WB*U((N],N&A,H'\$JCY94]5<$'T
MK^BK_@A/_P`'`]O_`,%!KN+X7?%"#3]"^+MI`9+*[M1Y=EXIB1<NR(?]7<``
MLT8R",E<8('\Z?Q1\):)9:NUWX4;6VT68;A::J(FO;`_W'DB^29?2150G^)%
MK*^'7Q'UWX-_$+0_%OAC4)M+\1^&;Z'5-,O(6PUO<1,'1O<9&".A!(/!KQ,W
MR?VL7SQM+HSZ#_9,PH>UP[3MV[^9_<1%)O7J"1QQVJ1>5->8?L:?M$V7[6_[
M*GP^^)FGQ"WM_&^@VFJF#)/V:62,&6+_`(!)O7_@->H(,9K\VE%Q;BSYIIIM
M,=1110(****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`
M"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`*
M***`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HH
MHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`I"P!I:C?EB#0`\
ML![TW?Z<5Y!^UI^W7\*/V'?`_P#;_P`4O&FC>%+.12;>&XEW7=X1_##`N9)#
M_NBORG_:5_X/)_#.B:A/8_"+X/:KXDC4E8]6\3ZDNF19[,MM$DLC*?\`:>,^
MU=.'P->L_P!W%LWIX:K4^"-S]N!*"<<YIOG`U_.0W_!XE^T$;XR+\-/@\MON
M_P!68M1+X]-_VCK[X_"O>?V;_P#@\ET/5+V&S^+?P<U'0XCC?JOA?51J"*<\
MEK69(W51_LR2'VKKJ9)BX1NX7.B>68B*ORG[@[Q@>]`.:\5_9`_X*"?"+]O'
MP;_;7PM\;:1XGAC0&YM(Y/*OK$GM-;OB1#]1BO98GWY/(&.]>7*+@[25CA<6
MG9DU%%%`@HHHH`_'K_@[7_;]O/@E^SEH'P5\/WYL]2^)I>ZUR2)\2+I<+#]U
MZ@2RX!]50CH37D__``0,_P"#=#3M>\,Z+\;?VA=":[^VJE]X6\%WB%(HXB`4
MO+^,\LS<%(#P``S@D[1Z?^T/^Q5%_P`%$O\`@YN-OXLMA?\`P_\`@MX.TK6;
MVSE4F&\E9I'MX&&>4:8[V'0B+!!!-?L+'"L:!0`JC&%`P%'3`_*O7J8QT,-'
M#T=&U=OKZ'?+$>SHJE#KJSXV_P""N_\`P5:\+_\`!+#X%61L[*RUGQ_X@B:U
M\,>'PPCB"H,&YE5>4MH^!P!N.%'J/YIOVD/VF/'?[7_Q9OO'/Q(\1WOB?Q'?
M,?WLYVP62=/)MXA\L,0`&%4>Y).:]=_X+!_M.ZG^UG_P4;^*/B&^GF-CH>L3
M>&])@<Y6UM;*1H<`=/FD5W/'4BOFJ,8Z_P#UJ_6>%L@I8+#QK35ZDDFWZZV7
M;S/S?-<QG6JN"^%:`#BC:3VI]%?6/NSQ[(CVGCBEQSSQ3Z1_NFG=A9#*Y3QC
MHRZ?=)<1+MBGSN`Z*>^*ZLDD^_:I-&^%VN?&[QKX=\%>&;-]0\2>+]4@TG2[
M<9_>3S-L!.!PHSN8]`H)[5Y>;0A]6E4G]E7/HN%\;4P^.BHOW9:-']0__!NU
M%=1?\$9O@:+L@NVE731\$8C-_<E.O^SBOMA6R*\Z_9/^`NF_LL_LU^!/AOI+
M-)I_@C0[31HI",&?R8E1I#R>68%CSU->BI]T5_/5>:G5E)=6S[&I*\FQ:***
MS)"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH
M`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`
MHHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"B
MBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`IKG`'/>G4CG"]<4`0-.5/!_2
MOS7_`."Y'_!?71?^";^FS_#SP";#Q)\:M0MED:"7$EIX6B=04GNL<-*RD,D.
M02"&;"E=WMG_``6E_P""E]M_P3+_`&/;WQ-IRV][\0?$LC:/X/T^4;UGO67+
M3NO\44"_O&[$[5_BK^5W7I]1\<>,=6\2^)]2NO$/B;7;R74=3U&\<R2W=U*Q
M>25B>K,Q)S_0"OJN&^'9YA/VLO@7XLQJ8_#X1>TKZ]DMW_P"C\;_`(X^._VI
M?B5?^,O'WB#6O%WB347+37]Z[2E1V1!]V-!T"H`!7(364ULN7BF4'N8R*]`#
M$8P2.^!Q0SLW<G/KR#7ZC3X?IP@HP>QST^/9Q?N44H]KN]O78\Y8'`R.O>A#
MGHW-=U-X<T_4+A&NH)50MF0VSA)".^,@C/UZ^W6O0?&'[!.O:K\%+OXE_#6^
MC^(_@O2`/[?6Q@9-7\*L>GVZSY=8S@XG3=&>>17E8_"2PMG-Z=SZW*>*<)C7
MR_#/L_T9Y=\&OC1XO_9V^(]AXP\">)-4\*>)=*<26VH:=.895_V6QPZGH58$
M'/(K^C/_`((=?\'"VC?M\RZ?\,/BF]AX:^,BQ$6<R`0V'BU47+&'G$=R%!8P
M_P`0!*9`('\T*`N`58$=00>M7-(U2Y\.ZO::A87=WI^HZ=<1W=I=VLQAN+2:
M-@Z2QR+\R.K`%67D$`UX&8972Q<&[6ET9ZN-R^G7C>*L^Y_<O;L7/+9Y/:I>
M.:_.;_@WY_X+&#_@I-\")_"WC:[MT^,?@""./52`(AX@M/NQZC&@X#$@+*JC
M"N<@!7"C]&%^8&OSRO0G1J.E4W1\=5IRIR<)[H?11G-%9D'F'@S]G'3?!/[3
M?CGXE6[H=3\<:;IVG7*[<%5L_-"G/OYOZ5Z4X"K]<5(5'<`_A3)!^[/!)HDV
M]P=V?R1_\%7/V<=7_99_X*)?%?PQJ\,L0OM>N=?TZ5EPMY9WLK3QR*>X!=D/
MH5KY]4_-CVK^IW_@K-_P2&\&_P#!47X:VHN[IO#/Q!\.1O\`\(_XBBB$GEAN
M3;7*=9;=CR0"&4_,IZAOYV_VR_\`@F3\;?V#_$MQ9^/_``1JJZ3"Y$7B#2X7
MO=)NEZ[Q*H.S/=7"D&OVWAKB7#8O#QI5)<M2*LT^MNJ_R/B,SRVI2J.45>+V
M\CPBBH8+Z"9?DFC?Z.#4GFC;U&/K7UR:>QXU@D[4VHWO(C,(Q(AD?Y0H.YC[
M;1R:^G/V0/\`@C]^T)^VQJ-N?"GP^U32=#D(+ZYXAA?3+%%/\0\S#R<<X1>:
MYL3CL/AX<]>:BEW-J6'J5)6IQ;?X'S++,L*@LV,G:``26;T`'7\.M?NO_P`&
MX?\`P1CU3X/W=O\`M"?%K1GT_P`4:A:E/!VAWD>)](M9!\U[,I_U<\JG"H?F
M1#S@M@?1/_!+S_@W^^&7[`7V?Q1XE\KXE_%!H@IU;4+938:/G[R6-LV0A/>5
M]TAQQL!*U^@,*D,<Y/N:_*>)^+EBXO#832'5]7Y+R/K<IROV#=6I\3V\E_F/
M$0!S3@,"BBO@K(]T****8!1110`4444`%%%%`!1110`4444`%%%%`!1110`4
M444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!11
M10`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%
M`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`$X%,<
M948]:<PR*\[_`&L?C/;_`+.O[,GC[QU<N(X?">@WFJ;B<#=%"S+_`./`4Z=-
MSFH1W;M]Y,FDKL_G+_X.(_VQW_:P_P""CFN:3:79N/#/PJC/AO3$5LQ^?D->
M2C'\3287/7$:CM7PM&=PYZXYI]_K]]XLU&ZUC5)7N=4U>>2_O96.6DGE8R2$
M_P#`F--3[OTK^B\JP,,)A88>"^%?>^Y^>8W$3K57.;]/)!L%*!BBBO0.08W]
M:]!_9:_:C\9_L:?&W2O'_@._^Q:UI9V36\I)L]6MB?WEI<IT>&0<$'D9R.17
MGY3DFD*8&2`1Z>M95J$*T'3J*Z>C3+IU)4Y*47JM4?HM_P`%!_\`@E[X*_;B
M_9'B_;$_90T5[#3+E))O'WPZ@7?-H=Y'S=O:HHX:(MN>)0`\966,`'8?RC1Q
M,@D4@YK]5O\`@VP_;MG_`&7OVX(OAUK-X%\"_&7&G7,4Q'DVNKHI^R3XZ`RC
M=`WKYD1/W!7+?\')7_!*"+]A']H^/XB^"=-^S?"_XEW,DJP0K^ZT/4^6FMQC
M[L<G,B#M\RCI7YE.,LOQCP-5WB]8/R[/S6Q^P<,YX\134*KU_4^*OV(_VN_$
M?["G[47A'XJ>%Y)3?>&KL/<VR-M&H6C?+/;MZAT+#ZX/:O['/@)\;="_:.^"
MOA7Q[X8N5O-`\7:9!J=C*#UCE0,`?<'Y3[@U_$6`47!Z']:_HA_X-"_VP9?B
M3^RUXQ^#^IWCSWWPUU%+_2T=\L-/NRQVC_9299..V\5X_$F#O!8A+5:,]'/,
M+=*JNFY^PD9R5^E24V-<?A3J^-/FPHHHH`*IZGIL.J6LEM<PPW%M,NV2*5`Z
M./0@@@CV-7*:T>XY[T)A8^>/BM_P2D_9R^-M^]WXE^#/@&^NY<EYX]+2WE8G
MJ=T>TUP=I_P00_9'L;B.5/@IX99D.0'>9E/U!?!K[#\OWH]CS7;#,\7!<L:L
MEZ-F#PU%N_*ON/%_@_\`\$^/@A\`I(Y/!_PJ\":!+'G;+;Z1$95^CL"U>QI#
MY:87`7H!V'TI_E[L<]*<1@`'!KEJUZE27-4DY/S;;_$TC3C'2*MZ#AP**.M%
M06%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110
M`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!
M1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%
M%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`(3R*^+_P#@X2\3
MR^&/^"0GQC>(D-?6%MI['_9GNX8F_1C7V>?O`5\>?\%\_!<OCG_@D;\:;>%#
M))8Z.NI;0,DBWGCF/Z(:[LJ:6,I<VW,OS1SXJ_L96WLS^6`_-FGH,`_6F%@Q
MR#D$9!['WIR_=;ZFOZ-6R/S;MZ#J***8PI'^X:6D?[IH`GT3Q/>^"]<L-;TZ
M5H=0T6YCO[613ADEB<2*1COD5_4O\?O@IHW_``60_P""1XTFX-L+KXC^$K?5
MM)NW`VZ=JRPB2";/.%6<;6QR49QD9K^5YE#X!&0>M?T[_P#!N/XWG\=_\$B/
MAB)W,CZ*U[I0)[+#<R!1^`(K\\\0*%J%'$QWB[??K^A])PU6<:LHI^?XG\IN
MMZ+?>'=8O-)U2VFL-3TNXDL[RUE7;);3QN4DC8=F5U8'Z5^@_P#P:Z_'6X^#
MW_!7/PKHIF,>G?$?1M1\.W(9L(72W:]A/UWVNT?]=#ZUQW_!Q;^SE#^S=_P5
MN^)<%G$(=,\;FW\86JA=N6O$)N"/^WE)S_P*O%_^"7?C:?X>?\%+?V?M6AF^
MSB'XAZ'!-)GI#->Q03?G%*X_&O,K26)R]R[Q_0_7JC5?!N3ZH_LN1N?K3ZBC
M.6Z=,U+7YPE9'QH4444P"BBB@`HHHH`*,9HHH`****`"@G%%,>50V">10`NY
M<\8S2Y]OUK@/CO\`M,_#W]F+PH-;^(?C/PYX-TIB0D^K7R6PF(P2(PQW.1D<
M*">:^(/BK_P=,?LB_#:_EMK+Q-XK\8M$VW?H.@2R1M[J\YB!'O6M/#5:FL(M
M_(TA1G/X4S]'B?>DW^YK\N-,_P"#N']E6^NXXYK#XLV"/@&6?P]"43ZA+AC^
M0KZ'_9V_X+L?LJ_M-7]M8Z!\7O#^GZM<MMCL=<6329B?0&=50GV#&M)8&O%7
ME!I>A4L-4BKN+/L+(]115.RU"#4K**>":*:WG02121N&216&0RL."""""/6K
M*N`Q`Y-<OD96'T444Q!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444
M`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`
M4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1
M110`4444`%%%%`!1110`4444`%%%%`!1110`TMA17(_'OX76GQN^"?BSP??(
MLMGXIT>ZTN52<`B:%D_K78'IS45P"%&/6G"3C)2CNB9)-69_%=XI\#:C\,/%
M>K>%]7B>'5?#=[-I5XCKM820.8R2/?;G\:IITK])?^#FW]A>?]F_]L^#XH:9
M;,OA+XO;I9)$7$=KJL2#SHV]#(F)%SUP_P#=-?FU&..>IYK^BLHQ\,7A*>(A
MU6OD]K?>?G>,H2HUI0D.HHHKT3E"D<?+2TC'`H`:OWATZ]S7],O_``;0Z)-H
MG_!(GP&TZE?M]_J5W'D8RC7;X/Z5_,R;>:\(@MXVEN;@B*%%ZN[':H'XD5_7
MK_P3M_9_/[+?[#GPN\`R`K<>'?#UK#=#;@B=E\R7/OO=A^%?GGB#6C'#4Z/5
MRO\`=_PY]#P[2;J2GTM8_%__`(/,?`46F?M)?`_Q2L)$VL^&]1TJ67LPMKJ&
M5!]1]J?\Z_+[]@;3I=;_`&\O@98P#,][\1/#\,0SU9M2MU'ZFOUO_P"#T:]B
M;6OV=+;>/.$?B"4IW"_\2\9_.OSY_P""!/P<;XW_`/!7[X'::T#36VBZQ+XD
MN6QE85L+::YC8^G[](5'NPKY[+JO+E7.^B9^KX.?+@')^9_7'&?WA%/9<U''
MRX.:EKX<^7"BBB@`HHHH`****`"BBB@`HHHH`:>_O7R3_P`%F?\`@HHG_!,S
M]B/7?'MC:6NI>+K^=-'\-6=SDP27\P.V24`AC%$BM(RC&_:J97?D?6S<"OSN
M_P"#F/\`8\US]K3_`()JZO=>%K2ZU+7OAOJ,7B=+"W0R37UK&C)<K&HY9UB<
MR@#D^40,DBNC!1A*O"-39LUH<CJ+GV/YK/C5\</B+^V/\3K[QK\1_%6K^,/$
MNI2,TVIZI("D>3GRX8E`CAC7G;%$JHHX"BNN^$4GPE\!2)<>+/A_XJ^)%P(]
MKVS^*AH%AN['$$$D[#V\Q<UQ]B89+&%K<QM;L@\ME^ZRXX(^O/Y&G[1GC\J_
M=L-D6%C24+75NA\OF'%F,E-TJ'N16B2WMY];GU9\/_VF/V-DU*-/%G[$&ZSX
M$DND_%S7Y)@.YVRW"*3[9%?6?[/_`/P3;_X)P_\`!4VX;0_A7XF^(7P8^($\
M>ZW\-ZCJ[2RN>O[I+TS?:5&.1%-N]<5^4)&&SS4EG?7&EZA;WMG=7%C?64JW
M%K=02&.:TE7E9$<8*LIY!!S7!C>$\/.-\-*4)=[MK[FV<F%XDQ=.2<Y77F?L
MQH?[*/[:?_!OI?CQ+X"\2W'[17[/NG2&36?"863[786O)::&W8N]NZKEMUN[
M(<?O$(Y'Z_?LE?M,>$OVQOV>O"WQ,\#WPU#PUXMLQ=VSG_61,&*202#^&2*1
M7C9?X60CM7C_`/P1O_:8\2_M??\`!-[X:>./&):?Q+?64MG?7;)@ZB]M,\'V
M@CUD$89L<%BV.*],_9=_91T/]E'5_B'!X686GAOQQXED\50:.D>RWT:YN+>&
M.Z2$=!%+-"T^T8"O/+@`&OQ_'-^TE3J)<T6TVNI]A]85:"J-:O4]>HHHK@)"
MBBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`**
M**`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHH
MH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@
M`HHHH`****`"BBB@`I'4,.:6FR9P,>M`'C/[=G[%_A/]OG]F7Q%\,O%L7EV.
MLQ"2ROHD#7&D7J9,%W%Z.C>XW*74\,:_E+_:R_9/\;?L2?'G6_AU\0--;3]<
MT>5C%.@/V35K;)\N[MF(P\4BX/JIRK`$5_8N(^ASSFOG3_@HO_P3+^&__!2W
MX4?\([XWLI;35;$,^B^(+$*NHZ+*1]Z-C]^,G[T;95AZ'FOJ>%^(Y994<*EW
M3EOW7G_F>3F>6QQ,;QTDOZL?R5[<C)ZYJ2OK;]OC_@B3\>?V!-7OKO4?#%_X
MZ\!P,S0^*_#5I)>6Z1#H;NW0-+:D<99E,>3@28KY"AU.WN@3%/#(!W60'%?L
M^#S"ABH>TH24EY?UH?&5<+5I.U169(_WC0V<<]JBN+Z"UYEEBCSTW,!GV^OM
MW[5]J_\`!-[_`((8?&;_`(*"Z_8ZE=:1JGPV^&;.K7'B?6;-K>:\B[BPMI0'
MF8]!*5$0/\3$;:6-S'#86FZM>2BEW_0*&%J5I<L$SJ/^#>?_`()U7W[:7[9^
MG^,M8TXR_#;X47":GJ<TR9AU'40-UI9+QAB&`EDXP$4`\N*_IC'`R202?PKS
M?]DO]E'P1^Q3\"="^'?P^TI-)\.Z''A03OGO)C@R7$TG625SRS'Z<``#N?%W
MB33O!?AC4-:U>\MM-TK2;66\O;RX<1PVL$:%Y)'8\*JJI))Z`&OPSB#.9YGB
MW52M%:17EW]7U/NLNP2P])4UN]V?SJ_\'@'QF@\;?M^^`O!UO('_`.$'\'^=
M<@?\LY[VX9RI_P"V4,1_X%7J7_!G;^R%+?\`CCXD_'34K4"UL[5?"6AR.O5W
M=9[MU^@2%,^["OS@_:'\6^,_^"QW_!47Q+J/@RPN]5UKXK>)FM]`MG4YM=.C
M_<VS29^XD=M&KN3@##9K^J?]@O\`8XT#]@O]E'P=\+O#:K):>&;)4N;HC#W]
MVWS3W#>[R%C[#`[5UYA56&P,,*OBDKGU6)JJCA8T%N]6>S*!GCM2TV-2.M.K
MY@\0****`"BBB@`HHHH`****`"BBB@``Q44B`G/0@YS4I.!43`LW3B@-=T?E
M;_P4D_X-D?!'[3WC'4/&WP?U:S^%_BS5YGN=3TJ6V:30]1F<Y:58T^:VD8DE
MO*^1B2=@.2?R]^,7_!OU^UI\'-4EA;X8/XKM%8A+SP[J4%VDJYX8(2KKGT89
MK^I4K\G%"YV]\U]/EO&&88."IIJ45W7Z[GE8G*:%>3FU9OJC^2WP]_P1_P#V
MI?%&H"UM/@3X_60,$8W%JENBG/4L[`8]37V1^Q#_`,&KOQ2^)GB6UU+XY:GI
MW@#PK"ZO/I.E7:WVL:@G4QB1/W5N#P"V689/'<?T%;#CJ:/+;%=V,X[S"M!P
M@HPOU2N_Q,:&18>#O)M^IS'PG^%6@?`[X:Z%X/\`"NE6NB^&O#5C'IVG6%NN
M(K:"-0JKZD\9+'))))R2374(`N2`!2.#GI^M/`&/K7Q+DY.[W/:C%)60M%%%
M,84444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`
M!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%1S,5Q@D?A2;`>N
M3U%#`GI7,>(OBYX5\'7K6VK^)_#^E7(Y\F\U&&%P/]UF!JB/VBOA_@?\5QX/
M/_<:MO\`XNJ4)=$-1D];';45B>%O'VB>-H7DT;6M*UB./AWL;R.X"?783BM=
M&+=#FD]'9BL244BG(I:`"BBB@`HHHH`****`"DV"F.Q#=2!63XF\;Z1X(LEN
M=:U;3=)M6;:)KVZCMT)],N0/PH6KL@2;V-D@COFD^:N+7]HOX?GKXX\'_P#@
MYMO_`(NMGPO\0]!\<QROH>M:1JZ0\2&QO([@1_783BFX26K13C);HW:*9&3G
MDT^D2%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%1OR]24
MA0$T`0&#'\1Y%>._%7_@GC\"_CAJ3WOBSX1?#S6[V0EGNI]"M_M#D]29%4,3
M[DU[.J]\9I<Y[XITJU2F[TW;T9$H1E\2N>)_"G_@G7\"?@=J<=_X3^$/P\T.
M_B.8[N#0X/M$9'0B1E+`^X->S&#?CD]>:E``.<_I00%'7M55*U2H[U)-ONW<
M(0C%:*PV0[(P>IK\B?\`@X?_`."@'B+XMW,7[&OP$LK[Q=\3/'ZI#XJ32?G;
M2[!V!-I(XXC,HQYI8@+%D,?GQ7Z?_'?P3XJ^(_@"YT3PKXM/@>]U(^1-K4-B
MMW>V4)'S&V5SY:SGHKR!U0G=L8@"N*_8[_X)^?"W]A[PY>VG@3P[Y>KZO(T^
MM>(M3G-_KOB"=B6>:[O),R2LS$G&0HSPJCBKP]2-.7M)*[6R.BE.,)<S5V?,
M_P#P0[_X(C:)_P`$O/AY/XC\2RV7B/XQ^)[98]4U&%-UOHL!P38VA/)7<!YD
MG!<J.`H&?T&0Y&/:FB%5Z#':GC&VIK5YU9NI4=VR:E2523G-W;'44CG"TP,0
M>OX5E=$#SDCI1M%,9B1FO+?CY^VM\)OV6=.^T_$3XC^#/!\8!*IJ>J0PS28[
M+'NWL?95-52IU*DN6G%M]DKO\"9245=L]4ZGTI?NCK7YW_$;_@Z!_9+\#W$D
M6F>*?%WC1X\Y.A>%[MXR?023K$A^H)'O7E>L?\'=7P/A=A8?#+XQWH#8#R6V
MF6ZL/7F[)_`BO7I</9E47NT9?=;\SEJ8_#P=I31^L@!]?THY%?E'X?\`^#N?
MX#7LRIJ?P[^,NF*<;I$L-/NE7U^Y=YX^E>O?#+_@YB_9%^(T\<%YX]UGP=<S
M8`C\0^';VU4?658WB'U+XJ:N09C37OT9?=_D.&.H3^&:/OX=..,4,/;->=?!
M7]J?X<?M%Z0M_P"`_'?A+QC:2#B32=4ANL>Q5&)!]B!7H(<A?0FO*G3E!\LT
MT_-6.F,E)7BR6BHR^3P33P<D<]JFZ*%HHHI@%%%%`!1110`4444`%%%%`!11
M10`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%
M`!1110`4444`%%%%`!1110`4444`%%%%`!1110``8KY4_P""UW[3WB7]CC_@
ME]\7/B'X/G%IXGTG3(+/3KHKN-E->7D%D)U'0O&+@NN<C<BY!%?52DGK7PC_
M`,',"X_X(F?&D>VB_P#I\T^ML+!3K0B^K7YFE"*E4BGW1_*EXO\`$.H>/O$E
MQJNO:CJ&NZK=N9)[S4+A[F>9R<DL[DDDFLTV5LV1Y$8'^Z*G+<G@=:1#\O2O
MU%4J:T27W'WT:,%HDON.]_9O_:<^('[(7Q%L?%7PU\5ZMX1UFPE$P>SG*P7&
M#DI-#]R5"."K`Y%?U,?\$6?^"MGA_P#X*H?L[-?S"TT?XE^%1';>*]#C)`B=
MA^[NX`>3;S;25ZE6#*>@)_DKY#`\CZ5ZO^Q1^V5XU_8%_:0T'XG^`KP0:QHS
M&.YM')%OJUFQ'G6DP'6-P!_NLJL,$"O(S7*(8FG>FK26QYF8Y=&I#F@K-']I
MD9!&00>]/`&/:O$OV"_VZ/!'_!0C]FS0_B5X)NB;'4HPE[82L#<Z1=*!YMK,
M!_$IZ'HPPPX->UQ_+]#7Y].,HR<9:-'R4DXNTMQ]%%%,D****`"BBB@"-AA2
MW4U_*E_P<F?M"^*_C-_P50^(?AO7=7O+CPYX$EM]+T72O-;[)9QB!'9Q'G;O
M=W8EL9Z=ABOZL"<"OY&?^"^W_*8/XY?]A>'_`-)HJ]WAZ$98KWE?1GJY+&,L
M1:78^.#96^/]3%_WR*^R?^"!OQL\0_`__@J[\&HO#NI75A9^*]>70=7LTE86
MVHVMS%)&R2Q@[6VL5=21\KHI[5\>G%?2O_!&@_\`&V+]GG_L=[+_`-FKZS,:
M,5AIZ+;L?19C3BJ$M$?V'J>@]*<GW13%_P!<:>GW17YJCXA"T444P"BBB@`H
MHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`H;H:**`&H`1TH
M0Y8\8IU%`!0>E%1<B,Y[4`*\@102<#ZUX1^WE_P4-^&'_!.SX6KXG^(^N):-
M=EX]*TFVQ+J6LRJ,LD$.<D`$%G.$0$;B,C-+_@I+_P`%`?#/_!.7]EW6/B#X
M@C-]>(?L>BZ2CA)=6OG!\N$'/"_Q.W\*@]Z_EC_:C_:A\<?MF?&_5_B%\1-8
MDUGQ+JQV9Z6^GP`DI:VZ=(X4S@*/O$DMEB2?JN&N&)YG+VM32FM_/R1X^9YI
M'"KECK)GV#^WA_P<;?';]K6^O])\&WA^$W@B9FCCM=(DW:M<IDC]]=]5)[K&
M`!ZU\!ZS?W/B37)M3U.ZN]4U.X8O+>7<SW,\I[EI')8GZFHQECR.WY5]<?\`
M!+O_`((W?$O_`(*A:Z^HZ2\'A'X;:9<_9M4\57UN94DD!&^WLH>!<3*#R<A%
MXW-G"G]7C1R_*<.YM*,5N^M_S;/E'/$XRIRW;9\BRS+"FZ1P@`SN<X`'U-4Q
MXETXL<7ENXQG*-O`_$9K^I3]E#_@W]_9C_93L;20?#^P\?\`B"!09-9\8*-6
MED?'WE@D'V>/GILC!'J:^OO#_P`/M!\*:<MGIFB:1IMK'\JPVMG%#&H]`J@`
M#%?)XKQ#HQE:A2;7=NU_S_$]:EP[)J]25G]Y_%C;:U9W[;8;NVD8_P``E7=^
M6<U:!*X/(S^M?V*?%_\`8Z^%/Q^TN6S\;?#7P+XJ@F7:W]J:';7+J/\`9=DW
M*?0J017YG_M_?\&K'@?QOHFH:_\`L\ZG-X%\2(K2IX;U2[ENM%OSU\N.5]TU
ML3SCETS@%5'(Z<OX_P`+5GR8B#A?K>Z_S1&(R&K!<U)I^5M3\)/#.OW_`('U
MV+5=#U#4-$U.!LQWFG7#VMQ&?4.A!S[&OO[]B+_@Y'^/?[+M]::=XUNX?B[X
M1CVI)!JS>5JL"<<Q72CYCCM(#GUKX;^+_P`(?$_[/_Q,U?P;XTT._P##GBC0
MI?(OM/O$VR1'JK`]&1A@JRY#`\5S@;*GCVKZS$Y;@L=2_>Q4HO9_Y,\BG7K8
M>7N.S/ZT/^"??_!3[X3?\%(?!3ZG\/\`7`NLV$:RZOX?OB(=4TK=QN>+/S1[
MN!*F5/J#Q7T?&X+8!SQ7\8OP8^,_BO\`9T^+&B^.O`VNWOASQ=X=F\^PU*U;
M#H3PT;CI)$Z_(\;Y5U)!%?U&?\$A?^"F.E?\%.?V6[?Q3]FBTGQEH$PTOQ3I
M<9REK=A01+%U)AE7YTSR.0?NY/Y'Q/PK/+6JU%WIO[UZ_P!>1]=EF:QQ"Y9_
M$?65%%%?(GLC3@COQ2,X7`R!23XCC+'/'I7@_P"W=_P41^%W_!.WX5R>*/B-
MK9MGE4KINC686?5=:E[16\.06)/5F*HO5F`JZ%&I6FJ=.+;>R6Y$ZD8)RF[)
M'M>N>(;'PWH]UJ&HW=K86%FAEN+BYE6*&!`,EG=B%50.I)Q1H.OV7BC2[?4-
M,O+74+"\C$MO<VTJRPSH>C(ZDJP/J#7\KG_!3K_@L'\4?^"G7BR:UUN>3PK\
M-K:;S-,\'6%R3;X'W9;V08^TS_4>6G(5<_,?V;_X-==4N=1_X)-Z#!+,\D.G
M>(]7M;5&)(@B%R6"+Z*"QP.P-?1YGPO6P."CBJ\ES-VY5TNNYYV%S2%>LZ4%
MI;<_1D=****^9/4"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`**
M**`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHH
MH`*^#_\`@Y>_Y0F_&GZ:+_Z?-/K[PKX/_P"#E[_E";\:?IHO_I\T^NK`_P"\
M4_\`$OS-L-_%CZH_E'/WG^IIN<=.E./WG^II$^8_05^H+;0_0$&"Q'K2'(?D
MX-?:/[.'_!)/7/VP?^"7?BWXU_#]+_4?&?P\\1W%OJFB(?,_M/3$@21G@4#/
MG1$D[>=ZYQR!GXPAD6Y@#`Y![UA2Q-*LY1@]4]3"CB(56XQ>J/KO_@CG_P`%
M6_$7_!+']I.#6U:\U3X<>(W2U\6Z$A+>?#D`7<"]!<0Y)'3>N4/4$?UA?"3X
MN^'/CI\-M"\8^$-8LO$'AGQ+9QWVFW]K)OBNH7&58=P>Q!P5(((!!%?Q`H2O
M(Z]:_3__`(-U_P#@M++^P=\38_A+\0]3D;X/^,K[?:7<\A(\*:A*0#*OI;2L
M1YBCA7^<=7+>!GN5>T7MZ:]Y;KNCQLVR_F_?4]^I_35156QO([NWCEBE6:*5
M0Z2*X974C(((X((YS5JOBSYD****`"BBB@`K^1C_`(+[?\I@_CE_V%X?_2:*
MOZYZ_D8_X+[?\I@_CE_V%X?_`$FBKW^&_P#>_DSU\B_WGY'Q]7TK_P`$:/\`
ME+%^SO\`]CO9?S>OFJOI7_@C1_REB_9W_P"QWLOYO7U^9?[K/T/I,R_W>7]=
M4?V'I_K#4E1Q_P"L-25^7Q/@UL%%%%4,**0L!W%+D>HH`**,CU%)N'K2N`M%
M&1ZBDR!Z4P%HI`P/<4I.*`"BBB@`HHHH`***,CU%`$6_GG;2^9M]ZANKA+6&
M221TCC12SLQVJH'4DG@#%?!7[<O_``<<_LX_L57]YHD7B"X^)'BVTRCZ5X7V
M7*0N/X)+@D1(?HQ/M6E*A4JRY:46V53I2F[139]^&0[?>FER3P!BOYMOVE/^
M#N;X_P#Q0NIK?X<^&/!OPQTQB0D\D1UK4L=`=\H6$'V\LX]37Q1\6O\`@K!^
MTU\<)93XE^.WQ+N$E/S0V>LR:=;_`(16WEJ.G85[-'AW$R5YVB>G1R:O-7>A
M_9%O+'G`%)O(/&*_B!U;XU>,O$%T)M1\:^,=0F!R)+G6[J5@?JTAKJ?AW^VW
M\9?A)JD%YX8^+?Q)T6>W.8_L_B.[V+_P!I"I_$5U/ABK;XT;_P!@U;?$C^U5
M9"3S_*C>$/)K^5W]G;_@YJ_:U^!.I6_]J>,]+^)&EHR^99>)M+B=W4#&!<0"
M.4$_WB6Y[&OU-_8/_P"#K#X,?M(W=GH7Q0TV[^#WB6X81">YG^V:+.YXXN0J
MM'_VT4`>IKS<3DN*H^\XW7EJ<5?+*]+62OZ'ZLT5F^'O$=EXJTBUU'3;VTU'
M3KV,36]U;3++#<(1D.CJ2K*<C!!K1#`]"*\HX!:CD!P<<FI*IZG>KINGW-R_
MW8(FE/T49/\`*A1O*PG*VI_-7_P<C?MJ77[4'_!0O5/!EA?22>$/@\G]AVUN
M#^ZFU-AOO9\=RI*0@]O*;'6OS]"8[UJ>/?&ES\2OB/XE\27CL]WXCUF]U29B
M<EFFN))#SW^]BLVOZ+RG!0PN$IT(]$K^O4_.<96=6M*4NK/6OV"?V2-1_;L_
M;`\#_"W3Y)K>'Q'>[M4NXQDV.GQ#S+B7/8[1M7_:=:_K6^"OP7\-_L_?"S0?
M!7A'2K?1/#?AFT2RL+*!0J11J.I]6)R23R223UK\!/\`@U#T2RU'_@HEXKO9
MPK7MAX.E^RY`)3?<('(].,"OZ)DY(!ZU^6\?XVI/'*A]F*3^;/J<@HQC0]HM
MV/\`+]Z#$":=17PQ[PU8@M#1!P,]J=0>E`'PI_P6Q_X)`:-_P4E^"<VK>';>
MQTSXQ^%K5Y/#^IMB(:FJ@DZ=<O\`\\I#PKG_`%3D,.-P/\R&N:!J'A;7[_2=
M6L+O2M8TJYDLK^PNHC%<6%Q&Q22&1#RCJP((/IQD8-?VK2QY7D`CWK\^?^"J
M?_!O_P##[_@HGXLE\=:'JTWPY^)DL8CN]3MK07-EKBJN$%W!E27&`!*A#`=0
MW&/M^%.*OJ5\/BF_9]'_`"O_`"_(\/-<J]O'VE/XE^)_-+U/<XK]<?\`@T/B
MUD_M,_%Y[87']@#P_9"\(/[D7)F;RP?]O9N/KBG>#_\`@T0^)-[XGBC\0?&#
MP58:(&`EN-.TNYN;ME]5CD*)G'JU?KO_`,$_/^"?OP__`."<7P,B\#>`K6[,
M4TQO-3U6^<2WVL71`#33.`!T`"J`%4#`'<^YQ3Q1@:^#EAL-+GE+ULEWU2U/
M.RK*Z\*RJU%RI'O*CD_6EI,@#K2YK\KNCZT\._X**?M8-^Q%^Q;X_P#B?'9Q
M7]YX7TYI;*VE)$<UPS".(/CG;O8$X["OY/\`X^_M"^-OVJ?BKJ'C7XA^(K[Q
M-XFU20O-<W,F4MUSQ#"GW8HEZ!5&``.]?TJ_\'$!S_P2*^+6?^>%I_Z50U_+
MP0.U?J_A_A:7U>>(M[U[7\K(^1XBK3]I&E?2UQ,8`K^D3_@UF&?^"4VF\XQX
MJUC_`-'BOYNP,`"OZ1?^#68@?\$I]-)[^*M8_P#1]=_'R7]GK_$OU,<@_CNW
M;]3]'Z**0N!WK\9NC[06BC(]11FF`44$XI-P/?I0`M%)O'K2YQ0`449'J**`
M"BDW#UI<CU%`!11D>HH)Q0`4444`%%%%`!12%P.XH#`T`+11D>M&1ZB@5PHH
MI-X]:!BT4FX8SD4N1ZB@`HHR/44A8`T`+12!P>XI<CUH`**,CU%&:`"BBC(]
M10`4444`%%%%`!12;AG&12@Y%`!1110`5\'_`/!R]_RA-^-/TT7_`-/FGU]X
M5\'_`/!R]_RA-^-/TT7_`-/FGUU8'_>*?^)?F;8;^+'U1_*.?O/]32'[PI3]
MY_J:0'=CVK]0CT/T!JZ/Z-O^#/@;OV!/'F.O_"9RG_R7BKY;_P"#E'_@AU)\
M#]>U3]HKX1Z,!X,U.=I_&VAVD?\`R`KEVS_:4"+_`,NLC$B51@Q.0X!1V\KZ
MD_X,\@7_`&!_'?;_`(K.7_TGBK]8?$7AVS\5Z)>:;J-K;WVGZC"]M<V]Q&)(
MIXG!5T=3PRD$@@]C7Y[5QM3#8Z52'?4^+JXB5'%2G!]3^&D`,>,'(SQTIKH"
MN"`0>*_13_@OK_P1<O?^";/Q@;QIX*L;FX^"_B^[;[%(JEQX;NW);[#*W4(>
M?*8]0-N<BOSLQD^W\Z^ZPN+IXFDJD-CZS#8B%>FI+J?O%_P;*_\`!;)?$7]F
M?LT_%K6?^)G&@A\`ZY>29^WJ.NE3.>DH',+$X<!H\[Q&)/W"B<.K>QK^&&RO
MY](U""\M;BXL[RSE2>WN+>1HYK>5&#)(C`@JZD`@@@@@&OZ>?^#?+_@M';_\
M%$?@]'X"\>W]O'\:/!MHHO7<K&?$UJGRB^C7C]Z!@2JHX;Y@`K87Y+/,K=.3
MQ%)>Z]UV?^1\WFN7^SDZD-OR/TJ'2BF"3Y`<<FG@YKYH\4****`"OY&/^"^W
M_*8/XY?]A>'_`-)HJ_KGK^1C_@OM_P`I@_CE_P!A>'_TFBKW^&_][^3/7R+_
M`'GY'Q]7TK_P1H_Y2Q?L[_\`8[V7\WKYJKZ5_P""-'_*6+]G?_L=[+^;U]?F
M7^ZS]#Z3,O\`=I?UU1_8?'_K#4E1Q_ZPU)7Y?$^#6P4F`#[TC/@UYA^UG^UQ
MX&_8G^!NM?$'XAZU!HGAS1H_F=VS+=RD'9!`G625R,!1SU/0$U48N4E&.[*B
MFW9'H=_J,.GZ=+<3S0P6\*F2661PD<:CDEF/``&<DU^<'[=/_!T)^SO^R3JM
M_H/A*XU#XR>+;(M%)!X;9!I-M*/X9=0?]VWO]G$V""#@BOQI_P""KW_!=SXJ
M?\%+M?O=`M;N[\#_``CCE(M/#5C.8Y-10<+)?2KS,Q'/E_ZM3V)&:^&&98D&
M,(HP`!V^@KZK`\.-KGQ#^2/=PF377/6=O(_47X]_\':/[2GQ.NY4\&Z;X(^&
MVGOD(MO9'4KH#MNEG^7/N$%?,OC#_@N#^UKXXNC)=_'KQ[:EC]W3;I;!?RB5
M0*WOV./^""O[37[:VDVVKZ'X$F\,>&[L;HM6\3.=-BG4_P`4<;#S7'OM`/&"
M:^U/!'_!FS\0;RUCD\0_&7PGI\C`;H['3)[C;ZC+%0:]"4LKP_N65_O_`,SL
MYL!2]W3\S\ZK#_@K7^U#I\[R0_M`?%E))/OM_P`)'<-NYST+5Z;\-/\`@X;_
M`&O_`(67<<D/Q@U+78X^L.N6-O?(_P!2R;O_`!ZOK3XJ?\&='Q6T+39KCPA\
M4_!OB">-28[6^M)K)I3Z;OF4?C7YS?ME_P#!.7XT?L">(DL/BGX'U/0;:=]E
MKJT:_:-+O#Z)<IE,_P"RQ#>U;4:F78A\L;-^B_X!K3J8*L^6*5S]-?V6/^#Q
M7QCX>U&VL_C/\,-+\0Z6<+-J?A2<V=]$,\O]GG8Q2''\(DC^M?KO^PI_P5&^
M"?\`P48\-->?"[QI9ZEJ5L@DO="O%-GJ^G9Z^;;2?,5'3S(]\9/1C7\<@<[N
M.E;7@#X@Z]\)_&^F^)/"VM:IX=\1:1*+BQU'3KAK>ZMG!R"KKS^!X/<8-88W
MAVC4BY4?=?X&.*R6G/6EHS^XE6R=H()'44^(GG-?E#_P09_X.#(/VXWL?A-\
M8+G3M*^+MO#C3-315M[3Q<B@9^7[L=YCYBBX5^2H'W1^KL3Y!KXS$X>I0FZ=
M16:/FZU*5.3A-:DE'6CI4;3;.3T%8F0-((Q\QP*\6_;>_;R^&G_!/?X+77CS
MXG:\FD:2I,-E:Q#S;_6;C;D6]K`"#)(<>H51EF95!:I/VZOVV/!7[`?[-VO_
M`!*\<W@ATS28BMK9HP^T:M=,#Y5K"#U=V_(9)X%?RJ?MF_MB?$C_`(*M_M*7
M/C[XBZ[9Z/IT;-;Z3:W$C+IGARR+9$%O&`6=S@%W`W2,,DX"@>OE.4U,94T7
MNK?O\CIH4(M.I5ERP6[9ZY_P5&_X+_\`Q@_X*,ZGJ&A:=>77PX^%SRD6_A[2
M[DK<WT8/RM>W"X,K$`$QKB,?[6,GX.M8XY)E@ARTC'"QHI9V/;`'-?9'P%T[
M]C[X*W,%WX[T'XM_&_48L&6TM)XO#VC%NX^\;B0?\"2OOO\`98_X+\_LJ?LT
MVMK8>&_V3U\$V\9&;G3(+*YN@<]3*X\U^!U+5]LL!B</#EPN';7JO\[F_P#K
M/EV&_=TFF?CUX4_92^*GCVV$NA?#/XB:U">1)8^&[V=#^*QD5=US]C'XQ^&+
M-KC4_A)\4-/MT&6EG\*WT:*/<F/`K^GW]F7_`(."_P!E[]I;4;;3(/'D7@W5
MYR$2R\40'3`S$XVB5OW7YL*^T=.U2#6-/AN[6XBNK:X198I86#QRHP!#*PX8
M$'@BO#Q6>8S#SY*U'E?G<Z:7$CJ:TTG\S^&S5=/FT*^:UOH;BQNDX,-Q$T,@
M/NK`$?E46WGKD_6O[7_C;^R7\,?VD]%ET_Q]\/\`P=XOMIE*D:KI,-RZY[J[
M+N4^ZD$5^8W[=?\`P:1?"KXG6%WJ_P`#M:O?AIKIRZ:3>SR7^C3''W%+DS0_
M7<X]A6F%XEI2ERU8\OGT.VCGD).U2-C^=@=.:5E##&`1WS7L?[:/[!7Q4_X)
M^?$X^%OBEX6N]!N9B38:@H,NFZL@ZO;W`&Q_=<AE[@<5XVQP>G%?14JT:L>>
M#NO(]RG5A./-%W1]F_\`!*[_`(+7?%3_`()?>+;>ST^[N?&'PQN9PVI^$;^Y
M8PJIP#)9NV?L\V/0;&VC<#U'].7[#W[='PZ_X*%?`JP^('PVUDZGI-T?)N[6
M=/*OM)N0/GMKF+^"1?J58<J64@G^,$*2P(KZ'_X)G?\`!27QS_P3&_:1L?&W
MA.>2\TB[>.V\2:"\F+;7++<-R$=%F49,<G\+=<J2#X.;9+"M%U*2M)?<SQ\R
MRN-1>TI*S_,_L<SD9!Z=:J:_I:ZSH-Y:-C;=P20G/^TI7^M<'^RI^U#X/_;(
M^`/AGXD>!-3BU7PUXGM!<V\BD"6!^DD$J_P2QON1U/1E/M7HS#:,=QS7PR4H
M2UZ'R<U9V?H?Q6:[X<G\'>)]5T6ZC\FZT6_N=/GCQ@I)%,\;#\UJ"OM+_@O_
M`/L;W7[(?_!27Q==6]J\/A7XGNWBW1IMN(O-F;%Y!GINCGRV.RS)7Q67(R#U
M'Z5_1N68N&)PE.M#9I'YSBJ3I590?1GU)_P1A_;'L?V&_P#@HGX*\7ZY<BT\
M*:L9/#VNSG[MK;7.%6=O]F.7RR3V4L>U?U96.H17]O'-!*DT,ZAXW0[ED4@$
M$$<$$$<^]?Q32QB:)E8!E8$$'N,=/\^M?JY_P1B_X.(9_P!ECPSI7PJ^.4NH
MZQX$T]5MM"\3QJT][H4/`6WN5'S30+_"X^=`-I#`#'Q?&O#M7$M8S#J[2LUU
M:77U/9R3,(TTZ55V3V/Z""0*,C&>U<O\*_C!X9^.'@>Q\2^#]?TCQ-X?U-!)
M;:AIMREQ!*",XW*3@C(R#R#P0*Z2.7>,]N17Y-).+Y9:,^MBTU=$M%-WG'2G
M4D[E!1113`*;*,K3J1UW"DP/)_VU?VCX?V0?V5?'OQ.FTQM:3P3H\VJ"Q67R
MC=,@^5-^#M!8\G!XK\5YO^#NSXQ2REX?A-\-(8GY2.2^OG9!Z$@@'ZX%?ME^
MV'^S99_M>_LQ>-_ACJ.H7&E6/C729M+DO($#R6V\<.`>#@@<'K7Y(1_\&?5P
MJ!?^%X@[1C/_``CX_P#CE?6<.2R94Y_VDO>OIOM;R/'S&.+<E]7V^1\Q?MO?
M\'%_Q,_;H_9C\3_"[Q!\/O`>BZ5XHCCCGO=.N;M[B$)(L@*ASM.2N.?>OSYV
M@D\5^G?_``4(_P"#<"7]@_\`9&\6_%.3XJGQ$/"\<,@T_P#L<0?:=\JQXW[S
MC&[/3M7YBU^I\/O+G0D\N^"^NZUT[GRV8_6%47UC>WX#&&&XK[L_X)X_\%]?
MB+_P3B_9QMOAKX8\!^"?$&EV^H76HB\U2XNDN&>X?>5(C.W`[>PKX4.2WI7Z
M-_\`!+W_`(-^I?\`@I-^RG;?$Y/B:?"GGZI>:;_9_P#9/VD)]GDV;]^\?>ZX
MQQ59]]06'3S'X+KOOTV)P"Q#G_L_Q'HI_P"#NKXS?]$I^%^?^OR^_P#BJ:?^
M#NCXS.ZY^%/PO.#VO+_/X?-7I/\`Q!^W/_1<1_X3X_\`CE-/_!GY<@<?'!<^
M_A\8_P#1E?&^TX5[?^E'LN&;6_X*/TS_`."87[:ES_P4&_8S\+?%"]\/Q>&+
MW6S/#<V$-R;B*)XI#&2CD`E3C(R,BOH4<')/U->)?\$^/V+-/_8"_92\,_"[
M3-6NM=BT)97FO[B,1O=2RN7=MHR%&3@#T%>PZIK-MHVF3W=[/#:6MK&TT\TS
MB..)%!+,S'@*`"23VK\ZQBI/$2^K_#=V]+Z'TM#G5./M-[:EMY!M&?R[U\K_
M`+=?_!9/X"_\$^&EL?&_BT:GXK5-T?A?P_$-1UA_]^-2$@'^U.\:G'!)XK\R
MO^"P'_!R3K7C;6M4^&_[..KR:-H5NS6FI^-X5Q>7[`D,E@3_`*N/J//QN/5,
M=:_'^>1[JZGN)I)KBYNI&EFGFD,DT[DY+N[99F/<L237VN1<#SKQ5;&MQ79;
MOU[?F>)C<\C3;A2U:Z]#]:/VCO\`@[5^)OBZ\N+?X5_#GPYX.TXMB&]U^=M4
MOV7/WC'&5B0GT^?'J:^3/B%_P7;_`&L_B5<O+<_&36])1_\`EEH]M;Z>B_38
MF[]:\I_9*_8#^,?[<VL&U^%W@/6/$=K')LGU9U^S:3:MG!#W+X0D=U3<P]*^
M^?A=_P`&EOQD\1V$<_BKXB>!O#4K\M;VD,U\R<9Y;Y5/X5]7*EP_EWN34;^?
MO/[M6>2I9AB?>BW;[D?#]Q_P5,_:6N+Q;A_CY\5C+%]U_P#A(9OE_(XQU[5U
M'@W_`(+6?M7>!+N.:S^.7C*\\L@[-3>*_1L?WA*C5]R>*/\`@T-\96VFE]%^
M-'A^ZO-H.R\T>2*-CW^96)QZ5\:?ME?\$._VBOV)=)NM:UWPA_PE/A6T!DGU
MKPRS7\=J@ZO-"!YJ*`,EMI`'4BM<-CLAQ3]G#D;?1Q2_-(B=#'TO>?,OG<^@
M?@#_`,'6/Q[^'MU#%X\\-^"OB-IZ,!(RQ-H]\R]]KQ[HMWU3%?IW^P5_P<%_
M`#]N/5K'P\^K7GPW\=WO[N/0?%`2W6]DXRMK=J3;S<\!=R2M_P`\Q7\P\-PD
M\0=&5E89!!!!_*B6T2YA,<BB1&Z@]_3\1V/7/>EF'!>78B-Z*Y)=U_EL/#9U
MB*;M-\R\]S^U]9`&Y..]/^^I([U_/#_P1J_X.#/$G[+NOZ3\-OC9JU_XH^&D
M[QVFG:]=R-/J/A?)"JLDA^::T''WLO&!G)'`_H/T37;7Q!HUI?V-U;WMC?0K
M<6\\$@DBGB8`JZL.&4@@@CJ#7Y/F^2XC+JJI5]4]GT9]9@\;#$PYX=#3`P*;
M)VY`I5;<H/K4<Y.!CJ3@5Y+V.P3S%13E@!C/L!7QW^V-_P`%VOV;/V*-1N])
MU[QVOBCQ5:#Y_#WA*W.KWRG.-DC(1!"P])IHS[5^8W_!Q!_P6)\:^-_CUXD^
M`GP\UR[\->#/"DBV/B.[TZ8PW>NW90,]N95.Y((PP!52-S9!.!BOR<M[9+>+
M9&BH.2<#J2>2?7_/6OT+(>!OK%&.)QDFD]DM[>;/G<?GJI2=.G&_F?LO\<_^
M#N_7+^XEA^&'P:L].MP2J7OBO5O-G<=C]GMOE4^WFM7RU\1O^#D[]K7Q\THM
M/&/AOPM!)TCTG0804^C2[V_6OA!P2!D\^_->M_L>_L)_%;]O+Q[)X?\`A?X2
MO=>DM"!J&H2'R--TH'IY]P?E5B.0@RQ].]?:KA[*,'!U)TXI+K)W_,\1YCC*
M\K1D[]D=QXC_`."QG[4_B:8O<_'GXA0%CG_0[U;1?RC5<?E6%#_P5)_:6M[D
MS)\>OBPDCDEF'B";+9_'^E?HS\%/^#17Q%J>GV\_Q"^+MAI5P^#+::%I;7/E
M>WF2,H)'KC%>H2?\&@_P\,+`?&3QP'(^\VFVQ`/TS_6O+GG_``]3?*HQ?I#_
M`(!TQR_,)>\VU\S\Q/!O_!;3]J[P+,DEI\</%U[Y>,)J0BOE./42HQ-?1OP0
M_P"#JK]H?X?7D2>,-%\#?$*Q4CS!):OI5V5[[9(<H#]8S7=_M&_\&E_Q$\':
M/<WWPR^(V@^,9(`633=7M3IUQ-_LK(I9`V/7%?EW\;?@9XQ_9L^)>H>#?'WA
MO5/"GB?3,&:PU"+8Y0])(V^[+&>SH2#SW&*[,/2R',TXTHQOZ6?Z&-6>/PVL
MVU\[G]&/["7_``<9_`3]LK7K/PSK%SJ/PF\:7C*D&G>)FC%C?R'/R6U\A,+M
MT`67RG8GY5;!K]`5F65`RLK!P&!'(([&OXHIHDN(FCD0.C=589!YK[__`&#_
M`/@X=^+W[$_[/>N^`;JWA\?Q6]GY7@Z[UB=GD\/2GC9*WWY[=1DJA.00!NV]
M/FLZX#:_>9<WK]E]O)_YGJ8+/[KEKKYH_H'_`&N/VY?A5^PYX$'B'XI>-=(\
M*6,I(MHIBTU[?L/X+>VC#2S-T^XIQGG%?E)^T]_P=S;KJXLO@Q\*)Y(%)6/5
M_&5R(3(/[RV=NS$#/(WR@XZJ#Q7Y"?'7X[^-/VG?BCJ'C;X@^(]2\5^*=3_U
MU]>MN,:C)$4*#Y88AG`C0`<#@GDYOPS^%_B7XT^.K+PSX.\/ZSXK\1ZF?]%T
MW2K9KFYE'=L#HH[NQ"CN:]/+>",'AJ?M<>^9^;M%?YG-B,\K5)<E!6[=S[&^
M*'_!QE^UK\29)/*^(&E^%X')Q%HFAV\(0'T>0.Y_$UY-K/\`P5U_:AU^5VG^
M/?Q+0OE2MOJK0+S[(`!7U'^S[_P:Q_M"?%33+;4/&&K^$/AS#<*'-I<S-?WL
M0/9UB^0'VW&O=8_^#02]%H/,^.,7G8QA?#_R@_\`?S-=+S#AS#OD7)?RC?\`
M&S,EA\QJ*[O]Y^:VG?\`!4S]I736+0?'KXJQL<*<Z_,<X_$UW_P__P""[?[6
MGPZNXYK?XRZWJBIUBUBTM[]&^N],_D:^EOC?_P`&GWQL\$:;/=>"O&W@WQOY
M0+)93"33IY0.P9MR9^IK\XOCK^S]XW_9@^(]SX1^(GA;6/!_B*U&]K/4("GG
M1YQYL+CY)8^"`R$C(QUXKT\)/)<>[45"7E9)_=:YRU5C*'O3<E\S],OV<?\`
M@[.^*O@Z^M[?XI?#_P`->-]-!`ENM#E;2K\#^\%?="Y_V?D'O7ZS?L!?\%8_
M@K_P4>T-W^'OB5X?$5I%YE_X8UF(66M6`_O&$DK*G_36!I(\\;LY`_DW/*\\
M<8]<5J^`O'FN_"OQSI/BCPQK&H>'_$N@W`N].U.QF,5S9RC^)&'.".&!R&&0
M17G9MP/@\1!O#+DFNVS]5_D=6#SRM3E:K[R_$_M+B<'."#3P<BOB#_@A]_P5
M-7_@I3^S3-)KXM;7XF>"GCL?$=K"`B7>Y<Q7L:]DE`.0.%<,/2OMM9"RCBOQ
M[%82IAJLJ%56<78^NHUHU::J1V95O]6MM*LY[JZN(;:VM8VEFFE8)'"B@DLS
M'@*`"22<#%?)'Q/_`."]_P"R#\(O%4NBZO\`'+PQ/J$#F.4:3:WFKPQ,#@AY
MK2&6-<'KEN*^;_VF9/$7_!:K_@HYXF_9WL]>U;P]^SG\%5B?X@RZ5,;>X\6Z
MD^"FG&5>D2D$$#^ZQY.W&7^SI^U5XCL;'XI^&?V>OV*_AYJ7@+X->)+SPE>1
M6^L6MI?ZD]J3EEC>(M,[)ALNS$EL$DUZV'RB'+^]NY63:3223VNWU?:QA/%.
M_NV2\TW>V^Q^C_[//[67PT_:U\)?V[\,_'/AGQOI2X$DVD7R7#6Y/\,B`[HS
M[.`?:O2(6#1J1TQ7XO>)OAYX;_:*_9?E_;C_`&-]`N?@Y\9/A[/<OXH\+VL2
MV]EXBAM&S?Z?=VJ8B=O+!=6"C=M'1]K+^I/[$'[5VC?ML_LI>!_BEH*"*P\8
M::EXT&[)M)@2DT)]TE5U]\`]ZY,=EZH+GA>U[-/=/L^GHT:TJW-H_5>AZW13
M8W+YR,4ZO..@*^#_`/@Y>_Y0F_&GZ:+_`.GS3Z^\*^#_`/@Y>_Y0F_&GZ:+_
M`.GS3ZZL#_O%/_$OS-L-_%CZH_E'/WG^II$^\/I2G[S_`%-(O4?Y[5^H1Z'Z
M"C^D'_@SZL$@_P"">'C"<;O,G\:W(;)X^6"$#^=?K,>BU^4'_!GY_P`HXO%?
M_8[7?_HB"OU?8X"U^99G_O4_4^!QG\>7J<3\?/@9X6_:7^$GB'P)XUTBUU[P
MMXHLVLM0LIQ\LJ'D$'JKJP#*PY5E!!!%?R=?\%;O^"67BG_@E=^T=)X7U![K
M6O`^N[[SPGXA:+:NHV^[F"8CY5NH<[9%'WAM<`!P%_KZ**WI@UX?^WW^PIX)
M_P""B/[.FL_#GQO9A[6]4RZ??H@^TZ/=J/W5S"W9E)Y'1E)!ZUKE>82PU2[^
M%[HTR_&2P]2]]'N?QDGG(KK_`(%?'+Q7^S5\8/#_`(]\$ZM-HGBKPS>+>V%Y
M'R`XZHX_BC=<JRG@J2*Z_P#;?_8J\;_\$_?VB]<^&OCVR\C4]+?S;.\C4BVU
MBT8D174)/5&`Y'56RIY%>08V>HK]$4J=:G=:Q:_`^S3A7IW6J9_7Y_P26_X*
MB^%O^"I/[,-MXPTA(]&\5:.R6/BK06E#R:3>;0<KT+6\HR\<F!D9!^96`^JU
MQMK^-#_@G9_P4`\:_P#!-?\`::TCXC^#)VGCC'V/6]'>0K;:[8,P,EO(/4'Y
MD?JC@$<9!_K=_9`_:R\%_MN?L_>'OB3X"U,ZCX?\0P"0!CB>RE'^LMIE_@EC
M;*L/;()!!/Y_FV62PM3FCK![/]#X_,,#*A/^ZSU6BFJP)X/:G5Y"=SSPK^1C
M_@OM_P`I@_CE_P!A>'_TFBK^N>OY&/\`@OM_RF#^.7_87A_])HJ^@X;_`-[^
M3/7R+_>?D?'U?2O_``1H_P"4L7[._P#V.]E_-Z^:J^E?^"-'_*6+]G?_`+'>
MR_F]?7YE_NL_0^DS+_=I?UU1_8?'_K#3T^Z*C/5J<,;<G/6ORY.Q\(MC+\9>
M*]/\#^&-2UK6+VVTW2=(M9+V]NKAML5M!&I>21CV55!)/M7\FG_!:/\`X*N:
M[_P5,_:=N-3AGO;#X7^$Y9;/PAHSN0IBSAM0F7`'VB?`/?RT"H"<$M^M_P#P
M=I_MS7'P4_9+T/X.:'>M;:Q\5K@OJOEMAUTJ!@SI["678I]0K#H37\Y)^7@<
M<=*^QX=RZ+7UB:]/\SZ')L$G^^FO0<5(P%5FD8@*JJ69R>@`[D]`/>OZ)/\`
M@@U_P;OZ#^SYX1T/XO\`QRT6#7/B;J4,=_I7A^_A#6OA%&^:,R1DD27I7:S;
MAB$G8`6!<_`O_!L#_P`$_K3]K[]N^3QSXCT]+WP?\'88]6$<R[HKO57;_0T8
M$881[7F(_O)'V-?T[PIR3C&[GI4<09I-3^KTG:VY.;XZ7/[*GMU&I`-N>BKP
M`.@'M4I1<`'M3ZC)R>V*^32/`2&R*K#(&3G/6N9^+/PB\,_&_P"'FJ>%?%^A
M:9XD\.ZU`UO>Z=?P">WG0C!!!Z'T(Y!Y'-=.2,]C0,'K@?TIIM.\06CNC^5;
M_@N[_P`$9+S_`()9_&>RUSPJ][J?P;\<7#KHMQ.?,FT*Z&6;3IWSEP$RT4IY
M9`5.6C9F^!#\N37]C_\`P5+_`&1],_;C_8.^)7P[U"WBEGU'29;O2IF7+6>H
M6X,UM,IZ@B1%!QU5F4\,:_CCE@ELGD@GC,5S`[1RH1RCJ2K#\"#7WN08^5>C
MR5'[T?R/K<GQ;JTW"3U1;\.>)M1\&^(K#6='OKG2]7TFY2\LKNV;9+:S(P9'
M0CH5(S7];/\`P1-_X*/1_P#!2W]B+1/%M_\`9X?&V@M_8GBJUBZ+?1*/WRCJ
M$F0B0`]-Q':OY&1@'I7ZF?\`!I=^U#<_"?\`X*(ZG\-I[EAI'Q3T.X6*W+?*
M;^Q0W,;`=,F!;@9_V11Q!@U5H>T2UC^09QA%*G[1;H_I9&!@Y_*H[EE2!F)5
M0.23T'O3A]Q3G/%?)_\`P68_;T7_`()Y?L'^)_&-F8I/%NM,GAWPO;RC<LNH
MW*OM=A_=AB6:=L\$0X[BOA\+AYUZL:--7<FDCX^I-0BY2V1^&O\`P<&?\%!+
M[]O/]LB[\/6ERZ?#+X9S-I^A6:R'&JW0XN-0D7'`9@4C4Y)1-W1\5\,A1T`P
M`,+TX'M4UW>7&JWTUU>W,MY>W4C33W$AS)-(Q+,Y/J3^5-V"OZ"RG*Z6!H*E
M36JW?<^#QV95<4[2?NK9=$,8Y'<T`'H0,9SBI`,"DV"O5/-^1%+&LZ;7177T
M89'Y5]+_`+!O_!6CXV?\$\M=M1X+\33:KX424-<^%-:D>XTJY3/S!!]^W<]G
MB(P>JMTKYLV#WI2@-<V)P=#$4W3KP4D^CU_KY&U*M.E+G@[,_JD_X)A_\%B/
MAA_P4Z\(M'H4DGA;Q]IT/F:OX2U&X5KRU'0RP.`!<P9Z2(!C^)5/%?6^T2]<
M\?A7\7/PZ^(?B#X/^/='\5^$]:U#PYXET"Y6[T[5+"4Q7%I(#G@]U/1E(*L,
M@@@XK^E+_@B9_P`%E-*_X*4_#>3P]XG:RTCXP>&+57U:PB'EPZO#P/MULO\`
M=)X=!G82.Q%?D'$W"<L"GB,-K3ZKK'_-'U^6YLJ_[NKI+\SZM_:E_92\`_ME
M_![5?`7Q'\.6/B7PSJT95X)UQ);R8(6>&0?-%*N<K(A!!K^7?_@LC_P1H\7?
M\$IOBK%+%/>>*?A7XCF8:#XA:$"2!^OV.["\+.HZ,/ED`R`IW*O]:`"LH(->
M?_M,_LV>$?VN?@GK_P`/O'>DQ:SX9\26S6US`R_/$<?++&W\$B-AE8=".]?.
M99F4\+-.+]WJO\CZG!8R="5T].J/XG.E#$'/?M7NG_!1G]@[Q1_P3>_:P\0_
M"_Q,'N8K,B]T+5"FV/6M-D9O(N5]&PI1U_AD1QV!/A2_*<'M7Z-0K1K052#T
M9]K1K1J04X[,_4'_`(-D?^"H=Q^R)^U"/A#XHOW'PX^*]TD5MYLN(]&UC`6*
M=0>`DX`BD'&2(V_A(/\`3$`"@!-?PPV]Y<:5>V]S:3O;7=K(LT$T;;7AD4@J
MZGL00"#7]?/_``1Q_;8'[??_``3X\`>.KJ<2^(%M/[(U]<\C4+;$<K$?[>`_
M/4/7QO$.!4)JO!;Z,^9SK"*$_:):/<3_`(*V?\$T=%_X*:_LOW/A:>>#2?&&
MBNVH^%]8DCWBQO`N/+D'!,,H^1P#D`AADK@_RV_&;X->*OV=?BEK7@CQOHEU
MX>\5>'9C;W]A<=4/9T;H\;##*XR&!!R:_LY"Y'/.*^4?^"G7_!)#X:?\%./`
MT4?B.U;0?&VD1%=&\46$:B]L\Y_=2C_EM`3R8VZ<E2I)SU\+<4/+G]7K:TF_
MFGW7EW/B<URM5U[2G\2_$_E/0`KUZT;`O([U]'?M^?\`!*3XS_\`!./Q%,GC
MGP])J7A4R%++Q;I,;3Z5=+GY3(0-UO(1C*2`#/1FKYO5PR@@@@C((Y!%?LF%
MQ='$P56A)2B^Q\=6HSI2Y:BLSU+]EC]M?XK_`+$OBLZS\+/&VK^%+B5PUQ:P
MD36%]CM-;/\`NI/J5S[BOU?_`&,_^#MBW\NSTCX_?#^6S?`C?Q/X/)G@D/`W
M3:?+B2,<9+12RY).(U&,_B>1D>HI4&2?;O7EYEP[@,<KUJ?O=UH_PW^9U87,
M:]#X'IV/Z_?V8/V^/@_^V7H2WWPT^('AOQ1P#);6]T$NX">SV[XD0_5:]B5O
MI^5?Q3Z+JUWX9\06^JZ5>7VDZK9MOAOK"X>UNH2.A62,JP(/H:^[/V0/^#C?
M]I#]F+['8:YK5I\5/#EJ%C^R^(U_TU4`P`MT@#DX_O[O<FO@LQ\/ZT+RP<N;
MR>C^_;\CWL/Q!3E955;S/Z;NW7\J4$X]:_.?]B3_`(.4O@#^U%=66B>++V[^
M$GBNY=8EM_$##^S;B0D`".]7]V,G/^MV?4FOT)TG5+?6=-AN[.XAN[6YC$D,
M\4@DCE0C(96!P01W%?"XS`8C"3Y,1!Q?FOU/<HXBG57-3=T:%%-5@*=7*G<W
M"D"[<^_-+13`^(?^#B$?\:B?BT?[MO:?^E47^-?R^U_4)_P<0?\`*(GXM_\`
M7O:?^E4-?R]U^P>'_P#N,O\`$_R1\=Q!_'CZ?J-/WQ7](?\`P:S#_C5+IWOX
MKUC_`-**_F[?[QK^D7_@UE_Y13:;_P!C5K'_`*45KQ]_R+E_B7ZD9!_O#]/U
M/T>HHILG0<XK\:/M!6./I7X8?\',/_!6^YUGQ+J/[-'P[U-X=/L50^/M3MI?
MFN)&`=-*0CHJJ5>8@Y)98^SBOU:_X*,?M>6G[#/[&/CSXF7!B>[T#3F&F0.<
MBYOI3Y=LF.X,C*2/[H-?R.>(?$&H^,?$FJ:UK%[/J6M:W>3:EJ-Y.Q>6]N9G
M:2:5V/5G=F)^H':ON^!\CCB:[Q=9>[!Z>O\`P#P,[QSI0]E!ZLJ(%0*`,*,#
M"\8'?';I7Z/?\$*?^"(A_P""@6KGXE_$R*[L_A#H=R8+6PB+13>+KM#AT#]4
MM$/#L/F<_(",,U?#_P"RO^S?J_[87[2O@CX6Z#*UMJ/CC58]/-T%+?V?;\M<
M7)'?RX5D<#N0!WK^O?X+_"+P]\!/A1X?\%>%--@TGPWX6L(M-TZTB7Y8H8E"
MKD]68XRS'EF))R2:^FXUS^>#IQPN'=I3Z]E_F]KGF9+EZJR]K4U2_,O_``_^
M'>A?"WP;I_A[PYI&G:!H>EPK!:6%A;K!;VZ*``JHH``X_&MHH-N,G^52*H"\
M`4U\%3TS7XZVV[O5GV*5E9;";!3&A61&5@"C`A@W(([CZ4XMZ\4!@``2,TD[
MC5S\6O\`@X&_X(7:.OA36_C[\%-&32M1TL->>,O"UC;A;;4X,Y?4;5%_U4\?
M)EC4;94^8;'0^;^(\$HEB5U8,KC((Z8K^U74=/M]3T^>VN8HYX+F-HID=0RR
M(PPRD=P1Q7\DO_!43]EN']C/]OWXF_#^SA:#1['5&U#1U(P%L;D>=$H]EW,O
MT45^L\#9W5KQE@JSNXJ\;]NJOY'R6>X&-.U:"M?<\$E`;((!!&"/45^X7_!K
M?_P4PNO&6FZC^S=XROFGOM"M'U?P5=3R9:XLE(^TV!SU:$LLB8/,;.,`1\_A
MY7?_`+)_[0E]^R;^T_\`#_XF:=*\4W@O7;749@AP9K7S`ES$<?PO`\H/UKZK
MB'+88_`SIOXEK'R:_P`]CR\MQ3H5XR[Z']DB?<'TI)`".:IZ3J<&L:=;W=O*
MLMM=QK-"ZGAT8`J1^!%72<#'M7\_:IV9^@=#^/+]O2^EU']N[XW7$S;Y9/'N
MM!F[G%VZC]`*\L48%>G?MS#/[<?QJ_['[6__`$MDKRY_EQCWK^DL!_NU/_"O
MR/S;$/\`>R]6=M^SC\!=<_:F_:`\&?#;PY(D&L^-M5ATJWN'C\U+,.<R7#+D
M;EBC#/C(SM`XS7];'[('[)?@O]B7X`Z!\-_`>F1Z=H/A^V6/S"`;C49L#S+J
MX<`>9-(P+,WJ<#```_GM_P"#9GP9;^*_^"LWANXN(XY/[`\.ZIJ$&[G;(42(
M$>^';\Z_IBB0+GTXQ7Y9X@8R;Q4,-?W4KV[M_P##'U/#]"*I.IU;'11`#.,$
M4_;\F/:A5"]*6O@#Z$A\H$8P2*^-O^"T_P#P3,T;_@HG^RMJ<5M90Q_$CPA:
MS:CX6U)8\S&5%+-:,1RT<P&W!X#%6[5]FD?+UXJ.89E7C\:VPF)GAZT:U)VE
M%W,JM*-2#A/5,_BA4.HVRQ-!*A*21MP8V!PRGW!!'X4X1\=3TQ7N/_!3?X96
MOP<_X**_&SPU81>18:=XPOI+:(``)%*_G``>G[RO$*_H["5E5H0JK[23^])_
MJ?G%6')-P[.Q=\)^$-3\?^+])\/Z):F^UK7KV+3K"W'_`"WGE<(BG'/WF'/:
MOZI/^"5__!+OP9_P32^!%GHVF6EIJ?CG58$E\3>(VB`N=1N,9:-&Y*0(251`
M<8&3R37\^'_!$[P_;^)?^"KWP/M[I!)%#KQNPI&1OBADD0_@R@_A7]7`&6S7
MYIX@X^JJE/"1=HM7?GJTONL?2\/T(<LJK5WLO(0+N7D9/?FEV#Z9J1%`4<=J
M7:,YP*_-%?N?3D+H"2#S7S?_`,%//^"<GA'_`(*3_LT:IX.UZ"UL?$=K&]UX
M8UXQ;KC0K\*?+D!&&:%FPLD60'4XX8*P^E.G;-(RCK@<5MAZ]2A4C5INTHNZ
M:,ZE-3BXRU3/XK?%/A?5/`GBK5=!UNS>PUK0KR;3M0M7.XV]Q"[1R)[X93@]
MQ@U3(W=L8K[`_P""^/PQ@^%/_!6+XKVUK&L-OK<UKK:HHP-UQ`I<_BRDU\@%
M`37]&9?B77PU.O\`S)/[T?G&)ING5E!=&?<7_!NG^T+<_`C_`(*G^#=,$S)I
M?Q&MKCPU>Q[]JNYC,T#$="0\>!_O5_3RJD#KWK^0S_@FQJ4NB_\`!1OX!W$!
MQ*GC[24'/9YPC?HQK^O1C\AQ7Y5X@45#&PJ+>4=?DSZSAZ;>'E%]&?F9_P`$
M$+J'PI^TQ^V9X2U*,6WBZQ^)LNH7<<K9E>UE#>4W^[P<'IS7S?\`L=>!_P!J
M#Q%8?MH:C^SY\2?`WA&&P^*NOFZTW5=`:ZO[RX52Q>"[W;86,>U5#1-AESN7
M-?6O_!0']B3XK?`S]L.S_:Q_9JL+?6_&:62Z9X\\#2S""/QKIR8PT))"_:D4
M#;G!)4$$G*MY-^Q;_P`%8/V4?V-X_B*-4T?XR_##Q;\1/$EQXJ\2^'?%?AJ]
MN)XM0F&)8H6CC*M'D8&<9KAC6=2,Z]"//SJ%U9.S6Z:>MM-&=;BHVC)VM?7U
M/6/^")_C'X9Z-_P1:?Q-X>T[4=!TJ&UUJ^\6_P!L:@M_=2:C'YGVZ:68*BL&
M*[@`H`4@8.,FU_P;)>'[[1?^"1O@NXNXI(;;6-7U;4=/1P1_HKWCA"/;Y6QV
MKY/^$OP$\2_MV_#'5O@%^S=X0^)7PG_9?\8^(IO$'CGQQXV5K6\U6&5U>73M
M*MF`<12LHR>F,AF`)1OV/^#WPGT'X&?"[P_X-\,V$>F>'?#&GPZ;86T:@"*&
M)0JCCJ>,D]R2>]<6:5(TZ<Z=[RG)2L]TDG:_GKMY&N'BY-2Z)6]3IX!P><YY
MJ2C&**^?1WA7P?\`\'+W_*$WXT_31?\`T^:?7WA7P?\`\'+W_*$WXT_31?\`
MT^:?75@?]XI_XE^9MAOXL?5'\HY^\_U-(O4?Y[4I^\_U-(O4?Y[5^H1Z'Z"C
M^DC_`(,_/^4<7BO_`+':[_\`1$%?J^W05^4'_!GY_P`HXO%?_8[7?_HB"OU?
M;H*_,\T_WJ?J?`XS^-+U%(.3TILB[EY`-/HZUP/8Y;(^-O\`@L?_`,$EO"W_
M``50_9V;2;CR-'^(GAB.6X\):_MYM;@KS;3XY:UF*JKCJIVNO*X/\HWQF^$'
MB;X`?%+7_!'C/2+K0/%/AB\>QU*QN%PT$JGJ#_$C##*XR&5@02#7]OLBB1L=
M,5^:7_!P7_P13@_X*'?"MOB!X!LK>#XS>#[0BW1%"?\`"3VB`L;*0\?O!R8F
M.>?EZ'CWLES7ZO+V-3X7^!ZV6X]T9<D_A9_,.`<<5]Q_\$/?^"O^L?\`!+K]
MH);76)[O4/A#XQG2'Q'IH)<Z<_W4U"!>TB#[ZC[Z9[A<?$VH:=<Z1J-S9WEO
M-97EG*\%Q;S(4E@D1BK(ZGE65@00><BJP&XD&OM<1AZ>)I\DM4_ZN?45J,*]
M.TM4S^XWP'XVTCXB^$=-U_0=0M-6T36;6.]L+VUD$D-U#(H9'5AP001BMG>,
M8Q7\Y/\`P;8_\%L3^RMXRT_X`_%+50OPW\1WOE^&-4NI,)X9O9G_`./>1C]V
MTF=NIXBD;)PK,5_HSB9B#D8]J_-\=@IX:JZ<EZ,^*Q6&G0J<LB4-E0?6OY&/
M^"^__*8+XY?]AB'_`-)HJ_KGZ`9K^1C_`(+[_P#*8+XY?]AB'_TFBKU>&_\`
M>ODSNR/_`'CY'Q_7TK_P1H_Y2Q?L[_\`8[V7\WKYJKZ5_P""-'_*6+]G?_L=
M[+^;U]?F7^ZS]#Z7,O\`=I?UU1_8=_&:).1P>>U'\1ILK!$+$X"C<?H!FOR]
M]#X3HC^5+_@Y1_:+N?CW_P`%9O'=B9/,TSX?06WAJR0-N13'&LLS#T)DD(/^
M[7P4#W->H?ML>.YOB?\`MG?%OQ#,S.^K^,-5G!)R=OVN15_\=4"O,`,FOU++
MZ?L\/"*[(^\P5/DH1BC^ES_@UI^&6A?L^_\`!+ZV\5:K>Z=I-_\`$77;K5)I
MKJX2#S(HR((A\Y'`"$\>M?;?Q+_X*3_`'X/1R'Q+\9?AOI/EG#+-K]N67VPK
M$YK^-6^\2:AJVF0V%UJ>HSZ=:C$-K+=2-;PC/14)*CD]A629K*WEY:UCQZE0
M3^'>O`Q&0*I5E6J3W9X];*%*HZE2HE=G]87Q'_X.1_V/?AVDF?BK#K<L3$>7
MH^FW-X6QZ%4VD?C7A'Q#_P"#OG]G7PPTJ^'_``K\3/%#`G:R:?!9QR<]<R2`
MC\J_GB\#_!3QM\3)%3PSX+\7>(F;&T:7HMS=YST_U:&O;O`/_!';]JOXFHK:
M1\`OB28W`*R7NF?V>A'7[TY04+)<#3_B3_%`LMPD/CF?IW\1_P#@\\P'3PA\
M`I9.<++K7B=8QCU*0P-^6ZO!/B-_P=[_`+3'BDW,6@>%/A#X5MI2#%(NEWM_
M=Q?\#DNEC;\8:\Q^'?\`P:_?MB>.U@>Y\%^&?"Z3]3K/B2V4QC_:2'S6'X`U
M[M\/O^#./XV:S'&?%/Q5^&?A\-RXL+>\U(I]-RP`_I2]GE%/XFG\[_D2X9=#
MK<^6_B)_P<4_MF?$A9HI_C5=Z1:S<?9](T'3+$(,<[9%@\T?BYKXOU*_FUC4
M[J\NYY+B[O)7GGE<Y:61R69C[DDFOWC^''_!F3X:LE0^+_CIXBU'!RRZ/H,-
MF&'IF1Y2*]S\`_\`!I'^R]X8*MK%S\0O$S#K]JUD0*?PB5:VIYOEU#^%'[DS
M2&98.C_"B?S0O(J')(Q]:^VO^#=;X;>(OB3_`,%@OA%<^'(;EH?"MW=ZQK%Y
M'&7BL;);&XC<R-T7S#(L(]Y1Z5^^G@#_`(-XOV0?A\RF'X/:/J;IT?4[F>Z/
MU^9L5]-?!#]F+X??LV:))IOP_P#!GASP=938,T>E6$=L9L<#>RC<V.V2:X\=
MQ#3JTI4X1>O<PQ><QJ4W3C'<[R.0%%..#7X#_P#!VI^T'<>+/VH_AQ\,X;@G
M3?!VARZW/`",&[O'\M6/?<L,1`ST$C_WJ_?<95<=/>OY@/\`@XP\03Z]_P`%
M@/B4LWW=.LM*M(O9!9HW\V-;<#8=5<SYY?9BVO71?J?#9[4<,,TNKL?$*#YJ
M?34&#^%.K]L/B0HHHH`****`$?[IKK/@'\>O%G[+GQE\/?$#P1J3Z7XH\+72
MW=G-_!*.CP2C^**1<HR]P?6N2D&5I`<#WK*K3A4@X5%=/0<)N,E*.Z/Z[_\`
M@GK^VWX<_P""@7[*/A;XF^',6ZZQ`8M2T_.9-)OXCLN+9QV*N#C/WE*L.#FO
M;RV5(//%?SA?\&SO[>[?LP_MI_\`"K]:O"G@WXSNMG;AWQ'9ZXBG[,^.WGH&
M@..K&'TK^CQ>%'(K\#XBREY?C)4?LO6/H_\`(_0,OQ2KT5/KU/S7_P"#F_\`
MX)W6W[7_`.PC>>/=&T_S?B#\&Q)K-A)"N9;W3FV_;K5NY&P"91R0\``P';/\
MPB,)`'4Y#<@U_<UKNC6OB/1KO3KR-9K2]@>WGC89$D;J593[$&OXP_V_/V<W
M_9)_;8^*'PY*E(/"_B"YM[7C`-LS>9"1[>6Z_E7J<,XJZE0?35'V.18AZTGZ
MGD0'-?N3_P`&;'[04IOOC+\*[B;,*)9^*;")FSC)-O/C\1"3[FOPVK])?^#4
MKQP_A+_@KGINFK(RQ^*?".K:<Z`\2%!#=#(]O(->MG=+GPD[]-3TLWCS89^1
M_3_DN3BE\LY'^-)&V7J2OSFR/C&9NNZ!:>)M(N+#4;2UO["\0QW%M<Q++#,A
MX*LC`A@?0BOSA_;9_P"#8/X%_M'WEYKGP]EOO@UXFN=\KIHRBXT2ZE8YWR6,
MG$1[9MWB'<JQK]+]PQUICC*$9KKP>88G"2Y\/-Q?X?,YZV'IU8VJ1N?RZ?MA
M?\&__P"TC^R%'=ZC_P`(M%\1_#=L2QU3PF6NW51U:2V($R>^`P'K7Q9,KV5[
M);SQRV]S"VV6&:-HY8F[AD8`@_45_:V4&.#CW%?/G[77_!++X$_MQ6\[_$#X
M?Z/?ZK.FW^V+6/[)J2'^]YT>&)_WLU]YEOB#5C:.-CS>:W^[J>#B>'X/6B[/
MLS^2<DXP1CO29QTK]A/VR?\`@TU\3>&$NM7^!/CBU\06RDNOAOQ0PMKH_P"S
M#>("C'L!*@]WK\K?CU^SMX]_9:\>-X8^(_@_7_!>O*6\NWU2U,2W0'5X)!F.
M9?>-F&.]??Y=GV"QO^[U$WVV?W?J>!B,OKT7[\=/P.+>,2H58!E88*D9!'<8
M^GN*^E?V"/\`@K/\;O\`@G1K,"^!_$LFJ>$A(&N_"6NL]WI%PO?RAGS+:3'1
MX649QN5QQ7S8BD'G^5.;H:[L5@Z&)ING7BI1?1F%&O.E+FINS/ZF?^"8?_!9
MWX6_\%,=!:QTJ9O"?Q#LH/,U#PGJ4RFZ4#[TML_`N8O]I!D<;@*^PXY@[#&>
MG3%?Q8>#_%VK_#OQCI7B'P]J5[HFOZ'<)=Z=J-G*8KFRF7HZ..1Z$=",@@@U
M_2%_P0J_X+*Q?\%$_A[<^#?&SVMC\7_"5LDEZJ`1Q>(;3(47L*]F!XD0="01
MPW'Y'Q/PF\"GB<+[U/MU7^:\SZW*\VC7]RII+\S]$-_/>G`Y%01,6/(VGTZX
MJ9#E17PZ=SWCXD_X.(/^41/Q;_Z][3_TJAK^7NOZA/\`@X@_Y1$_%O\`Z][3
M_P!*H:_E[K]B\/\`_<9?XG^2/CN(?X\?3]1C=!7](O\`P:R_\HIM-_[&K6/_
M`$HK^;IN@K^D7_@UE_Y13:;_`-C5K'_I16W'_P#R+U_B7Y,SX?\`]X?I^I^C
MU,D`R*?3)/O"OQ=GVCV/QK_X.[OCU-I/PK^$WPQM;ED3Q#JMQK^H0@@"2.UC
M$<.>^/,E<_A7X:'[GUK],?\`@ZU\;R>(O^"C?A_1BS-#X<\'0*JGHIFFDD)_
M+'Y5^9K8`K]VX/PRI973_O7?WO\`R/@\YJ<V*EY:'ZB?\&I7P7LO%7[:GCCX
M@:GY45M\/?#:VUO-,X5(KB^D*YRW&1%"_P#WU[U^Z7C7]K[X4_"^WW^(?B1X
M&T=4&3]JURVC/Y%\U_'C::SJ&G65Q!::AJ5I;W?^NBM[J2&.?'3>JL`P'.,Y
MQFLBXM],LGWS+81-_>F9`1[Y:O.SGA!9ABGB:M6RLE9+:WG?]#JP.;*A25*$
M+L_JR^(?_!>7]DOX<%TN_C1X7U"6,'Y-+,E^6/H#$K#/XUX;X]_X.I_V8O#9
M(TF+X@^*&&1_H6A&%#CIS,R5_.IX5T6\\:7`MM`T[4M;G<[5BTJPENV/T$2M
M7KW@/_@G+^T+\4E5M"^!OQ4OD?@2OX>GMH^?]J4+Q]:XX\&9315ZU5_-I&SS
MG&3?N0M\F?K!X]_X/`/#5L&7PI\"_$]_)@[7U;7;:R7ZX19#7A_Q"_X.X?CK
MK;G_`(1?X9_"GP[&<X.IRW^K2*/4;)+<9_`BOGKX?_\`!O5^U]\08@R?"F/0
MHR1\VLZ]96I`]=JNS?IFO;/`7_!IY^T5X@6-]?\`%WPJ\,K)]Y([J\U&5!WR
M%BC4GZ,::P7#%!>^TW_B;?Y@J^9U=D_NL>2^._\`@X]_;"\:M(+;XE:+X8AD
M)S'HOA2P3:#V#7*3M^(.?>ODWXY_M`^-_P!ISXB3^+/B%XGU/Q?XDN(DMI-1
MOS'YIB3[B`(JJ%&3@`=Z_7/P%_P9^7/FHWBKX];E(^>/1_#"Q,I]`\TSY_%:
M]L\"_P#!IC\!-!*-KWC#XE>)&7[ZM?16D;_A&@Q^=;T^(>'\(^;#))_W8N_W
MV)J9=F%?^*_O9_/B>#SQ[GBFV^DW7C"ZCT;2[2;5-6U=OL5G96L9FN+N:3*1
MQH@R22S`=._UK^G7P)_P;C_LD>!6B8_#>76Y(_XM4U.XN=WU&X`U]"_`[_@G
MK\$OV9]4CU#P+\,/!WAO4801'>VVG(;F+/7;(V64^X(KGQ?B#AE3:HTVWYV7
M^8Z/#U924JDDD=?^S;X4U3P'^SQX!T+6VW:SHWAW3K#4#G=FXBM8TEY_WE;F
MNX(*I^%*D6ULY/6G-TK\HE+FDY/J?6*-HV/X[/VY_P#D^+XU_P#8_:W_`.EL
ME>8?Q#CN:]0_;G_Y/A^-?_8_:W_Z6R5Y@W4?Y[U_26`_W:G_`(5^1^:5_P"*
M_5GZ*?\`!K4V?^"JT?\`V)VI?^APU_2;US7\V7_!K7_RE6C_`.Q/U+_T.&OZ
M3AU-?CW'7_(S_P"W5^I]ED/^Z_/_`""BBBOC3VPJ.922*DILG:DQ/8_D]_X+
M4C/_``5A^.N.WB0_^B(J^8^M?3G_``6F_P"4L'QV_P"QB;_T1%7S$GW17]%Y
M-_N%%_W8_DC\WQG\>?J_S/K'_@A?_P`I:_@K_P!A:;_TEEK^JS=DD5_*G_P0
MO_Y2V?!7_L+3?^DLM?U5#[WXFOS#Q!UQT?\`#^K/J.'OX,O7]$2I]P?2EI$^
MX/I2U\(?0A4<O)/TQ4E1O]X_Y[4`?S1?\'.$*1?\%9==95"F7PUI;-[G;(,U
M\`5]_P#_``<Z?\I9-9_[%G2_Y25\`5_0?#O_`"+:/^%'YWF7^\S]3V#_`()V
M?\I#/@-_V4#1O_2I*_K[[?\``J_D$_X)V?\`*0SX#?\`90-&_P#2I*_K[/3\
M17Y]XA?[S2_PO\SZ+AS^%/U!XB1^(_#FJE[H%KJ,BO<6MK<2I]UY8E=E^A(K
M0HK\]B[:H^A:ON0);L%`)!QTP,`?A4RC"BEHI6&%%%%,`KX/_P"#E[_E";\:
M?IHO_I\T^OO"O@__`(.7O^4)OQI^FB_^GS3ZZL#_`+Q3_P`2_,VPW\6/JC^4
M<_>?ZFD7J/\`/:E/WG^II%ZC_/:OU"/0_04?TD?\&?G_`"CB\5_]CM=_^B(*
M_5]N@K\H/^#/S_E'%XK_`.QVN_\`T1!7ZOMT%?F>:?[U/U/@<9_&EZCJ***X
M3F$*@TUXP3DCIR*?2-TZ9I60'XG_`/!RQ_P0^?XFVNJ_M&_!_1&D\2V<1G\;
MZ%8Q9;5X4'.I0(.MPB@"55_UB*&QO5B_X#1R"4!E.X'D$5_=))$)8V#*"K#!
M4C(-?SD_\''W_!$(_LH^*;[X\?"K2G/PVU^[+^)=*MT&WPS>2-Q.B@<6LK'G
MM&Y`X##'U>0YMRVP];Y/^OP/>RG,>5JC4?H?DBR"1"K<J1S7]"__``;3?\%L
MV^/7A>Q_9]^*NL@^.=!MQ'X3U6\E^;Q!9HO_`!ZNYZW$2CY<\N@[E3G^>HK\
MP]^E7_#/B;4_!7B?3=:T>_O-(UC2+F.\L;VTE,5Q:3(P9)$8<A@1P:^AS'+X
MXNDXRW6S\SVL?A(XBGY]#^Y4$XY-?R-_\%]S_P`;A/CG[ZQ#_P"DT5?O3_P0
MC_X+&:=_P4]^`O\`9'B2:TT_XQ>";:./Q'8IB)=3B^XFI6Z_\\Y#CS%'^JD;
M'"LA/X+?\%]AG_@L)\<R.VLP_P#I-%7S&0T)TL=*G45FDSPLIIRIXKEDM;,^
M/Z^E?^"-'_*6+]G?_L=[+^;U\U5]*_\`!&C_`)2Q?L[_`/8[V7\WKZK,O]UG
MZ'T&9?[M+^NJ/[#Q]\_C5;5R5TBX*C<1$^!G&?E-61]\_C4=S"+BW>,G[RE?
MS!%?EZ>WR/A%LC^'_P"+#-)\5_%C.A1VUN^+*3D@_:9,C/>N?;J>U=S^T_X8
ME\$?M,_$C1ID,<NE>*M4M&4]BEY**X8]37ZQA_X<?1?D?H6'_@Q]$?T4_P#!
M`C_@EQ^S#^TS_P`$YO`/Q!\4?![PCXH\8W375MJM]J@EOA<313NN6BD<Q+\N
MW@(![5^E_P`,OV+_`(/?!4@^#OA3\./"A!W;M'\-65B<^N8HUYK\Q/\`@SP^
M/L7BK]DCXB?#J:=#>^#/$*ZA#%_$+>\CR&^GF1N*_8=&#]#D8K\YS*56&)G&
M4GOW/B<:YQK2BV]PA@2",(BJJ*,``8`%.V#.:=THKS[G&)Y:^@H\M?04M%`#
M1"H[4H4+_P#KI:*6@"!0*-@I#*J]2!2>>N[;GGTI:+0`*`8&!7\PO_!R#X5?
MPQ_P5V\?R."5UG3-)OXR?0VHC/ZH:_IZ=@R$_A7X)?\`!W!\"I?#W[17PJ^(
M\,)^R>)]&N=`N'`X-Q:2"9`?0F.9L9ZA&]*^PX'Q$:69J#^TFOU_0\;/:3EA
M6UT/R.`Z'VI:;&^[@=!3J_;CX@****`"BBB@!&&11L%+10!-H?B+4/!WB'3]
M:TJYDLM4T6[AU"QN(SA[>XAD66*13V*NBD>I`%?V$?L<_M`6_P"U1^RSX`^(
M=KLV>+M$MM0E5,8CG9`)4'^[(''X5_'<_P!_/^<U_1Y_P:X?%^7XA_\`!,BW
MT*>5YIO`_B&]TI2W186*S(H^GF-7Y[XA8-2PM/$16L7;Y,^AX?KM594NZO\`
M<?I"XPI^N*_E]_X.IOAVG@K_`(*SZKJ44(AB\3^&M-U!B.DDBJT+M_XX*_J%
MD8*A_.OYM/\`@[XO+>;_`(*+^$(XE`FA\%0^<<Y+9N9BOTXKX#AZ5L6K=F?H
M63NV)1^4M?H)_P`&OEG->?\`!9GX?O$FY+;1];EE/]U/L#IG_OIE'XU^?1Y'
M2OUA_P"#0'X1R^*O^"AGC;Q@R,;;P?X,DMMV1A9KRYB"CZ[()*^NSF5L'/T/
MH\TE;#21_2+&H!I]1(XW#D=*<9AG`/-?FJUU/B4A]!&:;YB^M*&!-%T`%`:0
M1@"G44P&>6IR0.?7O7"_'[]G/P+^U'\.+OPE\1/">A^,/#E]CS+'4[59D5N@
MD0GYHY%S\KH0RGD$&N\;H:BSVY_&B,Y1ES1=GW)DKJS5S^>__@K7_P`&X.N?
MLN:)JWQ%^!AU3QAX#L4:ZU'PY,3<:OH<(&6>%OO7,"CDC'F*HS\X!-?E?!,M
MQ&'1@Z,,@CN*_M=G0N3\I.017\Y7_!R/_P`$S=,_8Q_:)TSXD^"K"/3O`WQ3
MGE%S8PJ%@TK5T&^144?=CF3+@=`ZN!U&/U/A#BJI7J+!XMW?V7W\G^C/E\WR
MF,8NO1T75?J?FWL%=I^SK^T1XF_9'^.GA;XD^#KAX/$/@Z]6^@7>0EY&.)K:
M3UCECW(P]P>H%<8ARHI&)#*1P0>#Z&OT6M2C5ING45T]&?.0J2C)2CNC^R;]
MG'XY:)^TQ\"/"?Q"\.3B?0O&&E6^JV;9R565`Q1O]I6RI'8J17<H,CGM7YI?
M\&K?Q>N/B%_P3$E\/74S2-\/_%FHZ+;AB3Y=O((KR-<^@^TL!Z`"OTMB&5_"
MOYSS/"?5L74H+:+:^73\#]&PU95*,9KJ?$W_``<0?\HB?BW_`->]I_Z50U_+
MW7]0G_!Q!_RB)^+?_7O:?^E4-?R]U^J^'_\`N,O\3_)'RO$/\>/I^HQN@K^D
M7_@UE_Y13:;_`-C5K'_I17\W3=!7](O_``:R_P#**;3?^QJUC_THK;C[_D7K
M_$OR9GP__O#]/U/T>IDPR!3Z9*<8K\8/M3^:'_@YO<M_P5DU\%CQX<TO'/3]
MVU?GV1E>U?H__P`'2_A5]#_X*?QZ@R[8M<\)6,\9QU,;21D_I7YQ$93H!Q7]
M`\.3OEE!_P!U?@?GN9K_`&F?J?IC_P`&U'[&GP:_;5^*'Q5T;XL>!=)\:7>@
MV.G:CI`OY)@ENC/-',`B.JN"5C^\#C/&.:_</X<?\$W_`-GWX0-#)X9^"7PI
MT:YMQB.YM_"UDMR/3]Z8]Y_%J_`C_@VA^/4?P8_X*EZ)HMU*(K+XCZ+>>'SG
M[K7"J+F$?B87'N37]+\;`CCI_*OS'C2IB*68N'/+DDDTKNWW;'T^21IRPZ:2
MNKD>F:1::-:+!9VMM:0KT2"(1HOT`&*L-'@G&>?>G(,**6OC')O5GM)6&?9U
MW9QS2K$J]!3J*!B>6OH*01*JX`P*=10`WR@>M#)F@R!>O%,^U(6(#`D4EY`O
M(EI&Z4BRJPR#0S`CK30F?QW?MS_\GP_&O_L?M;_]+9*\P;J/\]Z]/_;G_P"3
MX?C7_P!C]K?_`*6R5Y@W4?Y[U_26!_W6G_A7Y(_,Z_\`%?JS]%/^#6O_`)2K
M1_\`8GZE_P"APU_2=7\V/_!K7_RE6C_[$_4O_0X:_I.K\?XZ_P"1G_VZOU/L
MLA_W;YO]`HHHKXT]L*;)VIU-D[4F)G\GO_!:;_E+!\=O^QB;_P!$15\Q)]T5
M]._\%IO^4L'QV_[&)O\`T1%7S$GW17]%Y/\`[A1_P+\D?G&+_CS]6?6/_!"_
M_E+9\%?^PM-_Z2RU_54/O?B:_E5_X(7_`/*6SX*_]A:;_P!)9:_JJ'WOQ-?F
M/B!_OT?\/ZL^GX=_@R]?T1*GW!]*6D3[@^E+7P9]"%1O]X_Y[5)4;_>/^>U)
M@?S1?\'.G_*636?^Q9TO^4E?`%??_P#P<Z?\I9-9_P"Q9TO^4E?`%?T)P[_R
M+:/^%'YWF7^\S]3V#_@G9_RD,^`W_90-&_\`2I*_K[/3\17\@G_!.S_E(9\!
MO^R@:-_Z5)7]?9Z?B*_/_$+_`'JE_A?YGT7#G\*?J2T445^>'T04444`%%%%
M`!7P?_P<O?\`*$WXT_31?_3YI]?>%?!__!R]_P`H3?C3]-%_]/FGUTX'_>*?
M^)?F;8;^+'U1_*.?O/\`4TB]1_GM2G[S_4TB]1_GM7ZC'H?H*/Z2/^#/S_E'
M%XK_`.QVN_\`T1!7ZOMT%?E!_P`&?G_*.+Q7_P!CM=_^B(*_5]N@K\SS3_>I
M^I\#C/XTO4=1117"<P4444`(W0UB>,?!VE^/O"VHZ+KEA::KHVL6SV=]97,8
MDAN(74J\;*>"I!(-;E,9`W!-%VM@NUJC^4[_`(+J_P#!&[5_^"8/QR&N^&X+
MK4/@OXRN&;0KULN^BSD%FTZX;^\,$Q.?OIQ]Y6KX+D!WYK^V3]IG]FWP;^UI
M\#_$7P\\>:1!KGA;Q-:/:WEO+PR_W98VZI+&V&1QRK*"#FOY,/\`@J3_`,$S
MO&'_``2]_:7N_!>O_:=3\-:B7NO"^OF+;%K-INX!(X$\>0LB]C@XVL*^XR/-
M56C["K\2V\SZC*LQYE[.H]>AY7^RY^TSXP_8X^/GASXE>`]2?3/$OAFY\Z%P
MW[NYB/$MO*O1HI$)5E/4'U%=9_P48_:FT_\`;6_;3\:_%/3-/NM)M/&4EO=F
MSN""]M*L$:2)D=5#JV#W&*\2QM&>H/M29XQ[YKW5A:;J^WM:1Z[PT/:*K;46
MOI7_`((T?\I8OV=_^QWLOYO7S57TK_P1H_Y2Q?L[_P#8[V7\WK#,O]UGZ&>9
M?[M+^NJ/[#T_UM#M@_0TB?>_.G/&"#[U^7]3X-'\C?\`P7P^!-Q\`/\`@K3\
M8-/>W^SV7B'4H_$=AZ20W<2N2/\`MJ)!^%?'PZ>E?O)_P>!_L53ZOX5\"?'G
M1[-I%T1_^$;\0O&F2D$I+VTKD=@^Y,G@;UYYK\&Y/E;GIFOTG)L0JV&BUNM&
M?;9564Z"\C[?_P"#>[]N^U_82_X*/^';O7;XVG@OX@PGPKKDCOMBMO.=3;7+
M]L1SA02>B2R&OZPX#EB#U'4^M?PN/&)8RC#*L,&OZ4/^#<3_`(+46?[87P=T
M[X-?$?6X8_B[X,M!;:=<WDP5_%^G1#$<RD@;KJ)`%E7)9PHER=S[?$XCP#;6
M(@O)_HSR<YP;4O:Q^9^K-%1I*64YQD?K3U.Y0:^23N>`+1111=`&.,4T_(M(
M).#[5QOQP^/'A']F[X7ZOXU\>>(=+\+>%-"A-Q>ZC?R^7'$HZ`=2[D\*B`LQ
M("@D@545=V06>R//?^"A/[=?@_\`X)W_`++GB#XF^,9"]KI8%OI^GQN%GU>^
M<'RK://\3$$D_P`*JS=!7X7_``J_X.X_CO8?'^PU3QCX;\%7_P`.KO4$6]T2
MQM'BNK2S>0*WDW!8EI40Y&X88C!`SQ\P?\%E?^"MOB/_`(*J?M"?VC&M]H7P
MQ\+R20>$]`F(#JC</>W`7@W,P`R,D1IA%)^9G\\_X)>?LBW_`.W7^WO\,?AO
M:VSW&G:CK$6H:Z^#MM]*M6$]V[$`XW1(8U)X,DL:_P`5?783*:-'"2JXE7DU
M?T/H</EL*>'E4K;V/['M.NH[ZPAN(B9(9D5XVP1E2,@X/3@U\6_\%_\`]C2X
M_;._X)J>+[#2;1KSQ5X&EC\8:'&OWII[17$T0]3):27,8']YU/:OMF-0(5P`
MH'0#H*BFA%Q"R,JLD@PRL,AAW!%?+X3$RP]>%>GO%I_<?-5::J0=.74_BBM+
M@7<22J25D0,I(P<'GIVJ:OL+_@N+_P`$[I_^">_[:^KP:3820?#CQ[)+K?AB
M95/E6^]MUQ8Y_O12$E1U\MT_NFOCO)5B#VK^B<OQM/%8>%>F[J2O_7H?G.(H
M2HU'3ET'44#ISUHKL,0HHHH`****`&-U'XU^[O\`P:!W\LW[.WQHM&$GDVOB
MJT>,G[I+V@W8_(9K\(@-QQ]:_H'_`.#2OX=7'AK]A3QMXCEB*IXJ\83>0Y/^
ML2WACCS]-Q(KXWCJ:65M?WE^9[&0K_:EZ/\`$_5:0;@0!U&*_E:_X.;/BQ;_
M`!3_`."O7CB*TE\V#PIINGZ&V#N"2QP[Y!['=)7]0'QC^*>D?!#X5>(_&&NW
M4-EH_AG3I]3O)Y7VI''$C.<G\*_BS_:(^--]^TA\>O&OC_4V8WWC'6KK5G#<
ME%ED+(OX+M'X5^<\-4.:NZO1(_4\DI7K.?9''9RY%?T;?\&IG[/=O^S;_P`$
M[/&'Q?\`%+V^CP>/M0FU,WEV1$EOI5BC()7<](\B9\YQCFOP7_8V_92\1_MO
M?M,^#_A?X7@FDU+Q5?+!+,B%EL;8?-/<-Z*D89CGC@5_2-_P7$^%R_LS?\$#
MO&O@GP%!)8:'X9TO1-$9+8;6735U&SBN.!V>,L'Q_"[D\9KULYJ*K4IX).SG
M)7\C7B'&<E/D7J?*O[8'_!V=<6OC:]TKX&>!=.U30[.4QQ^(?$;R+_:.UB#)
M%;)AEC/\)=@Q'.!FN3_9]_X.V_'.D^-(5^*WPWT'5?#,K@7$_AR62"^M$_OK
M'*2LN.25RI..*_(;:-P''3'7/':E"E6X..G0X_E7W4>#LKC1]ER:_P`S;N?D
M;SC$RJ<ZEIVZ']DW[/G[0/A#]J'X0:%XZ\$:Q;Z[X9\00">SNHOR9'4\I(K9
M5E/(((KMPV,>YK^<O_@V[_X*9G]E']I$?"3Q?J:6_P`//B;<B.QEN)`L.CZP
M1B,\\*DX'EGH-VSUK^C&.4E\9`(-?DF?9/4R[%.C+6+UB^Z_K<^NP&+6)I*:
MWZHL`Y%%%%>,=P4444`,8Y-?GQ_P<V^`[3QE_P`$H?%=Y/'&UQX=U73]3M7/
M5'$P0X^JN17Z#2`J>".E?E]_P=6_M"V/PW_8`TSP(MQ#_;7Q'UZWAC@WCS/L
MMM^^FDV]=H(09Z98"O7R"$Y9C15/?F7_``3CQ\DL/-OL?SQI]T4CC(_E3J;(
MZQ_,Y"JGS,2<``=S[5_0NR/SL_>[_@T.TR>#]D+XN7;;OLMQXZ$46>-S)IMI
MN/I_$H_"OURA_P!6*^#?^#</]G2Y_9Z_X)5>"9=2MY+75?'US<^+[F*1=KHE
MTP%OG//-O'"1_O5]YQ_=K^>N(*\:V8UJD-G+\M#]#P$'##PB^Q\2?\'$'_*(
MGXM_]>]I_P"E4-?R]U_4'_P</_\`*(CXM<-C[/:9]O\`2XN?I7\O:$D<C%?I
M'A^_]AJ?XOT1\WQ!_'CZ?J-;H*_I%_X-93C_`()3Z=Q_S-6L#_R.*_FZ/7!]
M:_HS_P"#5;53>_\`!+IX-Z-_9_C+5H@`.4RT;X/O\_Y$5T<?+_A.7^)?J9Y#
M_O#7D?IA3)AGZT^F2GD8ZBOQ@^UO;4_#W_@[V^"LEOX@^#'Q'@B)BD2^\.7C
MJOW2-L\.X^_[S'T-?C&G"BOZK?\`@M)^QE-^W/\`\$]O''A'2[;[7XHTN-=>
M\/HJY=[ZURZQK[R)OC'O(*_E.C<N@)#(>A5N"A[@^A!X(Z@Y':OV;@;'*M@/
M87U@[?)ZK]3XK/Z')B.?I)&U\/OB)K?P>^(WA[Q?X:N19^(_">IVVLZ5.PRL
M=U;RK)'N_P!DE=K?[+&O[`/V4?VEO#O[7O[.WA#XE>%I3)HGC#3HK^&-R#+:
M.1B2WDQTDBD#1L/[R&OXYR=_<^E?I;_P;S?\%>;;]B7XDS_"GXBZDMI\+O&E
MT)K#4;B3;%X8U)L*68GA;>?Y0YXV.%;HS4N-LDEB\.L317OPOIW77[MRLCQW
ML:GLI[2_,_HU0Y44M4[&_CO+6.:&6.6"55>-T(974C(8$<$$<YJPDA9NN1]*
M_&GYGV5T2444TL=_48H&.HI-W7VJ*6X\E220`HR2>`!0!2\2ZY9>%]%NM2U&
MZALK#3X7N;JXF<)%!$BEG=B>``H))]J_!;]LO_@Z@^)NI?'O48/@G8^&+'X>
M:5<FVLKC5[%KFZUU4.#.WS#RXW(^4#G:<DUK_P#!PI_P7#M?C'%J?P#^#>L+
M=>&8G-OXR\2V,H>'5)%/S:=:NOWHE(_>R@X8_(N0&)_']58*$@ADGE9ECBBB
M4L\KDX6-0.2Q8A0!U)`K]-X5X4INB\7F$;W^&+[=V?+9MFD_:*A0?JU^1_6M
M_P`$N?VW1_P4+_8O\(_%&724T'4]4\^RU.PCD,D4%Y;RM%+Y;'DQL5#+GD!@
M#DBOHH-\V.U?.?\`P2F_9-N/V)O^"?WPQ^'>H1K'KNF:0MYK0`P5U&Z8W%RF
M03G9)*T8;N(P<#.*^C$4=:_.L9[)8F?L/AYG;TZ'T5#G]E'FWZG\>/[<_P#R
M?#\:_P#L?M;_`/2V2O,&ZC_/>O3_`-N?_D^'XU_]C]K?_I;)7F#=1_GO7]%8
M'_=:?^%?DC\YK_Q7ZL_13_@UK_Y2K1_]B?J7_H<-?TG5_-C_`,&M?_*5:/\`
M[$_4O_0X:_I.K\?XZ_Y&?_;J_4^RR'_=OF_T"BBBOC3VPILG:G4V3M28F?R>
M_P#!:;_E+!\=O^QB;_T1%7S$GW17T[_P6F_Y2P?';_L8F_\`1$5?,2?=%?T5
MD_\`N%'_``+\D?G&+_CS]6?6/_!"_P#Y2V?!7_L+3?\`I++7]50^]^)K^57_
M`((7_P#*6SX*_P#86F_])9:_JJ'WOQ-?F7B!_OT?\/ZL^GX=_@R]?T1*GW!]
M*6D3[@^E+7P9]"%1O]X_Y[5)4;_>/^>U)@?S1?\`!SI_REDUG_L6=+_E)7P!
M7W__`,'.G_*636?^Q9TO^4E?`%?T)P[_`,BVC_A1^=YE_O,_4]@_X)V?\I#/
M@-_V4#1O_2I*_K[/3\17\@G_``3L_P"4AGP&_P"R@:-_Z5)7]?9Z?B*_/_$+
M_>J7^%_F?1<.?PI^I+1117YX?1!1110`4444`(OW:^$/^#E__E"7\:/IHO\`
MZ?-/K[O7[HKX0_X.7SM_X(E_&CV&B_\`I\T^NC!?QX>J_,VPW\6/JC^4<_>?
MZFA.U#???ZT5^IKH?H*/Z1_^#/S_`)1Q>*_^QVN__1$%?J^W05^3_P#P9_''
M_!.;Q4/^IVN__1$%?K`PR!7YCF?^]3]3X'&?QI>HZBBBN(Y@HHHH`****`(W
M`<C(R#7S[_P4?_X)X^"?^"E'[-VJ?#SQE;B"5E-QHVLQ1![K0KP#"3Q9ZCLZ
M9`=<@]B/H08*_2E'7U-.G.4)*<79HJ,W&2E'='\4G[7G[)OC7]AS]HKQ'\,/
M'^GFR\0^'YL"5`WV?4K=C^YNX&(&^&11D'J#E3AE(KS-DVO7]9G_``6M_P""
M1>@_\%2_V=Y(+1+/2_BGX3CDN/"FMN,'>?F>RG;J;>;`'/W&VL.A!_E0^)WP
MT\0?!CX@ZUX2\5Z7=:%XD\/7;V6HV%RFV2VE0X(/J.X(X(P1UK]!RC-(XJG:
M7Q+<^ORS'JM#DE\2,*OI7_@C1_REB_9W_P"QWLOYO7S3GFOI;_@C1_REB_9X
M_P"QWLOYM79F7^ZS]#JS'_=Y?UU1_8@H_>#Z4^F+]\4^OR^)\(<'^TC\`O#?
M[4?P0\5?#OQ=9?VAX;\8:=)IU]%CY@K#Y70]G1@KJ>S*#7\?7[?W[#WBS_@G
M=^U3XF^%?B^-S/I#BYTO4-FV+6M-D9OL]Y'ZJP4JP'W9$=#RIK^SY^']L5\C
M?\%<?^"3/@W_`(*K_`8:'JKPZ%XX\/B2X\+>)4AW2Z9,P&^&3'+VTNU1)'GJ
M%8?,HKV,HS+ZK5U^%[_YGH9?C7AZFOPO<_D3K3\(>,-4^'_BW3=>T'4KW1M<
MT>X2[L;^SE,-Q:3*<K(CCD$&O0OVO_V+?B3^PA\8+KP3\3O#=UH&K0LQMIP/
M,L=4B!P)K:8?+(AZ\8(S@@'BO*E&#Z@]*_083A6A>-FG]S/LHSA6A>.J9^Z_
M_!,C_@[&L4T?3/!_[2]A/;W<"K!%XUTF`R1W('`:\MU^96Z9>,$'&=HZU^P_
MP`_:Q^&G[4?AU-4^'7CSPOXQM#&)&.EZA'/)"#_STB!WQ_1E!K^*&I--OIM$
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M+\+6$IDTCPMIKLNG:>>@=@>99<?\M'Y]`!7R^J[1A0`!3T+,RJ`69V"JH!)8
MGC``Y.?05[F"R7#X;WWK+N>IALLHX?WWJ^[&&01HSL0`.23_`#K^DS_@V'_X
M)57?[('P!NOC!XVTZ6S\?_$^T06=I/'MET;2,AXT8'E9)CB1AQ@!!U%?,?\`
MP0-_X-UM4\4>)-%^-W[07AY]/T2R*7WA;P=J"`7%_)D-'>7T9^Y$O5(6^9SA
MF`0!7_?.VA\N,K@`#@#L!Z#VKQ,]S:-1?5Z+NNK/*S3,%4_=TWIU'#(`&,48
M^7UJ6BOE[=CPSYQ_X*<?\$^O#G_!1[]ES5?`6L&'3]63-YH&KF/<VD7Z@^7)
MZF-C\KJ.JL>X%?RJ_'?X$^+/V8OB_P"(?`/CG2I=%\4^%[C[-?6S\J01E)8V
M_CBD4;T;N#[&O[,Y03@``GWKXR_X*]?\$>?"7_!43X:V\ZR6OAKXI>&8'3P]
MXE$9.$8[FLKL+S+;,PR,Y:)B63!9P_V'"O$O]GU/85M:<G_X"^_IW/%S7+%B
M(\\/B7XG\MX;`P>IXI0P-=U^TG^R[X__`&//BO>^"?B3X:O/#7B&R8@1R?/;
MWJ#I-;RCY98R.0RGZX/%<&IPPSFOVFC6IUH*I2=T^JV/C)0<9.,MUT'T445H
M0(QP*4'--?I35(SR>OY4!ZBNLLI"0H\DLIV1(B[FD<_*J@=R20`.Y(K^MK_@
MEE^RT_[&G[!/PW\`7<(BU;3-*2YU5<89;R<^=,I]U9]O_`:_%?\`X-R/^"5=
M]^U5\?=-^-GC/2Y%^&7PZO1=Z.DZ$)XDUB(YBVC^*"V<"5CT:58U^8!P/UH_
MX*Z_\%<_!7_!+#X&R:C?O:ZY\1=>@>/PQX;#_/>R@8\^?:<I;(3EFX+?=7DY
M'Y/QMF7UNO'+\/KRN[MW_P"!U/L>'LOG9U+:RT1\3?\`!V;_`,%*XOAS\(]-
M_9N\+7RGQ!XWCBU3Q9)%)\UAI:/NAMC@\/<2IN(/_+.(Y&)`:_G\B@>>XBBB
MCDFDE=8XXXU+/(S$!551R6)(``ZFNX\6>)_B#^V=^T-J>LZA_;/CSXD?$+5'
MNIQ;6[37>H7,C#Y(XU'RHHPJ(H"(BJ``%`'[W?\`!"'_`(-UH?V3KO2_C%\<
MK&PU7XFQXN="\/';<6GA-L?+/(>5EO?0@%83]TEOF7BA4I97A>63]YZV\_\`
M(_1X5*>!H<N\F>@_\&YW_!&ZX_X)_P#P:N/B1\0].$/Q=^(%FFZTE4%_#&GG
MYUM/:=R0TOH0J?PMG]#?CG\'-$_:$^#7BGP+XEMA=:!XOTNYTC4(>[0SQM&Q
M7T8!L@]B`>U=5'^[&T]<=N].D&5KXZKBJE2K[=OWMU^A\W7J2JR<IZMG\>/[
M9W[(?BG]@_\`:6\1_"[Q?&YU#093+8WI7;'K&GN3Y%[&>ZN%(;'W75U[5YE7
M]5'_``59_P""4O@O_@I]\'8=-U=XM"\<>'UDD\->)8X0\VGR,.891UDMI"!O
M0G@@,.0*_FG_`&N_V*OB3^PE\4Y?"'Q,\-SZ'?EC]BO4_>:?K$8/$MM.!M=3
MUP<..C`$5^U<,\24L?15.H[5%NGU\UW\^Q\%FF6SH3<XKW6>5MRN`S*00593
MM9"#D$'L00"#[5^]W_!"K_@O?I7QG\-:/\&_C;K-MI'C[38X[+P_XCO)1';^
M*8@`$BF=N([Q>%Y.V48(^;(/X(D],@FDEA$T11P'0\;2.E>GG>1T,RH>SJ:-
M;/JG_EY'+@<?/"SYH[/==S^U]&R>>..AJ7(-?R[?L1?\'`/[1/[%&FV6A_V]
M:_$OP;8*(K?1_%9>XGM(P,!(+U3YZJ``%60NJ@```<5^@'PM_P"#O3X?:AI\
M2^-O@YX]T:\``=]$OK/4X">Y'F/"X'X$U^38W@S,J$GR1YX]T_T9];0SG#5%
M=RMZG[$!PP]J0L%[@?A7Y6:Q_P`';'[/EE8AK3P1\8=0F*Y\D:5:18/H6>Y`
M_$9KYX_:)_X.Z/%6O:=<6?PI^$NF^'Y9%*1ZEXGU'[9)'Z,+:`*N0.S2$?6N
M7#\+9G6=E2:\WHC2IFN%@M97]#]DOVI/VI?`G['7P>U3QY\0_$-IX>\.Z2A+
MRRL#+=28RL$$8^:69B,*B@D_0$C^6S_@IW_P40\0?\%+_P!J2_\`'FK6TND:
M#91G3O#>CO)O_LRQ#9&XC@S2'YW(XS@#@5P'[4?[8'Q._;3^()\4?%/QGK'C
M#58P5M4N)!%9Z<A.3';6\86*!3W*J&;')/6O.,[\C))[FOTKAKA2.7OV]9\U
M1]MDO(^9S/-GB5R05HKOU'2-M3KCMDU]'?\`!*C_`()[:K_P4D_:\T7P3%#<
M)X0TR2/4_%M\@.+73U?)BW=I)B/+7V+-VKG/V%/^"?7Q-_X*)_%J#PM\.M&:
M:V5U&JZ]=JR:5HD)8;GFDQ\S#^&),LWI7].G_!.?_@G?X%_X)M?`.U\$>"[?
M[1=3L+O7-;G0?;=>O2,--*1T4#A(Q\J+P.<DG%/$M/!470HRO4DNGV5W?GY%
M95ELJT_:37NK\3W+0](M/#6CVNGV$$=K8V,*6UM!&NU((T4*J*.P"@`#VJ_$
M<QBG45^*/5W/MCY4_P""V'PYNOBC_P`$L_C1I5E&TMROA^6\C1>2QA992/R0
MU_*);2":%9!T=0WYBO[5?$NA6?BCP]?:7J-O'=V&I0/:W,$@RDT3J5=#[%21
M7\FG_!4/_@GSX@_X)P?M7:YX,U"VG/A:_GEOO"FI%#Y5]I[.2B`]/,BSY;+U
M&T'H:_3?#[,8)U,')V;U7GW_`"/F>(,-)\M9;;,^>">,5^VO_!H_^U3I$/A+
MXF?!*_NH;77$U,>,=%C=L-J-M)%';W2IGJ89(HB0.=LX/8X_$HC#8KI/@U\9
M/%7[._Q7T'QWX)UFY\/>+/#%TM[IM_``6B<`JRNI^62-T)1XV!5E8@@YX^WS
M_*WF&"EAT[2=FO5/0\'+L6J%=5'L?V>Y`8#BF.X##H:_)3]CC_@ZV^%GC7PG
M9V/QOT/6/A]XG@C5;G4M,LY=2T6]?H9$\O,T&X\['5@,_?:OI*?_`(.'?V/8
M++S_`/A<FF.,`[4TV\:0?\!\K-?B5?A_,*-1TY4I:=DVODT?;TL?AZD>:,U\
MS[8`!/3GK7\WO_!Q=_P2^N?V._VFKWXJ^$]/=?AE\4;Y[J=88_W6@:U*=\\)
MQPD=PV98^P=G08&VOW)_9"_X*:?`[]NW5-3L/A9X_P!+\3ZGH\0GN[)8Y+>Z
MBB)P)/+E56*9XR`1FO1/CY\!?"?[3OPAU[P'XWT6UU_PMXEM7L[^RG`(=#T9
M3U5U8!E8$%6`(.16V39E7RC&*=2+[26UU\_P)Q>'IXNER)^C/XU@<L/0]/>D
M>-)0590ZL,,I&00:^QO^"K'_``1L^('_``3/\=W6H)#?^+/A1?2G^R_$\49=
MK0$G%O?`?ZN51P'/R/U!!R!\=!L@8(YY'^U]/6OW7`XZAC*:JT9<R?;]>Q\+
M7H3HS<9JS1^B?_!*[_@X5\??L):9IG@CQY9WGQ'^&%J1%;@S_P#$XT&+&`L#
MMQ-$O'[IR"`/E85^X?[)7_!5'X#_`+:MA;/X$^(V@W.I3[0VC7\ZV6J1.>B&
M"0AF/^YN'O7\E83*].:AN;2*[7]]$DN.,.H;/Y]*^9S?@O"8R;JT_P!W)]5L
M_5?Y'HX/.:U&/)+WE^/WG]LWF#('6F2.$!)(`'<U_&MX1_::^)_P^TU;+P_\
M4/B=X?LT4+]GTOQ;J-K"!V`19@HQ[`57\;_M`_$/XG6C0>)_B+\0_$L+#!BU
M;Q1?WL9'H4DE*D?A7S*\.J]_XRMZ,]9\1TE]AG]3/[6?_!7;]GS]C&RN!XQ^
M(^ARZO`#_P`272)UU'4G(_A,,1)0Y'\96OQ-_P""H'_!Q+\1?VXM-U'P9X"M
M+SX:?#:[S#<JEQG6-:B[K-*O$,9'5(SDC@L:_.:"UCMAB*..,#IM4#'O4H/&
M21CN<\`>M?391P7@L'+VE6]22ZO]%_F>3B\[K5URQ]U?B,B@6&)8T555`%50
M!@```8_*OTG_`.#<3_@F//\`M:_M+6WQ=\56+?\`"N/A9>K<V(E3,>N:RAW0
MQKGAHK<@2.>[^6O/S8\<_P""4G_!'+Q[_P`%-?'D%^8;OPQ\);"<+J_B:2+!
MNE&"UM9!N)96'!<96/.2<X!_IH^`_P`!O"O[-?PET/P+X(T:UT'POX<M5M+*
MS@7Y40=68YRSL<EF;)9B2:X.+^):="D\#AI7E+=K[*[7[V.G*,ME4DJ]9:+\
M3M<`@'CGFGE<8^E.7H*:_2OR-)7/KGL?QW?MS_\`)\/QK_['[6__`$MDKS$?
M>'^>]>F_MT#'[</QK_['[6O_`$MDKS%?]8/QK^D\#_NU/_"OR1^:5_XK]6?H
MI_P:U_\`*5:/_L3]2_\`0X:_I.'4U_-A_P`&M/\`RE5C_P"Q.U+_`-&0U_2<
M.IK\=XZ_Y&?_`&ZOU/L<@_W7Y_Y"T445\<>V%(_W32TV1L`>]-">Q_)[_P`%
MIO\`E+!\=O\`L8F_]$15\Q)]T5]._P#!:AMG_!6'XZYXSXB;_P!$15\Q)]T5
M_1&3?[E1_P`*_)'YQB_X\_5GUC_P0O\`^4MGP5_["TW_`*2RU_54/O?B:_E6
M_P""&#8_X*U?!0?]1:;_`-)9:_JI'WOQ-?F7B!_OT?\`#^K/I^'?X,O7]$2I
M]P?2EI$^X/I2U\&?0A4;_>/^>U25&_WC_GM28'\T7_!SI_REDUG_`+%G2_Y2
M5\`5]_\`_!SK_P`I9=9_[%G2_P"4E?`%?T)P[_R+:/\`A1^=YE_O,_4]@_X)
MV?\`*0SX#?\`90-&_P#2I*_K[/3\17\@G_!.S_E(9\!O^R@:-_Z5)7]?9Z?C
M7Y_XA?[U2_PO\SZ+AS^%/U):***_/#Z(****`"BBB@!,Y(KY^_X*B_L=2_M^
M?L'?$?X26VHQZ3J/BS3D&GW<F?*CO+>>*[MO,QSY9F@C5\`G8S8!Z5]`XZ>U
M,EC#$$]O>G";C)2CNAQDU)-'\D6O_P#!OO\`MD^'M:N[-_@=K=ZUO(8_M%GJ
MEA-;S@'[Z-YXRIZC(!]0*J+_`,$#?VR#T^`GBC)/&;_3Q_[<5_70L01/2FE=
MP((&#7OKB3$VV1ZZSFN?#_\`P0!_X)]^+?\`@G1^P7;>%/'J6D'C'Q!JUQKN
MHV=M.)TT[S`BQP%U^5G54!8J2,G`)QFON3H33%4`COCIGM4A;&?:O"K5959N
MI+=GDSFYR<GU%HHHJ"0HHHH`****`"BBB@!C1AAQTK\X_P#@MU_P0-T#_@IC
MIO\`PF_@Z[LO"GQDTRU\B*^G4K9>((D4[+>[V@D,.BS`$J."&&,?HZP&?2D=
M0R8/-:8>O.C-5*;LT:4JLJ<N>#U/Y(_$W_!OE^V/X7UR[LS\#];O_LKE1<6&
MJ6$]O,/[R-YX)!^@/L*^I/\`@B7_`,$$_P!H7PS^WW\/_B-\3?!-S\.O"'P[
MU(:W+)J-W;M=ZC/'&XAMX88W=L&4H6=]H"`XR2!7]&BQ!2<#@]<4YH%+9QDX
M[UZU;/\`$5:;I-+4[:N:UJD'![,<G+`T^F+PU/KPXGFK81EW4WRSCK[4^BJ&
M>4_M5_L9_#7]MCX7S^#_`(F^%-,\5:+-DQK<IMFM'Q@20RKAXG'8J17XK_MO
M_P#!H+XDT&^OM9_9_P#&UMK>GNQDA\.>*)/(NHEZ^7'=JNU\=!YBJ?5N]?OZ
M4W#!I#$`<CK79A<PKX=WIOY=#IP^+JT7>#/XT_V@O^"6_P"T9^RS+.?'7P7^
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MEY'!B,QK5E:3LAT<)5RQ(.1Z4\+C/O2CI17F'`%%%%`"%2>](4Y)IU%*R`\>
M_:__`&'OAE^W3\,9O"WQ-\,V>O:<06@N/]3>V#]I()UP\3#V.#W!K\4/VW?^
M#6#XI?"2_O=5^"6LV_Q*\/#,D6D:G-'8:W;J!]P2-B&?'8Y1CZ'K7]!908([
M&D9,#``->QE>?XS`?P9>[_*]4<.*P%&NOWBU[K<_C,^,_P`"_'G[-NK&P^(O
M@?QCX#NB2JKKVCW%BDONDCJ(Y`>Q1B#7%_\`"16&1_I]C@_]/"?XU_;#>V$.
MH6SPSPQ3PR#:\<B!T<>A!X-<)<?LG_"JYNWFE^&G@"2>1M[2-X>M"S-ZDF/.
M?>OLJ/B+/E_>TM?)GD3X>A?21_(!\)?A=XK_`&@?$BZ-X`\*^)_'6K,?^//P
M]I4^I3+[MY2L$4=RY4`<D@<U^J/_``3K_P"#7KQ5XQU"V\7?M(W4/A#PO:@7
M+^%;&]22^O`/F*W=PA,<$>/O*C,V/XA7[Q:'X=L/#&F1V6FV5II]E%Q';VT*
MPQ(/95``KRO]H7]A?X=_M8SK'\2;#5O&&CH5==#O-8NDT?<#P7M(Y%BE/_74
M./:O.S#CK%XB+IT8JFGUW?\`P#JPN18>G)2F^:Q^?_[:?_!P1\,/V4]"M/@=
M^R+X8MOB_P#$.SMAI6CZ?X3L9+[1-$V_*%06X8W;KUV0Y4L?F?.17Q#\'?\`
M@WY_:W_X*B_&6Z^)G[0FM3>`5UV42W=[K^V?698^HB@L4.VW10<!'*;?[IK^
MA#X/_L^^!/V>?#:Z/X#\&^%_!FE!57[+HFF0V$3!1A<B)5W$#N<FNO$>T9]Z
M^8I9E*BG[&-I/>3U9])1Q/LE:DK>9\M_\$[O^"/?P4_X)HZ$!X$\/_;O%%Q&
M$OO$^K$76K7GR@$"0C$2'GY(PHY/6OJ58O+.<]:?DGO2C./>N"I4E4?--W9A
M.3D[R=Q-F>]`0D<FG45))$\/G+@]*X3]H']F3P+^U5\.;OPG\0_#&C^+-`O,
M[K74(!($;^_&WWD<=F4@BN^(SU-.'%.%24)*479HEQ35GJ?B1^V7_P`&E\;W
M5[JWP%\=_9$)+Q^&_%):6)3U"17B@N!Z>8K?6OS:_:%_X)+?M+?LO7<Z>+/@
MQXUGL(`SG5-`LVUW3P@.-[26N\QCT\Q5/M7]:[(%W'^]UQ2,@QD$_GBOKLOX
MVS##KDJ6FO/?[U_D>1B<DP]1W6A_$U=ZI;V%[):W$J6MS`=LD-R?L\B'T*R;
M2#[5)'<PS#Y)H7XR"'!!'K7]GGCSX.>$?BE#Y?B?PKX;\1H!@+J>FP7@QZ?O
M%->5:W_P2W_9L\2733WOP&^$LTSL69O^$5LUR?7B,5]#2\1H6M4HM/R?_`/.
MGP[_`"R_`_D7>ZB6,EI8PI!Y+@#\SQ4<&L6ES=);Q7$-Q<2G:D4+>;)(W]U5
M7))^@K^NG3?^"5?[-&E7BW%O\!?A''.IRK_\(M9D@_C'7J7P_P#@3X)^$BG_
M`(1;P=X6\-!A@_V3I-O99'OY:K55/$6G;]W1=_-V_((\./[<OS/Y4/V<_P#@
MD_\`M'_M5WMLO@_X.^-/[/NB"NK:W9-HFFA2<;Q+=!-X'?RU8^U?IG^Q1_P:
M:V=C>6FL?'WQI_:ZIMD;PUX8=X+9F[I-=L!(Z^H0+GUK]I43(QR?J:>8Q[\U
M\WF/&V/Q,7&%H)]M_O/2PV2X>D^9ZOSV.0^"7P%\'?LY_#RQ\*^!?#FE>%?#
MVGKB"QT^`0QK[MCEF/=F))]:[%%IVWY0*"=HKY&4Y2;E)W;/6C%15D+11104
M,=2PP.E>.?MH?L-?#K]O3X.W'@KXE:&NK::S^?9W43>3>Z3.!Q/;S+\T;CCI
MP>A!%>RL,C/2FE`XZG\*JE5G3DIP=FNJ)E%27+):'\Y7[:G_``;!?''X!:I?
M:A\*Y+;XO>%8R7AA22*PUR!/[K0N5BF(]8V!/]W/%?GW\5?@;X[^`]\UMX[\
M!^.?!,ZGYDU[P_>6`'N&>,*P/J"17]FIA4-D`<4I13&P(#`]<\U]Q@^/L;1C
MR5XJ?GL_Z^1X=?(*$VW%N)_$F?%&FL<_;K4>G[P`G^M>@?"?]G+XC?'VYCA\
M"?#KQ_XT>;[K:+X=O+R/'3<9$C\M5S_$6`'<U_8^GAG38IA*MA9)*#D.+=`V
M?7.*NJA)X/3\!7=6\1*G+:%+7S?_``#&'#D+WE(_&;_@W\_X(E?%K]EC]HA/
MC3\6(8O!CV>D7&GZ7X=CNTGO;@W&W>]TT9*1JH48C#,2QR<8K]FEAPO8\4>6
M.2>>W6I`O&.U?"9GF=;'XAXBMN]--K'N8;#0H4_9PV,KQ1X3T[QGX?NM+U>P
ML]3TR_C,-S:7<"SP7"'JKHP(8'W%?E)^W1_P:K?#[XK7M[KWP/U]_AGJ]PQF
M?0[Q6O-#E8DD^6,^;;]N%)4?W:_6]ADBF.FYC3R_-,5@I\V&FX]^S]4%?"TJ
M\>6HKG\IW[1__!$3]J3]E^ZG.J?"77_%>EP9(U3P@G]N0NH_B,4/^D*`.3NB
M&*^4_$D<W@S5WT[6[6]T._B^_:ZG:RV4R_5)55A^(K^UT(H;Y?E/?!K/UWPO
MIOBJS^SZEI]CJ-N?^6=U`DR?DP(K[/">(>)BN6O34O-.W^9XU7AZD]82:/XI
MEU^P(_Y"%@/4_:4_QJ73+V/7M1BL]/+ZC>3'$<%G&US+(>P"1AF/X"O[(I?V
M2?A7+=><_P`,_A\\Q.XR-X=M"Q/KGR\YKK?#/@71?!MN8-'TC2])A/\`!9VT
M=NI_!`*[)^(JM[M'7_%_P#'_`%=C_,?RE_LY?\$=?VF_VH[Z)?#?P=\6Z5IT
MI!&J^*+5M!L@AZ.IN0LDB_\`7-&K]3?V$/\`@U0\'?#O4;'7_CQXB'C_`%&`
MK*OAW2P]KHL;#!Q,YQ+<#/8[5/I7Z]NHP`>?J:1%VL>@_K7SV8\:8_%)P@U"
M/EO]^_Y'H8;)J%)\V[\S-\(>"M*\`>&[+1=#TZRTC2--A6WM+&S@6"WMHQT5
M$4``#V%:PBVCWIRC!-+7R;?,[L]=*VP4R5@BC-/IDZ[P!_DTF!_-#^WC_P`$
M.OVH]0_;-^*.K^'?A5J'BWP]XD\47^LZ;JFF:C9^3/!<3-*H*R2JZL-V"".H
MKR8?\$.?VO<Y_P"%"^*1_P!Q'3__`)(K^K7&!P*%78.I(K[;#\>8VG3C!1B[
M*W4\.>1492<FV?B%_P`&[O\`P2=^/'[+W[;>H?$3XF^!IO`^@6/AVYTR!;V^
MMI;B^GFDC("1PNY"JJ$EFQU`%?N!G#FF)$JMD"I!\R\U\UFN:5<PQ#Q%9)/;
M0]+"86&'I\D-A:***\\Z@J*=BK#T^E2TR098>U)O0#^>/_@L5_P1?_:.^)7_
M``42^(_C7P+\-K[QKX3\:7T>J6-_IVH6B^63#&LD<D<LB.C*X(Z$$8(-?,O_
M``X[_:]7_F@OBG_P/T\_^W%?U9,BDY.:DWG;TK[/"\<XVA0A148OE277I\SQ
M*N1T)S<VWKJ?SX?\$8/^"-W[1WPF_P""B/@'QUX\^&]YX)\*>#YI[V]O-1U"
MT8RL8'1(HHXI'=V+..<`#!YK^@R-]V.,$]J<0,=.GO2*F!@'%>#G&<ULQK*O
M625E:R._!X.&&@X1U)$^X/I2TB#"BEKRSL"HW7+FI*C)PYSTI/L!^&/_``<&
M_P#!)SX]_M*?MW+\1/AKX"N?'/AW6-"M+"1K"^MHY[&>#>"LB2R(<$,"&&1U
MZ5\,'_@AY^U[V^`OBG_P/T__`.2*_JS"*Q!]#3S@]J^PP'&F,PM"-",8M15E
M>YXE?):-6HZC;NS^;7_@G-_P0X_:@TK]N+X6^(O%/PQO/!OAGPAXGLM<U/4M
M4U&S*I#;R"4HD<4KN[MM"@`8&<DU_2.IW`]CU%+(!(>>GI2%<*!D<"O&SC/*
M^95%5KI+E5E8[L'@H8:#C"[N344=:*\D[0HHHH`****`"BBB@`HHHI60!111
M3`****`"BBB@`HHHH`****`"BBB@`P/04444`%%%%`!1110`4444`%%%%*R`
M*,#T%%%,`HHHH`****`"BBB@`HHHH`38*7`]!110`4A0$YQ110`M(%`[444`
M`0#L*6BB@`HHHH`****`"BBB@!"H-!4'M110`!`.U&P444``0#M05!HHH`-@
M':EP/0444`%%%%`!1110`4444`&.*0*!110`%`>U`4+T%%%`!L%+110`4444
M`)M&<XYI:**`"BBB@!-H]*7`]!110`4444`%%%%`";!05!HHH``H%+110`44
M44`%%%%`";!1L%%%``%`I:**`"BBB@`H(S110`FP#M1L%%%`"XQ2;`.U%%`"
..T444`%%%%`!1110!_]D_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>robin.jpg
<TEXT>
begin 644 robin.jpg
M_]C_X``02D9)1@`!`0$`8`!@``#_X1#L17AI9@``34T`*@````@`!`$[``(`
M```+```(2H=I``0````!```(5IR=``$````6```0SNH<``<```@,````/@``
M```<Z@````@`````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M`````````````````````````````````````````````````$IO92!486QA
M;6\````%D`,``@```!0``!"DD`0``@```!0``!"XDI$``@````,X-```DI(`
M`@````,X-```ZAP`!P``"`P```B8`````!SJ````"```````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````,C`Q,CHP.#HS,"`Q-#HQ,CHR,0`R,#$R.C`X.C,P
M(#$T.C$R.C(Q````2@!O`&4`(`!4`&$`;`!A`&T`;P```/_A"QUH='1P.B\O
M;G,N861O8F4N8V]M+WAA<"\Q+C`O`#P_>'!A8VME="!B96=I;CTG[[N_)R!I
M9#TG5S5-,$UP0V5H:4AZ<F53>DY48WIK8SED)S\^#0H\>#IX;7!M971A('AM
M;&YS.G@](F%D;V)E.FYS.FUE=&$O(CX\<F1F.E)$1B!X;6QN<SIR9&8](FAT
M='`Z+R]W=W<N=S,N;W)G+S$Y.3DO,#(O,C(M<F1F+7-Y;G1A>"UN<R,B/CQR
M9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2)U=6ED.F9A9C5B9&0U+6)A,V0M
M,3%D82UA9#,Q+60S,V0W-3$X,F8Q8B(@>&UL;G,Z9&,](FAT='`Z+R]P=7)L
M+F]R9R]D8R]E;&5M96YT<R\Q+C$O(B\^/')D9CI$97-C<FEP=&EO;B!R9&8Z
M86)O=70](G5U:60Z9F%F-6)D9#4M8F$S9"TQ,61A+6%D,S$M9#,S9#<U,3@R
M9C%B(B!X;6QN<SIX;7`](FAT='`Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"\B
M/CQX;7`Z0W)E871E1&%T93XR,#$R+3`X+3,P5#$T.C$R.C(Q+C@S.3PO>&UP
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M83X-"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@/#]X<&%C:V5T(&5N9#TG=R<_
M/O_;`$,`!P4%!@4$!P8%!@@'!P@*$0L*"0D*%0\0#!$8%1H9&!48%QL>)R$;
M'24=%Q@B+B(E*"DK+"L:("\S+RHR)RHK*O_;`$,!!P@("@D*%`L+%"H<&!PJ
M*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ
M*BHJ*O_``!$(`*\!+0,!(@`"$0$#$0'_Q``?```!!0$!`0$!`0``````````
M`0(#!`4&!P@)"@O_Q`"U$``"`0,#`@0#!04$!````7T!`@,`!!$%$B$Q0083
M46$'(G$4,H&1H0@C0K'!%5+1\"0S8G*""0H6%Q@9&B4F)R@I*C0U-C<X.3I#
M1$5&1TA)2E-455976%E:8V1E9F=H:6IS='5V=WAY>H.$A8:'B(F*DI.4E9:7
MF)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7V-G:X>+CY.7F
MY^CIZO'R\_3U]O?X^?K_Q``?`0`#`0$!`0$!`0$!`````````0(#!`4&!P@)
M"@O_Q`"U$0`"`0($!`,$!P4$!``!`G<``0(#$00%(3$&$D%1!V%Q$R(R@0@4
M0I&AL<$)(S-2\!5B<M$*%B0TX27Q%Q@9&B8G*"DJ-38W.#DZ0T1%1D=(24I3
M5%565UA96F-D969G:&EJ<W1U=G=X>7J"@X2%AH>(B8J2DY25EI>8F9JBHZ2E
MIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(R<K2T]35UM?8V=KBX^3EYN?HZ>KR\_3U
M]O?X^?K_V@`,`P$``A$#$0`_`/I&BBB@`HHHH`****`"BBB@`HHHH`****`.
M;U;P3::WXBCU2_U36#"L0C;2X[]TLY<'.7B7&X]B"<$=0:Z)XHY(C%(BO&PV
ME&&01Z8IU%'2P=;B*JHH5`%4#``&`!2T44`%%%%`!1110`4444`%%%%`!2$D
M$<?C2U7O;J&SMFGN9/*C7J^"<?@*`)6+=57</KBE#!OPKBKGQ[!?2&VT"T_M
M=NY$AAQW_B7Z_E70:##=1PR27EI]E>3'R>8'Z9[B@#7%%`HH`****`"BBB@`
MHHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"B
MBB@`IDA/`4;CZ?UI]12G)V@YXSM]:`$`(+>:^[G@XQBHY[Q+.V>XNGVQIU;'
M7\JY[7/&NGZ'_HR#S[P_*+4,02>G7&*P[32?$/BN]6Z\0`VNG#_5V1"[B.H.
M]2#Q0!:N/'%[K-P]KX1T]KLYPURLJJ$_X"X&>*++X?/?7(O?%%[]MN!]Q1&8
MO+]1\K8.>*ZZTTZ#3X$M[6';"HX&>1^/6KBA@3SD=N.E`$%M9P640CMHL*/?
M_&K*].:.<=:1>_.:`'4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`
M!1110`4444`%%%%`!1110`4444`%-;<3A>/>G4Q\9`+8ST'O0`GS9Z'./O4B
ML1G>P;G@@8_"LW7-?L-"M"^H7"1MCY%)P6.#@?H:XZ#5_$GBR^)TZ+[+I0/E
MEW0,7Y^\"/\`984`=EK.O6&B6IFU*=8_[BG(W=<#]*XM]4\0^-IC%I49L-,!
MVF1U5_,'J#P1P:Z>P\'Z?:N)I_,N)^K&20LN?H:VA"B+Y:QJJ?[`VXH`P-`\
M%Z?H)$@S-=L/FE=BP)^AZ5TL:;![]Z:%P`%^91V[T],XYH`=1110`4444`%,
MDR%W*,D=*?2,<#CKVH`A90"%YPWWCGI6;K6OVF@:9)=:A,J!!DY],_\`UZN:
MC?0Z783WUR<11@%N>G./ZUYUX.T^Y\8Z@^NZXK/;*Q%LG16()4Y'0]!0!W>C
MZY::W9+=V,P*9^<=>*U4((^4<>M<%=00Z/X\LAIP:/[4ZQRQYRH4+D<=!7>1
M*%7@YH`?1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!4;R*
MLF'^4=F/0GTJ2JM]<P64+7%TZI&HR6<\#WH`FRQ!.>!R!ZUS'B7QI9:&#%$#
M=7[C9%#&1G<<XX/N,5@ZCXQU'Q'>MI/@^!B"=LMZR[XU&2IY!R,9!K9\/>"8
M-,'VO4'^UW[-N=Y#O4'@G:"..0<?6@"CHGA:;7;@:[XF+-<,=\$&2JQH2'56
M7H2"6!KN;:&."!8X41%`Z(N!4(9L;50KC@+C]?I5B($)\W7O]:`'T444`%%%
M%`!1110`4444`%(P)'%+4<S*L9+MM'KF@#S?XD7D^JZCIWAFQ8^?>,ZS!3]T
M!5=<C\*[.V^Q>'="ZK'!;KEFZ#)Z_K7#^$"WB+X@:CK[#,,8C$3$<`A2A_E6
MAJLK>*]:_L33V+6$1S<2H>H89ZCW%`#_``I9SZSK5UXBO045@$@5OX2I(S^(
MKNXSQBJT=I'#;I;P*$B"A6VC''^-6(P,EE.1C%`$E%%%`!1110`4444`%%%%
M`!1110`4444`%%%%`!36))('&*=3&."2QP!0`QF8#<H.??I2+)@[AER>/EZ5
M1U;6K;1+%[O49$2/'RJ2`6^F37%P:EXE\77;0VD#:;I3=)FC>*0^N&!(H`Z/
MQ!XTT_0$\MIDN+MON6T3`R9[<$US$.CZYXWG6\U=Y]/T_=Q;Y:-V7U(Y!!!K
MJ-.\%:;8NLDBF^GZF6]Q*X/L2,UOJBHVT*0`N,#[HH`IZ9I%EHUNL%C;I&@4
M`N%`+=.I`YZ5H(!@XSR<\U&-VQ@</R<;><5)&<IU'''%`#L#.<<^M%%%`!11
M10`4444`%%%%`!37&X;<X)IU(<#ZT`-R3*1V%<[XZUA-%\'7=T6.5"X`/)^=
M1Q^=="2<!>[5YK\2IY-6US2_#UB`YD:03`C*CY5=<X^G<4`4M+D?2/#-MH&C
MGS-1NF?S)EY$8W;UW8Y'!(KT#PMHD&B:6($!,Q),CORYR<\G&<<\5%HWA>TT
MAMR+YTA`Q))AF'U./>MU%Y+'&3Z4`/P/2@`#H,444`%%%%`!1110`4444`%%
M%%`!1110`4444`%-)P><X]J=45Q,D*%I9%2,?>9CC%`"EFZ[DV_6N;\1^--*
MT$*CN]W='[MM;,CN>G5=P/0USWB+QY->R?V7X1@DNY6X::)"ZKT(^9&XZ$=*
ML>$_`PLI#?\`B9EU#4&Y4R'S0.OW=ZYS@B@"MI>G:YXNU-=4\2VX@L$.8[%X
MW5CVYC<$<\'K7HL$$,$"QP1+$BCA54`#\!3%<<;%``ZJ1\P'L*G48'4GZT`+
M@>E%%%```!T`%``'08HHH`****`"BBB@`HHHH`*1L#DDTM(<$@&@!`6//`%,
M<$L`64`^_/X4Y@6.`<`>E<[XJ\667ANQ+ONN+@_ZN&/#NW(SA<@G@YH`B\5>
M-+?0+1!;Q/=:@^?+M(U#R\%<Y3<#]TY^G-<AX/TK4IO'!N=9?S+RWP9D)8[`
MR,%X89&1CK6EX&\*:E)=R:]XMV7%Y-CRHY-SF/`9#PXR,C;T/-:WA.>*]\2Z
MY>P`L)5@`=L%CA2.M`'7,,!CG&:<,9P*;C<,&G`#)(/6@!:***`"BBB@`HHH
MH`****`"BBB@`ICF3_EF%XZYI],<?.&W$`=AWH`8691N7<2>QZ4K2B(;G)P>
MXZ"J&J:Y9:+"\U_<QI_=CWC<?P)]ZX2/_A)_'%R72YGT?3/^6;0.T<CC'.X'
M(^\OY&@#K]8\666EVY:":.\F[10,)&ZCL#GH<_A7%+;^*/'MQON)+K1],?[J
M(9(93@<[E.1]Y>/8UW.G>%=*LXU!LX9)U_Y>&0%SU[X]#BM=5VL2&(_V>U`&
M1H?A?3/#]N(]-MHP_P#',44.W)[@#U-;*JC!3MZ=,CI0H(Y;"_2G(25Y&*`#
M8N[=M&[UQ2T44`%%%%`!1110`4444`%%%%`!37;;TY/I3J9)Q@C&?>@"-IB'
MVJ"6]3]T4U[CRE\QR-HZG_"J>L:W8Z+;&XO)45<?ZO<-['V&>:X=+S7?'-VO
M]GB?2],CX!.Z%W!YZ'(/(/YT`;WB/QK'ID)AT:)]4OI/NK;KYRIR,[MIR."?
MRJCX9\'3RW#:MXJ=;NYD^[!*WF)#P5.T,,C(P3ZUTFF^'=.TJ,"SMT64??N`
M@$C?4CZXK31=VX,.#T)ZGZT`4M4U%-)TN>_N&"A-O!/3)`_K7-?"B"3_`(0Z
M&[N4*W$Y??N&#Q(X'7GI6=\4[B:\:PT2RE(EO?,\Q%;ILV..GXUW^G6D-C:+
M;6\81$[`8'/-`%J@`#H***`"BBB@`HHHH`****`"BBB@`IA;;GJ13ZS-5UBT
MT6WDN+Z90HZ+D;OP%`%YIEBB,DK!4'=CBN*\1_$!8)FT_P`/P&_O,XRJEHQT
M_B4^E8IU37OB!>F'3A)8Z6#AI,E&<=>A_&NST#PGIGAJ$+8Q`OCYYMN&8\_X
MT`<SI/@.\UB9-1\9737$_5;8,)(U['J,]@:]"MX4AMUC2-45>BKT'--5MJ9`
MPIZ'O4R`A1D`'T%`"@`=*0J#U%+10`A`/49I:**`"BBB@`HHHH`****`"BBB
M@`IK-@X[XS3JJWU];6,+2W4\<0"DY9@./;-`$HE+9V#IUW<5@>)?%5MHMDP#
M+-<L=L<49W-D\#(!SUKF+WQQJ&NW[:9X6MC(`2K7<@9,#V/0\&M/0O`,=EJ`
MU'5[A[Z\;)(E`(4^Q%`&?HWA#4-=N5UGQ;*9)6^:.Q9MT2COP1D8QFO0K:&*
M&,)"NQ%^Z@&`OTI!&0Q+-N/8GJ*E0L1E@`?:@!V`#]:8^`=V<8[>M/KF_'6O
MIX>\-S7(;$_R^6/7YU!_0T`<EH1_X2CXH:EJK+OM].\KR0>A\R$JV/Q6O3T&
MT8)R>Y-<?\-]#DT3PK$UTN+N;/FYZG#OC]#78(.,GJ:`'4444`%%%%`!1110
M`4444`%02W,4.1),BGK\S`5/6%JGARRU6\66\B&%/3KNYS0!AZ[\0H;>Z.FZ
M1#+<WV<#]VVS/3[PX]*S=/\`!&I>(;\:EXON"P)W):DAEC[X!Z]:[JPT>RTT
ML;*T2`]MI)S5I@IP9ERW;VH`9;6<5I`L%L@AC3A56K(4<''(IG##+CZ4\'(S
M0`N.:***`"BBB@`HHHH`****`"BBC/.*`$S3#)^\VCKC//2GG`Y-4-3U6QTR
MW:XOY@D:#..IX!/3\*`+C.0">PZU7EO88`7:X08&2KL!Q7`W7B'Q)XIOC!X2
M3R;(-AKLN$8#.#A6'/#*:V;'P/%)$LGB*Z;5K@X+&9`NWV^4^N?SH`JZYX_:
M"<V6@VKWMVQV_.K*B\D9#`8ZXJE!X*U7Q-*EYXNO',1Y6S!#H!UZ]>Y%=UI^
MEV>G1A+&!;=0,;5S_6K;!N<#=]30!2TG2-/T:U6VTRV2"-1C"C%7ER<@CCM2
M#)7GY3[4J-G(]*`%*@G)'(H("Y/3-+37&X8/2@!&<XXZUY=XEW^+?B%9Z2J"
MXL;'S!/D_*VZ,,OZK79>,M>30=#DNQS,,",>N6`/\ZROAIH<NE^'UN+XYO+H
M9D<]?E9@/T(H`[(CYE7J1T;TIZGDKZ4P`QQ8W;F]:<&^8CN*`'TA['/2DS39
M)5BC+NP4"@!W4YR<>E"L"3R:9YGF*KQ$,O?FI`3NZ<8H`6BBB@`HHHH`****
M`$VC&,4H`'2BB@!"H)R1S2T44`%%%%`!1110`4444`%-W?.1CI3JBE0,?WC?
M+_=Q0!)GWJK=:A;V4+S74JQJ@R>_%<_XG@\27"B'P_(;6,\&0%&QQZ-6-:?#
M1[^5+GQ3JC:FW&8V@$>/;*-]:`(]5^)1U.\;3/"5NUW<$[3(V8@IR1GYEP><
M4[3O`-WK,JW_`(UN#=2!LI`P&%7@@94CU85VUAIMEI%NEO8)Y$0``09/MW^E
M7.<95,_C0!!8V5M96J6ME&(X(U"A!GL`._L!5H`8P!TXI.2OS#'M0C!@=O8X
MH`<0#UHQ110`FQ=V<<T'KUI:1L=.^*`$R1DMT[5&\J*O[QN,9.:&!$8).:\R
M^(_BJ_DO$T'1F,<LQP[C!Z$'HP],]Z`,3QGK]QXG\6FPT:,WL5D2IC8[`=RA
MAR1[&MU-)^(DT"R?;VMQVA#1,!^/ZUTW@GPC#X0T>*W`$LY!\Z?H2<G'&2.A
MKIFC4L`5W%NIS0!Y<UU\2M%&Z6Q2]B_VKJ)?Y#W_`$JL_C[Q;H]U%<:YI02V
MESA5G5^@Q_"N>I%>M?*@V,V1Z8ILT4;QE)5RG:@#S:X^-&G1Q_Z/:O-,>D95
MU'Y[:IH_C;QJ2RC^SK0<@+)&^[\\$=*]+&E61=9(H0<>Y_QJRPPC$KL`'7.:
M`/*?!/BS4="UN7P_XME9G)_=.V.Y)_A&.GO7K*3)(%V,"",C'-<]XH\':5XK
M@"ZA;!I`/DGW-E3ZX!%5?!_@Z]\,B2.?67OK<_ZN(VZIY?/J"2>.*`.OY!ZT
MO>D(Z>U+WQ0`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`"!0#D"
MEP!110`4@4*<@4M%`";0#G'-+110`4444`%!&:**`$5%4`*,8JF-'L!JG]HB
M#_2^?WF]NXP>,XZ5=HH`9Y,>TKMX/7FG``$D=3UI:*`#K2;1D'TI:*`$VC.<
G<FD**2I(Y7I3J*`$"*&+`<GK0$4#`'O2T4`)@`TM%%`!1110!__9
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
